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Zusammenfassung 
MicroRNAs sind essentielle post-transkriptionelle Regulatoren der Genexpression die 
an unterschiedlichen Prozessen wie Entwicklung, Signaltransduktion oder 
Wachstumskontrolle durch Bindung und Inhibition der Translation ihrer mRNA Ziel 
mRNAs beteiligt sind. Obwohl angenommen wird, dass ihre relative Expression in der 
Zelle das Ausmaß ihrer biologischen Funktion bestimmt, zeigt die Beladung der 
„Argonaute“ (Ago)-mRNA Komplexe mit miRNAs deren Relevanz besser an.  
In der vorliegenden Arbeit wurde die miRNA Beladung der Ago-Komplexe mit den 
miRNA Profilen der Gesamt-RNA zweier diffus-großzelliger B-Zell Lymphome 
(DLBCL) Linien nach Epstein-Barr Virus (EBV) -Infektion, verglichen. DLBCL ist ein 
hochmaligner Tumor, welcher in Aktivierte B-Zell (ABC-) und Germinal Center B-Zell 
(GCB-) DLBCL unterschieden wird. Etwa 10% aller DLBCLs sind mit dem onkogenen 
EBV, welches selbst 44 reife miRNAs exprimiert, infiziert.  
Die miRNA Profile aus Gesamtzellextrakten und des Ago2-Profils zweier DLBCL 
Linen wurden durch Hochdurchsatzsequenzierung (RNA-Seq) analysiert. In den 
Gesamt-Profilen konnten zwischen 713-851 humane miRNAs identifiziert werden, 
während die Ago2-Profile 1102-1372 humane miRNAs ergaben. Bei Anwendung 
eines 0.1% „cut-offs“ verringerte sich die Zahl der funktionellen miRNAs auf 56-62., 
welche jedoch immer noch 92-95% aller miRNAs-reads ausmachten. In Abhängigkeit 
von Latenztyp repräsentierten die viralen miRNAs 1.6% - 28% aller „reads“. In beiden 
Zelllinien hatte die EBV-Infektion den Verlust von miRNAs im Ago2-Komplex zur 
Folge. Die erhobenen Daten konnten für ausgewählte miRNAs durch RT-qPCR und 
im Northern Blot bestätigt werden. Auch die Analyse der Ago2-Komplexe der 
einzelnen Zellen ergab eine auffällige Umverteilung miRNAs zwischen Gesamt- und 
Ago2-assoziierten miRNAs. Zum Beispiel war die miRNA miR-423 in allen Zellen 6-8-
fach im Ago2-Komplex angereichert, während die miR-142 im Ago2-Komplex 
depletiert vorliegt , was auf einen Funktionsverlust hinweist. Die hier erhobenen Daten 
werden zum weiteren Verständnis des Beitrags von miRNAs bei der Entstehung und 
Aufrechterhaltung von DLBCLs leisten. 
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Summary 
 
MicroRNAs are important post-transcriptional regulators of gene expression in all 
eukaryotic cells and play essential roles, i.e. in development, signal transduction or 
growth control by binding to and inhibiting the translation of their mRNA targets. While 
it is widely assumed that their overall level in a cell reflects their functional relevance, 
the loading and transfer of miRNAs to the “Argonaute” (Ago)-mRNA complex appears 
to give a more accurate indication of their activity in a cell.  
In this thesis, the miRNA loading of the Ago complex was compared with the total 
cellular miRNA profile of two cell lines derived from diffuse large B-cell lymphoma 
(DLBCL) in comparison with their Epstein-Barr Virus infected counterparts. DLBCL is 
a highly malignant tumor subdivided into Activated B-cell (ABC-) and Germinal Center 
B-cell (GCB-) subtypes. About 10% of DLBCL are infected with the oncogenic Epstein-
Barr virus which itself encodes 44 mature miRNAs.  
The cellular and Ago2-bound miRNAs in two DLBCL lines were subjected to 
ultra-deep sequencing (RNA-seq). In the total profiles, 713-851 human miRNAs were 
detected while the Ago2-immunoprecipitation (Ago2-IP) resulted in 1102-1372 
different miRNAs. When a 0.1% cut-off was applied which is considered to yield the 
functionally relevant miRNAs, only between 56-62 miRNAs were left. These, however, 
represented 92-95% of all reads. In the two EBV-infected counterparts, EBV-miRNAs 
represented between 1.6% - 28% of all reads depending on the viral latency type.  In 
the case where EBV miRNAs accounted for 28 % of total reads cellular miRNAs were 
replaced from the Ago2-complex. The results could be confirmed for selected miRNAs 
by RT-qPCR and Northern blotting. Also within each cell line, various miRNAs were 
enriched or depleted from the Ago2 complex. For instance, mir-423-5p and mir-423-
3p were highly enriched, by over 6-8-fold in Ago2-IP, compared to total cellular profile 
in all cell lines while miR142 was strongly depleted from the Ago2-complex indicating 
a functional loss in DLBCL.  The data obtained will help to further understand the 
contribution of cell and viral miRNAs in induction and maintenance of DLBCL.  
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1 Introduction 
1.1 Lymphoma 
Lymphoma is a tumor of lymphocytes, representing almost 5% of all new cancer cases 
worldwide (MUGNAINI, GHOSH, 2016). Lymphomas are classified into two main 
groups: Hodgkin´s lymphoma (HL), representing about 10% of lymphoma, and non- 
Hodgkin´s lymphoma (NHL), accounting for the remaining 90%. The incidence of NHL 
is increasing with age and most of the patients are above 65 years old. NHL is 
categorized into B-cell, T-cell and natural killer (NK) cell types (MUGNAINI, GHOSH, 
2016; SHANKLAND et al., 2012).  
1.2 Genetics of Diffuse large B-cell lymphoma 
Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive subtype of 
NHL, as it accounts for about one third of all malignant lymphoma cases in adults 
(MIYAZAKI, 2016). DLBCL is characterized by expressing specific cell surface 
markers like CD19, CD20, CD22, and CD79a on B-cells Even though there are 
different markers for characterizing DLBCL, it is a heterogeneous disease with distinct 
clinical and biological features. Based on microarray gene expression profiling (GEP), 
the World Health Organization (WHO) classified DLBCL into three major clusters: (1) 
Germinal Center B-cell like (GCB), (2) Activated B-cell like (ABC) and cases, which 
could not be assigned to either group and were therefore, termed unclassifiable 
(ALIZADEH et al., 2000; CAMPO et al., 2011; ROSENWALD et al., 2002; 
SWERDLOW et al., 2016). In addition to GEP for classifying DLBCL, next-generation 
sequencing (NGS), including whole genome and exome sequencing also allows to 
differentiate the genetic alteration patterns of ABC and GCB (ZHANG et al., 2013). 
Germinal centers (GCs) are the sites in secondary lymphoid tissue where B cells 
proliferate, differentiate and undergo immunoglobulin somatic hypermutation (SHM), 
class switch recombination (CSR), and affinity selection, to produce high affinity 
antibodies (VICTORA, NUSSENZWEIG, 2012). Due to the high rate of B cell 
proliferation and differentiation, germinal center cells can undergo genetic aberration, 
resulting in lymphomagenesis (BASSO, DALLA-FAVERA, 2015). GCB-DLBCL 
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originates from germinal center centroblasts, is more common among young people 
and GEP shows the characteristics of tonic B-cell receptor (BCR) signaling (COPIE-
BERGMAN et al., 2002; CUMMIN, JOHNSON, 2016). ABC-DLBCL (often also termed 
non-GCB), is derived from post germinal center cells. It has been shown that 
MYC/BCL2 double translocations, amplification of the oncogenic mir-17–92 
microRNA cluster, mutations in genes such as BCL2 , the proto-oncogene MYC (gain 
of function), histone methyl-transferase EZH2 (gain of function), S1PR2, GNA13 (loss 
of function), occur more often in GCB-DLBCL (INTLEKOFER, YOUNES, 2014; 
ROSCHEWSKI et al., 2014; SWERDLOW et al., 2016). In comparison to GCB-
DLBCL, ABC-DLBCL is often characterized by mutations affecting in B-cell receptor 
signaling, especially the NF-κB-pathway (COPIE-BERGMAN et al., 2002; CUMMIN, 
JOHNSON, 2016). ABC-DLBCL is preferentially associated with mutations in genes, 
such as CD79A, MYD88, CARD11 and TNFAIP3, which activate the B-cell receptor, 
the Toll-like receptor and also the NF-kB pathways (BASSO, DALLA-FAVERA, 2015; 
LENZ et al., 2008; SWERDLOW et al., 2016; ZHANG et al., 2013). 
This molecular genetic difference in gene expression profile and signaling pathways, 
can lead to the conclusion that there is a unique pathogenicity mechanism, 
differentiating GCB- from ABC-DLBCL, resulting in a different strategy for treatment. 
 
1.3 Clinical genetic diagnosis of DLBCL 
A diagnosis of DLBCL is obtained from a tissue biopsy of the enlarged lymph node 
and assessment of lymph node architecture. Since GEP is not routinely available as 
the clinical diagnostic test for differentiation of GCB- and ABC-DLBCL, the “Hans 
algorithm” (Figure 1) has been used frequently with an accuracy of about 90%, and 
recommended for routine diagnosis. This algorithm is based on 
immunohistochemistry (IHC) staining, and evaluating the expression patterns of 
cluster of differentiation (CD10), B-cell lymphoma 6 (BCL6), and interferon regulatory 
factor-4/multiple myeloma-1 (IRF4/MUM1) expression (HANS et al., 2004; 
SWERDLOW et al., 2016). Novel methods, such as gene panel (Lymph2Cx assay) 
from Formalin-fixed paraffin-embedded (FFPE) tissues (SCOTT et al., 2014), NGS, 
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flow cytometry, cytogenetic analysis using fluorescence in situ hybridization (FISH) or 
polymerase chain reaction (PCR), for chromosomal translocations or rearrangements 
of genes, can be considered as alternative medical genetic diagnostic methods, to 
differentiate various types of lymphoma. 
 
1.4 Medical Treatment of DLBCL; future perspective 
Diffuse large B-cell lymphoma (DLBCL) is a human malignancy with a very poor 
prognosis. About 15% of all DLBCLs are EBV positive by virtue of the presence of 
EBER-transcripts in the tumor cells (DELECLUSE et al., 2007; IMIG et al., 2011). The 
standard treatment for patients with ABC or GCB-DLBCL is R-CHOP therapy. CHOP 
is a combination of rituximab, anti-CD20 monoclonal antibody, cyclophosphamide, 
doxorubicin, vincristine, and prednisone (TOMITA et al., 2013; YU, LI, 2015). As 
DLBCL constitutes a distinct molecular disease and therefore has a different clinical 
and prognostic features, it is promising to use novel strategies, based on molecular 
insights of affected signaling pathway and targeting genes, which are characteristic of 
GCB- or ABC-DLBCL. For example, targeting BCL-6 to prevent  cell proliferation, 
using an HDAC inhibitor (PAREKH et al., 2008), etoposide to inhibit topoisomerase II 
(DUNLEAVY et al., 2013; KUROSU et al., 2003) or targeting of EZH2, which is 
 
Figure 1: Hans algorithm for differentiation of diffuse large B-cell lymphoma 
(DLBCL).  
Immunohistochemical staining (IHC) to differentiate GCB-DLBCL from non-GCB-DLBCL 
(ABC-DLBCL). Adapted and modified from (HANS et al., 2004). 
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mutated in GCB-DLBCL (BÉGUELIN et al., 2013). In the case of ABC-DLBCL, which 
has the worst prognosis among DLBCLs, targeting the NF-κB-pathway to prevent 
constitutive activation and overexpression of NF-κB, could have a potential 
therapeutic effect, such as using ibrutinib, which inhibits BTK in the NF-κB-pathway 
(WILSON et al., 2015). 
 
1.5 Molecular genetics of Micro RNA 
MicroRNAs (miRNAs) are conserved, short single stranded noncoding RNA 
molecules of 19-25 nucleotides in length, which are processed from longer hairpin-
structured transcripts (Figure 2) (AMBROS et al., 2003; CULLEN, 2004). The main 
function of miRNAs in the cell is to fine-regulate gene expression. The first miRNA 
was discovered in Victor Ambros’ lab in 1994, where it was shown that the interaction 
of Lin 4 with the Lin14 mRNA in the worm Caenorhabditis elegans (C. elegans) causes 
reduction in the amount of LIN-14 protein, resulting in a distinct phenotype. This 
interaction is important in the timing of the development and transition from the first to 
the second larval stage (BARTEL, 2004; KIM, 2005; LEE et al., 1993). A few years 
later, the Ruvkun group found the second small RNA, termed let-7, controlling the 
Lin41 mRNA. They also demonstrated that this interaction is essential for the transition 
from larval stage 4 to the adult (REINHART et al., 2000). Most importantly, they also 
found that a let-7 homolog exists which is expressed in humans and other species 
(PASQUINELLI et al., 2000). This important discovery opened a new era in molecular 
biology to understand the functional importance of miRNAs (AMBROS, 2004; 
BARTEL, 2004). 
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1.6 Biogenesis of miRNAs 
About 1% of the genes encode for miRNA, and it is estimated that about one third of 
all human genes might be targeted by miRNAs. MiRNAs are transcribed from either 
intronic (coding and non-coding), or exonic regions of the genome. The primary 
transcription is typically several kilobases long, with (a) hairpin structure(s) that 
contain(s) either one miRNA or a cluster of miRNA hairpin structures, as shown in 
Figure 2 (BARTEL, 2004; HA, KIM, 2014; KIM et al., 2009).  
The key proteins for biosynthesis of miRNAs are two RNase III type endonucleases, 
Drosha and Dicer, and the “Argonaute” proteins. The region of the genome encoding 
a miRNA is first transcribed by RNA polymerase II (Pol II), leading to a primary miRNA 
transcript (pri-miRNA). Subsequently pri-miRNA is recognized and cleaved in the 
nucleus by the RNase-III endonuclease Drosha, together with the cofactor 
DGCR8/Pasha. This cleavage creates a hairpin structure about 70-bp length with 2-
nucleotide long 3′ overhangs at the cleavage site, which is termed precursor miRNA 
(pre-miRNA) hairpin. Then the pre-miRNA is translocated to the cytoplasm by exportin 
5, which is a Ran guanosine triphosphate-dependent (Ran-GTP) dsRNA-binding 
protein (BOHNSACK et al., 2004; LUND et al., 2004). In the cytoplasm, the pre-miRNA 
is further processed by the RNase III endonuclease “Dicer”, which results in the 
formation of ~22-nucleotide mature duplex miRNAs (BARTEL, 2004; HA, KIM, 2014; 
KRICHEVSKY, GABRIELY, 2009). 
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Figure 2: Genomic organization of miRNAs. 
MiRNAs can be classified into different groups based on their location in the genome. a) 
MiRNA located in the noncoding region of TU like the miR-15a and miR-16-1 cluster in 
DLEU2 (non-coding RNA gene). b) MiRNA located in the intron of coding TU for protein 
such as miR-25, miR-93 and miR-106b cluster in MCM7 transcript. c) MiRNA located in 
the exon of noncoding TU such as miR-155 in the BIC1 Gene .d) miRNA located in the 
exon of protein coding regions such as miR-985 in coding region of CACNG8. MiRNA 
can be transcribed as a polycistronic TU (a and b) or single TU (c and d). TU, transcription 
unit. Adapted and modified from (KIM et al., 2009). 
 
1.7 RNA-induced silencing complex (RISC) formation 
The mature miRNA duplexes are then incorporated into the Argonaute/EIF2C 
complex. The one strand with less thermodynamic base pairing stability, for instance 
a GU base pair, as compared to a GC base pair at the 5´ end, remains in the Ago 
complex and forms a functional mature miRNA, termed guide miRNA while the other 
miRNA strand named passenger miRNA (miRNA*) is released from the Ago-complex 
and degraded. However, in other cases, like miR-142, both miR-142-3p and miR142-
5p, are incorporated into the RISC complex (KWANHIAN et al., 2012). Dicer1 is also 
believed to associate with Ago2 in this process. Finally, Ago2, Dicer and TRBP (TAR 
RNA-binding protein or TARBP2 form the miRNA Induced Silencing Complex (RISC), 
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to silence their mRNA target (Figure 3) (BARTEL, 2004; KIM et al., 2009; LIN, 
GREGORY, 2015). 
 
 
Figure 3: miRNA biogenesis. 
MiRNA genes are transcribed by RNA pol II into pri-miRNA and then processed by 
Drosha–DGCR8 to generate the pre-miRNAs. The pre-miRNAs (about 65-70 
nucleotides) are recognized by the exportin5 / Ran GTP complex and transferred 
to the cytoplasm. In the cytoplasm, Dicer (RNase III) further processes the pre-
miRNA to generate the mature miRNA duplex. The mature miRNA is loaded into 
the AGO-GW182 protein complex and forms the RISC complex. Finally the miRNA 
directs the “Argonaute”-complex to the mRNA gene target to perform the silencing 
effect. Adapted and modified from (LIN, GREGORY, 2015).  
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1.8 Mechanism of miRNA-directed regulation 
Once the “Argonaute”-complex has been recruited to the 3´UTR of its mRNA target, it 
interacts with the N terminal domain of the GW182 protein (Drosophila) or the 
TNRC6A (mammalian) protein. GW182 possesses at the N-terminus glycine-
tryptophan (GW) amino acid repeats and a crystallographic study showed that two 
tryptophan residues are important for AGO binding (SCHIRLE, MACRAE, 2012). At 
the C-terminus, GW182 through a RNA recognition motif (RRM) and a poly(A)-binding 
protein-interacting motif 2 (PAM2) motif, directly interacts with the PABPC (poly(A)-
binding protein C) on the poly(A) tail of the mRNA. GW182 also interacts directly with 
NOT1 which is a part of CCR4–NOT deadenylation machinery. Recruiting the CCR4–
NOT complex to the 3´ UTR results in removing and shortening of the poly(A) tail, and 
also leads to cap removal from  mRNA and calling the XRN1 exonuclease and finally 
degrading the mRNA (MEISTER, 2013). 
1.9 The Argonaute proteins 
Argonaute (Ago) are the key proteins in the RISC complex. The AGO families are 
divided into three subclades: PIWI, AGO and WAGO (Worm-specific Argonaute). The 
PIWI subclade, which has a homology to Drosophila melanogaster PIWI, is mainly 
expressed in the germ line and associated with PIWI-interacting RNAs (piRNAs). The 
AGO subclade, which is similar to Arabidopsis thaliana AGO, is involved in the miRNA 
or the siRNA pathway (MEISTER, 2013). In humans, four types of the AGO subfamily 
have been identified, namely 1) hAGO, EIF2C1 2) hAGO2, EIF2C2 3) hAGO3, 
EIF2C3 4) hAGO4, EIF2C4. The Ago family is highly conserved, ubiquitously 
expressed in numerous tissues, and have a molecular weight of approximately 100 
kDa (SASAKI et al., 2003; ZHAI et al., 2016). Among the human AGO subfamily, Ago2 
is the only protein which possesses the catalytic RNAse activity, and has an important 
role in RNA guided silencing processes. Recently the crystal structures of AGO2 were 
resolved and it revealed four main domains: an N-terminal domain, a PAZ (Piwi-
Argonaute-Zwille), a MID (middle) and a Piwi domain (Figure 4) (ELKAYAM et al., 
2012; SCHIRLE, MACRAE, 2012). As shown in Figure 4, these domains form a bi-
lobal shape, one lobe with N-terminal domain and PAZ domain and the other lobe with 
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MID and PIWI domains. These lobes are connected, by Linker 1 (L1) and Linker 2 
(L2), in order to form a hinge, connect the two lobes and bond them together. The N-
terminal domain is important for loading the RNA duplex and unwinding of miRNA. 
The PAZ domain binds to the 2-nucleotide of 3´ overhang of miRNA. The MID domain 
provides a binding pocket for the 5´ overhang of the guide RNAs, with preferential 
binding to U or A nucleotides. The PIWI Domain has a homology to RNase H and 
possesses endonucleolytic activity to slice mRNAs, between nucleotide positions 10 
and 11, from the 5´ end of the small guide miRNA. Therefore, binding of the small 
guide RNA at 5´end, to PAZ and MID domain in one hand, and the 3´overhang to PIWI 
domain on the other hand, cause the small guide miRNA to accommodate in an A-form 
helix conformation, between two lobes. It also causes exposure of nucleotide 2 to 7 of 
guide miRNA, termed a seed sequence, and the finding of a complementary sequence 
of the mRNA target. All human AGO proteins subclades were able to induce 
translational suppression, degradation of mRNA targets through the formation of the 
RISC complex. Ago2 is the only Argonaute protein that has the capability to slice 
perfectly matched mRNA (HA, KIM, 2014; LIU et al., 2004; MEISTER, 2013; PARKER 
et al., 2005; YE et al., 2015; ZHAI et al., 2016). Ago2 knockdown, using siRNA results 
in increased expression of other Ago proteins, especially Ago1 and vice versa 
(MATSUI et al., 2015).  
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Figure 4: Schematic depiction of the Ago2 protein. 
a) Ago2 consists of an N terminal domain, a PAZ domain (binds to 3´ guide miRNA), 
the MID (middle) and the PIWI domain (binds to the 5´ monophosphate of the guide 
miRNA). The numbers indicate location of each domains in Ago2. b) 3D structure of 
human AGO2 with guide miRNA in red color. Adapted and modified from (ELKAYAM 
et al., 2012; HA, KIM, 2014) 
 
1.10  MicroRNAs in cancer 
Since the discovery of miRNAs by Victor Ambros in developmental timing in C. 
elegans, the function of miRNA was extended to their contribution to cancer. We now 
know that miRNAs can act as oncogenes (oncomiRs), by inducing different 
mechanisms such as cell proliferation, migration and invasion, tumor growth and 
metastasis, or act as a tumor suppressor by inhibiting cell proliferation, migration and 
invasion (LEE et al., 2016). The most common molecular genetic changes in miRNA 
expression levels are as follows: 
1) Downregulation of miRNA processing enzymes, such as a) Drosha by inducing 
expression of the oncogenic transcription factor c-MYC or RNA-specific deaminase 
 
a) 
 
 
 
 
 
b) 
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ADARB1, which results in the reduction of pri-miRNA processing and downregulation 
of the tumor suppressor microRNAs MiR-15/-16 (ALLEGRA et al., 2014). b) Dicer 
downregulation by different mechanisms, such as downregulation or loss of function 
of transcription factor TAp63 (binds to the promoter of Dicer), or by miRNA-mediated 
downregulation such as let-7 (TOKUMARU et al., 2008), miR-103/107 (MARTELLO 
et al., 2010), and miR-630 (RUPAIMOOLE et al., 2016). c) Induced ago2 
phosphorylation at Tyr393, by the epidermal growth factor receptor (EGFR), which 
affects binding of Ago2 to Dicer, during hypoxia leading to reduced miRNA processing 
(SHEN et al., 2013). d) Mutation in the exportin 5 encoding gene, leading to decreased 
transport of miRNA from the nucleus to the cytoplasm, which induces expression of 
the EZH2 and the MYC oncogene (MELO et al., 2010; RUPAIMOOLE, SLACK, 2017). 
2) Downregulation of tumor-suppressor miRNAs such as a) the miR-34 family 
including miR-34a, miR-34b and miR-34c. b) the  let-7 family (consisting  of ten 
isoforms), involved in targeting many oncogenic mRNAs, like KRAS in the RAS 
signaling pathway, c) the miR-200 family such as miR-200a/b/429 and miR-200c/141, 
involved in epithelial–mesenchymal transition (EMT), which is important for 
metastasis and invasiveness of cancer cells (DE CRAENE, BERX, 2013), d) 
miR-15/16 located on chromosome 13q14 ,which is lost in B-cell chronic lymphocytic 
leukemia (CLL) and targets BCL-2 expression (PEKARSKY, CROCE, 2015), e) 
miR-506 inducing senescence by targeting CDK4 and CDK6  proteins (LIU et al., 
2014) and targeting  RAD51, a double-strand DNA damage repair gene, in ovarian 
cancer (LIU et al., 2015a), f) miR-520 (RUPAIMOOLE, SLACK, 2017). 
3) Molecular genetic alterations such as a) chromosomal deletion, for example, 
deletion(s) in the 13q14 chromosome, which is normally lost in B cell chronic 
lymphocytic leukemia (B-CLL), containing tumor suppressor miR-15 and miR-16 
(CALIN et al., 2002). b) Chromosomal amplifications such as amplification of the 
17q23.2 chromosomal region, which contains the oncogenic  mir-21, deregulated in 
many types of cancer (breast, lung, gastric, ovarian and prostate cancers) 
(KRICHEVSKY, GABRIELY, 2009) or amplification of the miR-17-92 cluster family on 
chromosome 13q 31.1, which is amplified in B cell lymphoma (MENDELL, 2008; 
RUPAIMOOLE, SLACK, 2017).  
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1.11  Epstein - Barr Virus (EBV) 
The Epstein–Barr virus (EBV), a human tumor virus, was discovered in 1964 by 
Antony Michael Epstein, Bert Achong and Yvonne Barr, using biopsy material of 
Burkitt’s lymphoma (BL) patients (EPSTEIN et al., 1964). It is estimated that more 
than 95% of the adult human population are seropositive for EBV infection. In the 
infected individual, EBV persists probably without any gene expression in CD19+ 
memory B-cells, where it is occasionally reactivated, and shed through the oropharynx 
into the saliva (THORLEY-LAWSON, 2001). Although the viral infection usually occurs 
without symptoms in the infected individual, EBV can induce tumors under certain 
conditions. EBV is responsible for approximately 1.8% of cancer deaths worldwide 
(DE MARTEL et al., 2012; KHAN, HASHIM, 2014; YOUNG et al., 2016). 
 
1.12 EBV latent genes and transformation 
EBV is a γ-herpesvirus with a double-stranded DNA genome of approximately 172 
kilobase pairs in length, encoding about 90 genes (KIEFF , RICKINSON 2007; 
SAMPLE et al., 1990; TASHIRO, BRENNER, 2017). The oncogenic potential of EBV 
is readily observed in vitro by transformation of resting B-cells into permanently 
growing lymphoblastoid cell lines (LCLs). These LCLs are correlated in vitro with the 
so-called “Post-Transplant Lymphoprolifertive Disease” (PTLD), observed under 
immunosuppression (DELECLUSE et al., 2007). EBV growth-transforms infected B 
cells by expressing a set of viral proteins, termed latent proteins including six EBV 
nuclear antigens (EBNA1, -2, -3A, -3B, -3C and –LP), and three membrane proteins 
(LMP1, 2A and 2B), (Table1). In addition to these nine proteins, EBV expresses two 
non-coding RNAs (EBER1 and EBER2), and 44 viral miRNAs (Figure 5) 
(GRUNDHOFF et al., 2006; PFEFFER et al., 2004). During latency, the EBV lytic cycle 
replication is usually repressed by different mechanisms, such as upregulation of 
important transcription factors like STAT3 (Signal transducer and activator of 
transcription 3) in BL or LCL cells.  STAT 3 upregulation can affect several Zn-finger 
repressors, such as ZNF253, ZNF257, SNF589 and SETDB1. Koganti et al. have 
shown a decline in B cells proliferation, when B cells from patients with hypomorphic 
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mutations in STAT3, are infected with EBV (KOGANTI et al., 2014; LIEBERMAN, 
2015). However, lytic cycle reactivation more likely occurs when the EBV-CD19+ 
memory in B-cells is recalled (LAICHALK, THORLEY-LAWSON, 2005; MIYASHITA 
et al., 1995). It has been shown that EBV lytic cycle can be induced, by activation of 
transcription factor BZLF1 or other proteins such as X-Box-binding protein 1 (XBP-1) 
and  protein kinase D (PKD), which has an  important  role in switching from latency 
to lytic cycle, during EBV infection (BHENDE et al., 2007; COUNTRYMAN, MILLER, 
1985; YOUNG et al., 2016) . 
 
Table 1: Different stages of EBV latency. 
Different EBV latency stages are associated with different tumors. Adapted and 
modified from (HEALY, DAVE, 2015). 
Latency 
Stages 
Expressed EBV 
protein 
Associated Tumors 
I  LMP2A, EBNA1 
Burkitt lymphoma 
DLBCL NOS 
T cell-rich DLBCL 
II 
Protein in latency I + 
LMP1,LMP2B 
Classic Hodgkin’s lymphoma 
Angioimmunoblastic T cell lymphoma 
NK/T cell lymphoma, N 
Nasopharyngeal carcinoma 
Gastric carcinoma 
III 
Protein in latency II + 
LP,EBNA2,EBNA3A, 
EBNA3B,EBNA3C 
 
Primary EBV infection 
Post-transplant lymphoproliferative disease 
AIDS-related lymphomas (plasmablastic 
DLBCL, 
primary CNS lymphoma, primary effusion 
lymphoma) 
EBV + DLBCL of the elderly 
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1.13  EBV miRNAs 
EBV was the first human DNA virus identified to encode miRNAs (PFEFFER et al., 
2004). EBV miRNAs are encoded in two clusters, the so-called BHRF1-cluster (Bam 
HI fragment H rightward open reading frame 1), which encodes 3 miRNAs and the 
BART-cluster (Bam HI-A region rightward transcript), encoding 41 miRNA (YOUNG 
et al., 2016). It has been shown that EBV miRNAs are important for keeping EBV in 
latency by targeting EBV proteins, such as BART(1-5p,16,17-5p), downregulating the 
LMP1 protein (LO et al., 2007), BART-2, downregulating the DNA polymerase BALF5 
expression (BARTH et al., 2008) and BART22, downregulating LMP2A (LUNG et al., 
2009). EBV miRNAs also have been shown by many research groups to target cell 
mRNAs and downregulating their protein expression. For instance, BART1 targets the 
tumor suppressor phosphatase and tensin homolog (PTEN)  (CAI et al., 2015), BART3 
and BART16 target IPO7 and TOMM22, respectively (DÖLKEN et al., 2010), BART9 
targets E-Cadherin (HSU et al., 2014) and BART6 targets Dicer (IIZASA et al., 2010; 
KANDA et al., 2015). 
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Figure 5: EBV BamHI restriction map. 
BamHI restriction maps for the EBV B95-8 strain and locations of latent cycle 
proteins and the EBV encoded miRNAs. The BamHI fragments are shown 
according to size using alphabetical letters, a capital letter A for the largest and 
small letter for the smaller fragment in descending order.TR, terminal repeats are 
shown as black blocks. BART, BamHI-A rightward transcript,(BHRF1) BamHI 
fragment H rightward open reading frame, (BARF1) BamHI-A fragment rightward 
reading frame, (LMP) latent membrane proteins, EBNA (Epstein–Barr nuclear 
antigens). Adapted and modified from (YOUNG et al., 2016). 
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1.14   Aim of the study 
A very promising approach to understand the involvement of a certain miRNA in the 
process of a disease such as cancer, is to assess the miRNA expression profile of 
cancer patients. The comparison with their normal counterpart is a very promising 
approach for understanding the involvement of (a) certain miRNA(s) in a disease of 
interest. This may lead to the discovery of a novel prognostic or diagnostic biomarker. 
Although it is believed that the miRNA profile from extracted total cellular RNA is an 
actual indicator of RISC complex-associated miRNA, due to quick degradation of non-
guide miRNA, this hypothesis was challenged by the Cullen group, when they 
compared the miRNA profile of the total cellular miRNAs with the RISC associated 
miRNAs (Ago-IP) pool. Intriguingly, they have found that the total cellular miRNA 
profile differs from the Ago-bound profile, and therefore they challenged the idea that 
the total cellular miRNA profile is accurately reflecting the Ago RISC-associated 
miRNAs (FLORES et al., 2014). 
The effect of EBV infection and dysregulation of the total cellular miRNA profile in 
DLBCL was reported by many researchers, as already discussed above. To the best 
of our knowledge, this is  the first time that Ago2 immunoprecipitation was performed, 
followed by sequencing (Ago2-IP-seq) in two different DLBLC cell lines and their EBV 
infected counterparts, in order to profile the miRNAs according to their functional level.  
The U2932 and SUDHL5 cells and their EBV infected counterparts were used as a 
model for ABC-DLBCL and GCB-DLBCL, respectively.  
 
The questions addressed in this project were as follows: 
 
1. Determination of differentially expressed miRNA in DLBCLs cell lines, in 
comparison with their EBV infected counterparts. 
2. Assessment of various expressed miRNA, in Ago2-IP in DLBCLs cell lines in 
comparison to EBV infected counterparts. 
3. Evaluation of enriched or depleted miRNA in the Ago2-IP, compared to the total 
cellar miRNA profile in each cell line by RNA-seq. 
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2 Materials and Methods 
2.1 Material 
 Laboratory equipment’s. 
Adjustable pipettes Gilson,Peqlab 
Agilent 2100 Bioanalyzer Agilent (Santa Clara, USA) 
Centrifuge Megafuge 1.0 R (Heraeus) 
Centrifuge 202 MK (Sigma) 
Centrifuge  1-16K   Sigma 
Chemidoc XRS system Bio-Rad 
CO2 incubator HeracellTM 150i (Thermo Scientific) 
Electrophoresis power supply Consort EV-231 (Consort bvba) 
Electrophoresis power supply Phero Stab 300 (Biotec Fisher) 
Heat block Thermomixer Compact (Eppendorf) 
Oven for hybridization UM 400B Hyp (Bachhofer) 
Phosphoimager 
PhosphoimagerTM-Typhoon with plates and 
cassettes for exponation (Molecular Dynamics, 
Amersham) 
Photometer NanoDropTM 2000c (Peqlab) 
Plates (MicroAmp® Fast 
Optical 96-Well Reaction (Carlsbad, USA) 
Real-Time PCR System 
(StepOnePlus™); 96-Well Applied Biosystems/Life Technologies 
Semi-Dry Blotter 2117 Multiphor (LKB Bromma) 
Shaker Thermomixer Compact (Eppendorf) 
Shaker POLYMAX 1040 (Heidolph) 
Shaker REAX 2000 (Heidolph) 
Shaker Edmund buehler 
Tank-Blotting chamber 2005 Transphor Electro Blotting Unit (LKB Bromma) 
Vortex Heidolph 
Weighing balance Sartorius 
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 Reagents and chemicals 
3-Mercapto-1,2-propandiol Sigma 
Ammonium persulfate (APS) Serva 
Bisacrylamide 2% Roth 
Blocking reagent Boehringer 
Blue protein standard  Biolabs 
Bovines Serumalbumin (BSA) Serva 
Bradford-Reagent Roti®-Quant Carl Roth 
Bromophenol blue Serva 
´´Complete Mini ``Protease Inhibitor 
Cocktail 
Roche Diagnostics 
Coomassie Brilliant Blue R 250 Roch 
Denhardt’s solution 50x Sigma 
Diethylpyrocarbonate (DEPC) Sigma 
EDC-Hydrochlorid Sigma 
Ethanol Roth 
Ethylendiamintetraacetat (EDTA) Serva 
Fetal calf serum (FCS) Gibco 
G 418 (Geneticin) Invitrogen 
Gamma  P-32 UTP Hartmann Analytics 
Glycin Sigma 
H2O2  30% Merck 
HybondTM-N membrane  GE healthcare life science Amersham  
IGAPEL CA 630 Sigma 
KCL Merck 
Klenow Fragment (DNA Polymerase I) Klenow Fragment (EP0051 ) 
Luminol( 3-Aminophthalhydrazide)  Sigma 
Magnesium chloride hexahydrate Roth 
Methanol Roth 
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Methylimidazole Peqlab 
TEMED Serva 
NaCl Merck 
Nitrocellulose membrane protran 0.2 
µM 
GE healthcare life science Amersham 
Neubauer chamber C-Chip Neubauer Improved , Digital 
Bio 
Nucleotides (dNTPs) Peqlab 
Nucleotides (NTPs) Invitrogen 
P-coumaric acid Sigma 
pH meter  Hydrus 300 Fisherbrand Hydrus 300 
PonceauS TM Sigma 
Real-Time PCR System 
(StepOnePlus™); 96-Well Applied Biosystems/Life Technologies 
Sepharose 4 Fast Flow Protein G GE Healthcare, Freiburg, Germany 
Skim milk powder Töpfer 
Sodium azide Merck 
Sodiumdodecylsulfate (SDS) Serva 
Tris base  Trizma Sigma 
 Miscellaneous materials 
mirVANA TM kit Ambion 
miScript II RT Kit Qiagen (Hilden, Deutschland) 
miScript II RT Kit Qiagen (Hilden, Deutschland) 
miScript SYBR® Green PCR Kit Qiagen (Hilden, Deutschland) 
Primers for qRT-PCR Qiagen 
Primers for NB Eurofins MWG operon 
RPMI -1640 Sigma 
SequaGel - UreaGel System National Diagnostics USA 
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 Antibodies  
Antibody   Source  and Isotype 
 
Dilutions 
used 
Reference 
 Ago2(11A9) Rat monoclonal IgG2a 1:50 a kind gift from Prof. 
Gunter Meister, University 
of Regensburg 
Sec 23b Rat monoclonal IgG2a 1:50 Prof.Kremmer, 
Dr.Szczyrba 
EBNA1(1H4) Rat monoclonal 1:10 Prof.Kremmer, 
Prof.Grässer 
LMP(S12) Mouse Monoclonal 1:10 a kind gift of Prof.Martin 
Rowe, University of 
Birmingham 
EBNA2 (R3) Rat monoclonal 1:50 
Prof.Kremmer,Prof. 
Grässer 
α-GAPDH(14C10) Rabbit 1:5000 Cell signaling 
Peroxidase AffiniPure Goat Anti-Rat 
IgG + IgM (H+L) 
1:8000 Jackson ImmunoResearch 
Laboratories 
Anti-Mouse IgG (whole molecule)–
Peroxidase antibody produced in rabbit 
1:8000 Sigma aldrich 
Anti-Rabbit IgG (whole molecule)–
Peroxidase antibody produced in goat 
1:8000 Sigma aldrich 
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 Buffers and Solutions 
Ammonium persulfate (APS) APS in dd H2O                           10% 
Blocking reagent 5% skim milk powder in PBS  
Crosslinking reagent for NB Methylimidazole                         245 μL  
EDC-hydrochloride                    0.75 g  
ddH2O up to 24 mL 
Coomassie-Brilliant blue stain (C.B.B) 300 mL Isopropanol 
780 mL dd H2O 
120 mL acetic acid 
0.3 g Coomassie Brilliant Blue R 250 
dNTPs dATP, dCTP , dGTP , dTTP  
each one                                   10 mM  
ECL-Solution A Luminol                                          1 gr 
DMSO                                      22.6 mL   
Up to 50 mL with dH2O 
ECL-Solution B P-coumaric acid                           0.5 gr 
DMSO                                        33.8 mL 
Up to 45 mL with ddH2O 
ECL-Solution C 1 M Tris HCl pH 8.5  
ECL  working solution Solution A                                    2.5 mL  
Solution B                                 1.113 mL  
Solution C                                     25 mL  
up to  250 mL with ddH2O 
for WB: 1 µl H2O2 added to 1mL ECL 
before use 
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Hybridization buffer 
 
20x SSC                                      7.5 mL  
1 M Na2HPO4                             0.6 mL  
10% SDS                                      21 mL  
50x Denhardt’s Solution               0.6 mL  
blocking reagent                         a pinch 
lysis buffer 
Tris/HCl pH 7.4                           25 mM 
KCl                                            150 mM 
EDTA                                            2 mM 
NaF                                               1 mM 
IGEPAL                                         0.5% 
Working solution: 
1 tablet complete mini protease inhibitor 
in 10 mL Lysis buffer before use 
MSE  5X 
MOPS                                                  1M 
NAAc                                                0.3M 
EDTA                                                0.3M 
H2O                  
PBS 
Solution A(10X) 
NaCl                                              80g 
KCl                                                  2g 
MgCl2.6H2O                                    1g 
CaCl2.2H2O                               1.32g 
Make the volume with dH2O to one liter 
Solution B(10X) 
Na2Hpo4.12H2O                     28.98g 
KH2PO4                                         2g 
Make the volume with dH2O to one liter 
working dilution : 1X from A+B  
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Polyacrylamide gel 12.5% 
(Separating  gel) 
Separating Stock buffer                  4 mL 
30% Acrylamide                           6.7 mL 
2% Biscrylamide                         2.68 mL 
ddH2O                                        2.62 mL 
10% APS                                     140 μL 
TEMED                                          14 μL 
Total                                         16.15 mL 
Polyacrylamide gel 10% 
(Separating  gel) 
Separating Stock buffer                 4 mL 
30% Acrylamide                          5.3 mL 
2% Biscrylamide                       2.12 mL 
ddH2O                                      4.58 mL 
10% APS                                    140 μL 
TEMED                                        14 μL 
Total                                        16.15 mL 
Polyacrylamide gel 4% 
(stacking gel) 
Stacking Stock buffer                1.25 mL 
30% Acrylamide                         750 μL  
2% Biscrylamide                        300 μL 
ddH2O                                        2.7 mL 
10% APS                                   100 μL 
TEMED                                        10 μL 
Total                                              5 mL 
Ponceau S-stain 
Trichloroaceticacid                        30 g 
Ponceau S                                      5 g 
Make up to 1 liter with dd H2O 
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“Low Molecular Weight” marker 
 
            
Protein  
 
kDa Concentration 
μg/μL 
Phosphorylase b  94  0.5  
BSA 67  0.7  
Ovalbumin  43  1.0  
Carboanhydrase  30  0.5  
Trypsin inhibitor  20.1  1.0  
Lactalbumin  14.4  0.5  
RNA loading buffer 
Formamide                                 750 μL  
5x MSE                                       150 μL  
formaldehyde                              240 μL  
50% glycerol                              200 μL  
dH2O                                          160 μL 
bromphenol blue                       a pinch  
xylene cyanol FF                       a pinch 
SDS-loading buffer 2x 
Tris/HCl pH 6.8                        130 mM 
SDS                                               6% 
ß-Mercapto-1,2-propandiol          10% 
glycerol                                         10% 
SDS-loading buffer 4x 
SDS                                            1,6 g 
β-Mercaptoethanol                       4 mL        
Glycerol                                        2 mL 
Tris pH 7 (1M)                              2 mL 
Bromo phenol blue                       4 mg 
ddH2O                                          2 mL 
SDS   Running Buffer  
for SDS-PAGE 
glycine                                          72 g   
Tris                                               15 g 
SDS (20%)                                    25 mL 
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Separating Stock buffer 
Tris                                               1.5 M 
SDS                                               0.4%   
pH                                                  8.8 
Stacking Stock buffer 
Tris                                                0.5 M 
SDS                                               0.4%   
pH                                                    6.8 
Stripping buffer for NB 
0.5% SDS 
SSC  20X 
NaCl                                               3 M  
trinatriumcitrat dihydrate              0.3 M 
Tranfer  Buffer for WB 
glycine                                          72 g   
Tris                                               15 g 
SDS (20%)                                 12.5 mL 
Methanol                                       1 liter 
Make up to 5 liters with dd H2O 
TBE buffer  10X 
Tris                                             0.89 M  
Boric acid                                   0.89 M  
EDTA                                          20 mM 
TE buffer (pH=8) 
Tris                                                10 mM 
EDTA                                              1 m 
Washing  buffer for IP 
Tris/HCl pH 7,4                          50 mM 
KCl                                           300 mM 
MgCl2                                           1 mM 
IGEPAL                                         0.5% 
Washing buffer I (for NB) 
SSC                                               5x 
SDS                                               1% 
Washing buffer II (for NB) 
SSC   1X 
SDS 1% 
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 Cell lines 
The following cell lines have been used in this study: 
U2932: a B-cell line, derived from a patient with HL followed by the NHL, and it has a 
characteristic of post-GC derived origin (ABC-DLBCL) of the tumor cells (AMINI et al., 
2002). 
U2932 EBV positive clone A: a U2932 cell line, infected with EBV-GFP, not expressing 
EBNA2 (BOCCELLATO et al., 2007). 
SUDHL5: a B-cell line, derived from a lymph node of a 17-year-old woman with B-cell 
non-Hodgkin lymphoma (B-NHL) and has characteristic of GCB-DLBCL. 
SUDHL5 EBV positive: SUDHL5 cell line, infected with EBV-GFP, obtained from Prof. 
Pankaj Trivedi, University of Rome. 
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 Primers for real time PCR 
 
The following Primer sequences were ordered from Qiagen for RT-qPCR analyses: 
 
Primer Sequences Cat. No. 
let-7c-5p UGAGGUAGUAGGUUGUAUGGUU MS00003129 
miR-10a-5p UACCCUGUAGAUCCGAAUUUGUG MS00031262 
miR-146a-5p UGAGAACUGAAUUCCAUGGGUU MS00003535 
miR-155-5p 'UUAAUGCUAAUCGUGAUAGGGGU MS00031486 
miR-15a-5p UAGCAGCACAUAAUGGUUUGUG MS00003178 
miR-221-3p AGCUACAUUGUCUGCUGGGUUUC MS00003857 
miR-28-3p CACUAGAUUGUGAGCUCCUGGA MS00009254 
miR-363-3p AAUUGCACGGUAUCCAUCUGUA MS00009576 
miR-423-3p AGCUCGGUCUGAGGCCCCUCAGU MS00004179 
miR-423-5p UGAGGGGCAGAGAGCGAGACUUU MS00009681 
miR-486-5p UCCUGUACUGAGCUGCCCCGAG MS00004284 
miR-92a-3p UAUUGCACUUGUCCCGGCCUGU MS00006594 
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 Probes used for Northern Blots (NB) and Ago2-IP NB. 
The following oligo DNA probes were obtained from Eurofins Genomics for generating 
miRNA probes for Northern Blots.  
 
Oligo probe Sequences 
let-7c-5p TGAGGTAGTA GGTTGTATGG TTcctgtctc 
miR-101-3p TACAGTACTG TGATAACTGA Acctgtctc 
miR-142-3p TGTAGTGTTT CCTACTTTAT GGAcctgtctc 
miR-142-5p CATAAAGTAG AAAGCACTAC Tcctgtctc 
miR-21-5p TAGCTTATCAGACTGATGTTGAcctgtctc 
miR-221-3p AGCTACATTG TCTGCTGGGT TTCcctgtctc 
miR-222-3p AGCTACATCT GGCTACTGGGTcctgtctc 
miR-363-3p AATTGCACGG TATCCATCTG TAcctgtctc 
miR-423-5p TGAGGGGCAGAGAGCGAGACTTTcctgtctc 
miR-4485-3p TAACGGCCGCGGTACCCTAAcctgtctc 
miR-4792-5p CGGTGAGCGCTCGCTGGCcctgtctc 
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2.2 Methods 
 Cell culture 
The U2932, SUDHL5, U2932 (EBV positive), SUDHL5 (EBV positive) cell lines were 
maintained in RPMI 1640 medium at 37 ℃ in a 5% humidified CO2 incubator. RPMI 
1640 was supplemented with10% fetal calf serum, antibiotic mix (40 IU/mL penicillin, 
50 μg/mL streptomycin, 1 IU/mL Neomycin-sulfate, 90 IU/mL Nystatin). An additional 
200 mg/mL G418 (Geneticin) was used for EBV positive cell lines. 
 Cell counting (Hemocytometer) 
The Neubauer Improved C-Chip was used to count the number of cells. Depending 
on the cell density, a 1:5 or 1:50 dilution was made in PBS and 2 to 4 outer big squares 
were counted. 
Cell density (cells/mL) 
                 = ((No. of counted cells): (No. of large Squares)) x 104 x Dilution factor. 
 
 RNA related techniques 
 
 RNA isolation 
Suspension cells (5 to 10 mL) were harvested by centrifugation at 500 x g for 5 
minutes at room temperature (RT). 700 μL of Qiazol (Qiagen) was added to the pellet 
and incubated for 5 min at RT. Afterwards, 125 μL of chloroform was added to the 
sample and vortexed for 15 sec, and subsequently again incubated for 10 min at RT. 
the sample was then  centrifuged at 12000 xg for 15 min at 4 ℃ and  the upper phase 
was transferred to a new  1.5 mL microcentrifuge tubes and 500 μL of isopropanol 
was added to the tube and incubated on ice for 15 min, followed by centrifugation at 
12000 xg  for 30 min in 4 ℃ . After that, the pellet was air dried at RT for 15 min and 
dissolved in 50 μl of RNase free H2O and the RNA was dissolved by incubation at 55 
℃ for 15 min.  
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RNA isolation for sequencing, qRT –PCR and Ago2-IP for NB was performed using 
the miRNeasy Mini kit (Qiagen) according to manufacturer’s instructions. Briefly, 700 
μl of QIAzol was added to 100 μl of cell lysate or directly to the beads, after the last 
washing step with PBS (Ago2-IP and control-IP).Then the mixture was vortexed and 
incubated at room temperature for 5 min. Centrifugation was performed at 12000 xg 
for 15 min at 4°C. Then the upper aqueous phase transferred to a new collection tube. 
Subsequently, 1.5 volumes of 100% ethanol were added and mixed by pipetting up 
and down few times, and the mixture was loaded on the spin column in a 2 mL 
collection tube. Next, the samples were centrifuged at 12000 xg for 1 min the 
supernatant discarded and this step was repeated, until all the solutions were loaded 
on the column. The column was washed once with 700 μl RWT buffer and twice with 
500 μl RPE buffer. All centrifugations were performed at 12000 xg for 1 min, and finally 
the column was transferred to a new collection tube. The RNA was eluted in 30 μl of 
RNase-free water by centrifuging at 12000 xg for 2 min. Tumor specimens from 
DLBCL patients were extracted from snap-frozen tissues using TriZol instead of 
Qiazol, as described above. The concentrations of all extracted RNAs, were measured 
by NanoDrop, and samples were stored at -70 ℃. 
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 MiRNA microarray and data analysis  
 
MiRNA expression profiling of 1205 human miRNAs and 44 EBV miRNAs was 
performed in triplicate using the Agilent human miRNA microarray (release 16.0, 
Agilent, Cat. No, G4870A). Briefly, 100 ng of isolated RNA from total lysates or 
immunoprecipitates from U2932 or U2932-EBV cell line was dephosphorylated, 
labelled with pCp-Cy3 and hybridized to the microarray according to the 
manufacturer’s instructions. 
Microarray data analysis was performed as described (LUDWIG et al., 2015). In brief 
microarrays were scanned using the Agilent Microarray Scanner and expression 
values were extracted with the Agilent Feature extraction software. Raw data of 
cellular input and immunoprecipitate arrays was quantil normalized separately using 
R software. Unpaired two-sided t-tests were performed. For identification of 
significantly differentially expressed miRNAs between U2932E-EBV vs. U2932 cell 
lines for total lysates and immunoprecipitates, two-fold changes and P-values of <0.05 
were considered statistically significant. 
 
 MiRNA sequencing and processing of data 
Sequencing was performed by next generation sequencing(IKMB, University of Kiel) 
using total cellular lysate and purified RNA from U2932, SUDHL5 and the EBV positive 
counterpart using TruSeq small RNA Library Type on the HiSeq 2500 system from 
Illumina. The analysis of sequencing data was performed by Tobias Fehlmann under 
the guidance of Prof.Dr. Andreas Keller (Chair for Clinical Bioinformatics, Saarland 
University). Briefly, the miRMaster tools was used to remove the trimmed adaptors 
and to quality filter the reads (FEHLMANN et al., 2017). Then the Bowtie sequence 
alignment software was used to map with Genome Reference Consortium GRCh38 
(hg38) with one mismatch pairing allowed (LANGMEAD et al., 2009). Those reads 
which mapped with hg38 were used for human miRNA quantifications and those which 
are not mapped to human genome were used for EBV miRNA. miRBase (v21) 
(KOZOMARA, GRIFFITHS-JONES, 2014) and the miRMaster tools were used for 
mapping of miRNA for human and EBV miRNA. 
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 qRT-PCR 
Quantitative Real Time-PCR (qRT-PCR) was performed to validate the NGS data 
using the miScript II RT Kit and the miScript SYBR Green PCR Kit on the 
StepOnePlus™ Real-Time PCR System. 
 
 Reverse Transcription to generate cDNA for qRT-PCR 
 
The extracted RNA was converted to cDNA in the following reaction: 
 
The reaction mixture was incubated for 60 min at 37ºC, followed by 5 min at 95ºC to 
inactivate miScript Reverse Transcriptase. The reaction was diluted 1 to 10 in RNase-
free H2O, and the samples were stored at -20 ºC until further use. qRT-PCR reaction 
was performed in duplicate and miR-30d was used as an endogenous control as our 
NGS data showed no expression difference of human  miR-30d  between U2932 and 
SUDHL5 cell lines and the EBV positive counterparts in total  cell lysates or Ago2-IP 
miRNA profile. Fold change in EBV negative versus EBV infected DLBC cell lines was 
calculated by the following formula for cellular input and Ago2-IP: 
Fold change diffrence = 2^((miR-XEBVneg – miR-30dEBVneg)- (miR-XEBVpos – miR-30dEBVpos)) . 
To define if a miRNA was deregulated two criteria applied to our data:  
 
Components Volume 
5x miScript HiSpec Buffer 4 μL 
10x miScript Nucleic Mix 2 μL 
RNase free water 11μL 
miScript Reverse Transcriptase Mix 2 μL 
Template RNA 200 ng for total cellular and  
20 ng for Ago2 IP  RNA extract (1 μL) 
 40 
 
1) At least 2-fold expression difference between EBV negative and positive 
counterpart. 
2) qRT-PCR result in the same direction as in the sequencing results. 
 
The following cycling program was used for StepOne instrument: 
 
 
 
 
 
 
 
 
PCR Initial activation step 95 °C     15 min 
3-step cycling:   
 94 °C      15 s 
 55 °C      30 s                
 70 °C      30 s 
 
  
Components Volume  
cDNA-Template (1:10 diluted) 2 μL 
2x QuantiTect SYBR® Green PCR Master Mix 5 μL 
10x miScript Universal Primer 1 μL 
10x miScript Primer Assay 1 μL 
H20 RNase-free 1 μL 
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 Northern blot for the Analysis of the miRNA 
Northern blot is a technique used to detect a specific RNA in a sample. This technique 
was performed to compare and validate significantly deregulated miRNA from NGS 
and qRT-PCR data in total cellular lysate and Ago2-IP data. 
Equal amounts of extracted RNA from total cellular (15 -20 µg ) or Ago2-IP and isotype 
control (200 ng of purified RNA ), were mixed with 5 µl RNA loading buffer, and  loaded 
on a 12% urea polyacrylamide gel. The gel was run at 20W for 3 to 4 hours in 1X TBE 
buffer. To check the loading control and the quality of RNA, the gel was stained with 
ethidium bromide (10 µg in 100 mL 1X TBE) for 5 min and the RNAs were visualized 
at 254nm. The ethidium bromide picture was documented, using ChemiDoc XRS (Bio-
Rad). An equal amount of 1.5 µg RNA, from DLBCL and lymph nodes of patient 
samples was loaded for Northern blot. 
 
Composition of 12% of a Urea polyacrylamide gel 
Components Volume 
UreaGel 29:1 Concentrate  24 mL 
UreaGel Diluent  21 mL 
UreaGel Buffer 5 mL 
TEMED 20 µl 
APS 10% 400 µl 
 
 Transfer of RNA to a Membrane  
To transfer the RNA to a nylon membrane (Hybond N; Amersham), an electroblot 
transfer sandwich was set up as follows: five pre-wet Whatman papers with dH2O, 
nylon membrane, gel, five more pre-wet Whatman paper. Transfer was carried out at 
15V for 30 minutes, using a semi-dry chamber with transfer from anode to cathode.  
Following the transfer the membrane, on top of three Whatman papers, soaked in 
freshly prepared EDC crosslinking regent and then the NB membrane was wrapped 
in Saran-Wrap and incubated at 60 ℃ for 1 to 2 hours. Following crosslinking, the 
membrane was transferred to a glass tube and incubated with 30 mL pre-hybridization 
buffer with continued rotation at 50 C for 30 min. Then the 32 P-labeled miRNA probe 
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(see below) was added to the hybridization buffer, and incubated overnight with a 
continued rotation at 50 ℃, in an oven. The next day the membrane was washed two 
times with 5XSSC and two times with 1XSSC (each time about 20 min). The 
membrane was wrapped with Saran-Wrap and exposed to Phosphorimager, and the 
next day scanned with the Phosphorimager TM Typhoon. 
 
 Generating radiolabelled 32P RNA probe 
To generate radiolabelled 32P RNA probes a two-step procedure was used. First a 
double strand DNA template from a single stranded oligonucleotide which has a 
CCTGTCTC AT at 3´ end (complementary to T7 promoter sequence) was generated 
using the mirVANA TM kit. In second step the 32p RNA probe was generated from 
the double stranded template. 
Double strand DNA (dsDNA) template synthesis; 
a) The following components were incubated at 70 ℃ for 5 min and then at RT for 5 
min. 
Components Volume 
H2O 6μL 
T7-Promoter Primer (100μM) 2μL 
Oligonucleotide Template (100 μM) 2μL 
 
b) To complete the reaction, the following components were added and this mixture 
was incubated at 37 ℃ for 30 min. The prepared double strand DNA template for 
miRNA of interest was stored at -20 ℃ until use. 
Components Volume 
Nuclease-free H2O  4 µl 
10 x Klenow buffer  2  µl 
10 x dNTPs  2  µl 
Exo-Klenow 2 µl 
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2. Generation of 32P RNA probe at radioactive lab 
 
Components Volume 
Nuclease free H2O 7 µl 
dsDNA template 2  µl 
NTPs(without U) 3  µl 
10 x RNA polymerase buffer  2 µl 
T7-RNA polymerase  2  µl 
32P -labeled  UTP (radioactive) 5  µl 
 
After adding the above components, the mixture was put on continuous shaker 
(700RPM) for 10 min at 37 ℃ and then 1 µl of DNase I was added and again put on 
continuous shaker (700 RPM) for 10 min at 37 ℃, and finally as discussed the 
prepared probe was added to the glass tube containing hybridization buffer and cross-
linked NB membrane. 
 
 NB stripping  
To re-probe the NB membrane with a different 32p-labelled probe, the previous signal 
was removed using stripping buffer. The membrane was put into a glass tube and 
incubated with warmed stripping buffer, for one hour at 70C in the oven under 
continuous rotation. After removing the stripping buffer, the membrane was wrapped 
with a Saran-Wrap and exposed to the phosphor imager overnight (Phosphorimager 
TM Typhoon) to ensure that the previous signal was erased. 
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 Protein related techniques 
 Immunoprecipitation and immunoblotting of Ago2 – IP 
 
To perform the RISC associated miRNA profiling, the Ago2 Immunoprecipitation was 
carried out as described previously (DEMBLA et al., 2014; DOLKEN et al., 2010). The 
cell lines, either U2932 or SUDHL5 or the EBV positive counterparts were cultured, in 
large scale (400 to 500 mL) in RPMI1640, supplemented with 10% FCS and antibiotics 
(see material and methods). After counting the cells, about 3.5 X108 cells were used 
for each IP (3). Antibody coupling was performed one day before performing IP. For 
coupling, about 200 µL of Sepharose Protein G beads were washed 3 times with cold 
PBS buffer (at 500 xg for 3 min), and then at the last step the supernatant was 
removed and the pellet divided into two tubes. In each tube, about 100 µL of 
Sepharose Protein G beads was incubated overnight with 1.6 mL monoclonal 
antibody, Ago2 antibody 11A9 (rat IgG2a) or with isotype control (rat IgG2a) antibody, 
on vertical rotator at 4°C. The next day the beads were washed three times with PBS, 
and once with lysis buffer before incubating with lysate. For Ago2-IP, about 3.5 X 10 
8 cells from U2932, SUDHL5 and their EBV positive counterparts, were pelleted and 
washed three times with PBS (at 500 xg for 3 min). Then, 1.5 mL of lysis buffer were 
added to the pellet in 1.5 mL reaction tube, and incubated for 30 min on the vertical 
rotator at 4°C. Subsequently, the tube was centrifuged at 20,000 xg for 30 min at 4°C. 
Afterwards, to decrease the non-specific binding, the lysate was precleared with 100 
μL of protein G-Sepharose beads (washed 3 times in PBS) alone for 60 min at 4°C, 
using a vertical rotator. Next, samples were centrifuged at 20,000 xg for 5 min at 4°C. 
100 μL of the cleared lysate was removed for preparing total RNA, and 50 μL as a 
protein input. The remaining lysate was divided in two equal volumes for the Ago2-IP 
and the isotype control-IP experiment and the volumes were adjusted to 1 ml with lysis 
buffer. The coupled beads were incubated with the lysis buffer overnight on a vertical 
rotator at 4 °C. 
The next day, the beads were pellet down at 500 xg for 3 min at 4 ℃, and washed 
three times with wash buffer (50 mM Tris HCl, pH 7.4, 300 mM KCl, 1mM MgCl2, 0.5% 
IGEPAL) and once with PBS. 25 μL of each immunoprecipitated fraction was removed 
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and this sample was used to check the efficiency of Ago2 IP, by Western blot (GROSS 
et al., 2010) and the remaining beads was incubated with 700 μL Qiazol regent 
(Qiazol, Hilden, Germany ), followed by RNA extraction, using the miRNA easy kit.  
 
 SDS-PAGE  
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), is used to 
separate proteins according to the molecular mass, under denaturing conditions. 
SDS-PAGE was performed as described by Laemmli, 1970; Sambrook et al., 1989. 
Before loading the samples, either the lysate or immunoprecipitated fractions from 
different cell lines were diluted in 4X SDS loading buffer and heated for 6 min at 94℃. 
Three µl of molecular mass marker proteins were also separated on the gel. SDS-
PAGE was carried out at 80V (stacking gel) and 125 V (separating gel), for about 3.5 
hours. 
 
 Western Blot 
Following SDS-PAGE, the proteins were transferred to a nitrocellulose membrane by 
electrophoresis, at 400 mA for 3 hours at 4℃. After blotting, the membrane was 
stained with Ponceau S, to ensure that the transfer was carried out properly. The 
membrane was destained with PBS for 15 min under agitation and then blocked with 
5% nonfat dry milk in PBS for 75 min under agitation at room temperature. 
Subsequently, the membrane was incubated with the indicated primary antibody, 
overnight at 4 °C. The membrane was washed 3 times with PBS, for about one hour, 
and then incubated with appropriate secondary antibody(conjugated with horseradish 
peroxidase), in blocking reagent (5% milk in PBS) for 2 hour under agitation at 4 °C. 
The membrane was washed 3 times with PBS for about one hour at room temperature. 
Finally, the membrane was developed using ECL (see Material and Methods part) and 
documented with the Bio-Rad Gel-Doc apparatus, using the Quantity One (Bio-Rad) 
software.  
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3 Results 
Here we tested (i) the miRNA profiles of the DLBCL cell lines U2932 and SUDHL5 
and their EBV-converted counterparts U2932-EBV and SUDHL5-EBV , (ii) the miRNA 
profiles of the Ago2-complex of four cell lines, and(iii) whether the EBV-infection would 
alter the loading of the Ago2-complex. Previous work had shown that the overall 
miRNA profiling of a cell line did not necessarily reflect the function of a given miRNA 
as the Ago-loading might be very different from its overall content in the cell (FLORES 
et al., 2014). 
In the following, we refer to the sequencing of cellular miRNA as “Total” and to the 
miRNA obtained from the Argonaute 2 immunoprecipitation as “Ago2-IP”. 
 
3.1 Characterizations of cell lines 
The type of EBV latency was determined by Western blot with antibodies against 
EBNA1, LMP and EBNA2, using U2932-EBV and SUDHL5-EBV cellular extracts. As 
shown in Figure 6, SUDHL5-EBV has the characteristics of type III EBV-latency as it 
expresses EBNA1, LMP and high amounts of EBNA2. In contrast, U2932-EBV clone 
A has the characteristics of type II latency, as it express EBNA1 and LMP1 but low 
amounts of EBNA2. 
 
 
Figure 6: EBV latency in U2932-
EBV and SUDHL5-EBV cells. 
Extract of the U2932-EBV and SUDHL5-
EBV cell lines was assayed by 
immunoblotting using antibodies against 
EBNA1, LMP and EBNA2 .The EBNA2 
blot was restained with GAPDH antibody 
as a loading control. 
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3.2 Microarray results 
The isolated RNA from the Ago2-IP in U2932 and U2932-EBV, was analyzed by 
microarray. In addition, the RNA was isolated from the total cellular lysate to determine 
the miRNA profile prior to precipitation. Two replicates of the total cellular fraction 
failed the array quality control and were therefore excluded (marked as None 
Applicable (NA) from the study. the summary of the microarray data is shown in Table 
2. We detected 206 miRNAs in U2932-EBV, and 170 miRNAs in the U2932 cell line. 
Of the total cellular miRNAs, detectable in both cell lines, nine were significantly 
upregulated (≥2) and 14 were significantly downregulated (≤2), in U2932-EBV 
compared to the U2932, respectively. Data are presented in Table 3 with the 
expression level taken into account. In the Ago2-IP, 386 miRNAs were detected in the 
U2932-EBV, and 395 in the U2932 cell line. In comparison with the Ago2-IP profile of 
U2932-EBV vs. U2932, 15 miRNAs were upregulated, while 169 miRNAs were 
downregulated. A complete list of up and downregulated miRNAs is shown in the 
appendix (Table A9).  
 
Table 2: Summary of miRNAs detected by microarray, in “Total” and “Ago2-IP” 
profile in U2932-EBV and U2932. 
No. of miRNAs Replicate1 Replicate 2 Replicate 3 Replicate 4 Mean St dev. Summary 
Total cellular 
profile U2932-
EBV 
219 219 208 NA 215.33 6.35 206 
Total cellular 
profile U293 
182 190 163 NA 178.33 13.87 170 
Ago2_IP 
U2932-EBV 
413 408 388 392 400.25 12.12 386 
Ago2_IP 
U2932 
417 409 397 408 407.75 8.22 395 
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Table 3: Top 10 up regulated miRNAs and top 14 down regulated 
miRNAs in U2932-EBV vs. U2932 measured by microarray. 
Total cellular miRNAs profile Ago2-IP miRNAs profile 
miR-551b 7.08 miR-551b 8.85 
miR-630 2.77 miR-137 6.89 
miR-363 2.58 miR-363 6.53 
miR-130a 2.45 miR-494 6.37 
miR-15a 2.24 miR-449a 5.08 
miR-574-5p 2.23 miR-130a 4.77 
miR-1268 2.21 miR-630 3.48 
miR-222 2.14 miR-3651 2.87 
miR-335 2.06 miR-10a 2.75 
  miR-718 2.67 
    
    
miR-140-5p -2.02 miR-148a* -5.69 
miR-25 -2.05 miR-199b-5p -5.85 
miR-374a -2.10 miR-1180 -6.19 
miR-3174 -2.12 miR-193a-3p -6.25 
miR-193b -2.14 miR-126 -6.44 
miR-134 -2.22 miR-624* -6.45 
miR-24 -2.30 miR-345 -6.48 
miR-148a -2.35 miR-1260 -7.17 
miR-21* -2.38 miR-1260b -7.32 
miR-125a-3p -2.45 miR-1274b -8.48 
miR-3656 -2.47 miR-720 -10.62 
miR-342-3p -2.58 miR-340* -12.56 
miR-642b -2.68 miR-1274a -12.75 
miR-4327 -2.79 miR-340 -75.41 
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3.3 Sequencing results 
In order to investigate the miRNAs that were differentially associated with Ago2-
complex, in comparison to the total cellular miRNA profile, and to determine whether 
EBV infection changes the loading of miRNA in the RISC complex, we performed 
Ago2 immunoprecipitation (Ago2-IP), in extracts from the uninfected DLBCL cell lines 
(U2932, SUDHL5) and their EBV infected counterparts (U2932-EBV, SUDHL5-EBV). 
The RNAs from the Ago2-IPs and from the total cellular extracts were subjected to 
next generation sequencing (NGS).  
The specificity of the Ago2-IPs was determined from an aliquot of the precipitate, 
before the RNA was subjected to sequencing. As shown in Figure 7, the Western blot 
of the Ago2-IP demonstrated that the Ago2 protein was successfully precipitated from 
all four cell lines, and that the controls did not contain Ago2-protein 
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Figure 7: Immunoprecipitation of Ago2 from U2932, SUDHL5 and their EBV 
positive counterparts. 
Extract of the indicated cell lines was precipitated with Ago2 specific antibody (11A9) and 
an appropriate isotype control antibody. The membrane was first stained with Ago2 and 
then with mouse-anti rat IgG coupled to horseradish peroxidase as a secondary antibody. 
The precipitated Ago2-protein was visualized by the ECL method. The molecular mass 
marker proteins (in kDa) and the position of Ago2 are indicated by bars to the left side of 
the blot. 
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The overall results from the total cellular profiling and the Ago2-IP are shown in Table 
4. We obtained about 8.7-15.3 x106 reads, corresponding to 12 to 23% of total reads 
that matched to miRBase. The total cellular miRNA profiling yielded 700-850 
annotated miRNAs from the four cell lines. The Ago2-IP sequencing resulted in about 
28-55 x106 reads, corresponding to 78.82-68.25% of all reads. The Ago2-IP miRNA 
profiling, yielded 1102 to 1372 miRNAs, annotated in miRBase. Thus, the total number 
of reads for known human miRNA reads, increased about 10 times, as compared to 
the total cellular profile, indicating that the Ago2-IP strongly enriched the miRNAs, 
proving the specificity of the procedure.  
  
 
It has been suggested that only miRNAs which represent more than 0.1% of the total 
reads are functional (FLORES et al., 2014; MULLOKANDOV et al., 2012). For this 
reason, a 0.1% cut-off was applied for further analysis in all cell lines for selection of 
functionally relevant miRNAs. This means that in our analysis, only a miRNA with at 
least an expression of 0.1% of the total reads in one of the cell line was taken into 
account.  
At the 0.1% cut-off level, only 61 to 62 of human miRNA remained in the total cellular 
miRNA profile of U2932 and U2932-EBV cells; however, these corresponded to 96.4% 
to 94.4% of total annotated miRNA reads, respectively. In SUDHL5 and SUDHL5-
EBV, 59 to 58 of human miRNA were detected in the total cellular lysate, representing 
Table 4: Overview of sequencing reads in “Total” and “Ago2-IP” obtained 
from U2932 and SUDHL5 and their EBV positive counterparts. 
 Cell line Total reads Total reads match 
with miRBase 
% of match 
reads 
Detected 
miRNA 
To
ta
l 
U2932-EBV  10423487 1,815,328 17.42 851 
U2932 8752305 2,076,239 23.72 758 
SUDHL5-EBV 11470056 2,019,181 17.60 763 
SUDHL5  15322853 1,944,300 12.69 713 
A
go
2
_I
P
 U2932 -EBV + 55928169 38,168,544 68.25 1372 
U2932 42384180 26,494,508 62.51 1185 
SUDHL5-EBV 34811526 27,005,099 77.58 1141 
SUDHL5  28245506 22,264,473 78.82 1102 
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73.3% and 97.0% of detected miRNAs, respectively. At the 0.1% cut-off level in the 
Ago2-profile 51 to 66 of human miRNA were detected in U2932-EBV and U2932, 
corresponding to 94.8% to 97.0% of the total miRNAs, respectively. In SUDHL5-EBV 
and SUDHL5, 50 to 54 human miRNA were detected in the Ago2-IP, representing 
68.6% and 97.2% of miRNA reads, respectively.  
The presence of EBV miRNA was also analyzed in the total cellular and the Ago2-IP 
miRNA profile. In U2932-EBV cells, six EBV-miRNAs (1.3% of all reads), and in 
SUDHL5-EBV cells, 26 EBV-miRNAs (23.4% of total reads), remained above 0.1% 
cut-off level, whereas in the  Ago2-IP profiling of  U2932-EBV cell line, 6 EBV (1.6% 
of total miRNA reads) and the SUDHL5-EBV cell line, 23 EBV miRNAs (28.2% of total 
reads) were present above the 0.1% cut-off level (Table 5). 
Table 5: MiRNA reads in “Total” and “Ago2-IP” at 0.1% cut-off. 
 Cell line Human  
miRNA 
EBV  
miRNA 
% of Human 
 miRNA 
% of EBV  
miRNA 
To
ta
l 
U2932 -EBV  62 6 94.4% 1.3% 
U2932  61 - 96.4% - 
SUDHL5-EBV  58 26 73.3% 23.4% 
SUDHL5  59 - 97.0%  
A
go
2
_I
P
 U2932-EBV 51 6 94.8% 1.6% 
U2932  57 - 97.0% - 
SUDHL5-EBV 50 23 68.6% 28.2% 
SUDHL5  54 - 97.2% - 
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3.4 Highly expressed miRNAs in U2932 and SUDHL5 and their 
EBV-positive counterparts 
There is an inverse relation between the expression level of a miRNA and its inhibitory 
potential for a specific mRNA target, and a crucial role for Ago2 protein in the RISC 
silencing complex (LEUNG et al., 2011; LIU et al., 2016). Therefore, we analyzed the 
expression of the most abundant miRNAs in the total cellular and Ago2-IP miRNA 
profiles in each cell line, separately, at the 0.1% cut-off level. The top 20 miRNAs in 
the total cellular and the Ago2-IP profile are listed in descending order in Table 6 and 
Table 7. These miRNAs comprised about 74 to 85% of all identified miRNA reads in 
the four DLBCL cell lines. For instance, in the total cellular profiles, miR-92a-3p and 
miR-191-5p were among the most abundant miRNAs in the U2932 cell lines and miR-
21-5p and miR-142-5p were, among the most highly expressed miRNA in the 
SUDHL5 cell lines. 
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Table 6 : Top 20 miRNAs in U2932 and SUDHL5 and their EBV positive counterparts  
in “Total” profile at 0.1% cut-off. EBV miRNAs are underlined. 
% of relative expression of total miRNA pool 
U2932 SUDHL5 
miRNA  EBV + miRNA EBV - miRNA EBV + miRNA  EBV - 
miR-92a-3p 16.783 miR-92a-3p 17.205 miR-21-5p 14.164 miR-142-5p 28.391 
miR-191-5p 9.169 miR-191-5p 11.556 miR-142-5p 6.891 miR-21-5p 10.992 
miR-181a-5p 7.785 miR-148a-3p 8.417 miR-BHRF1-1 5.971 miR-181a-5p 5.613 
miR-146a-5p 5.849 miR-181a-5p 7.073 miR-148a-3p 5.807 miR-26a-5p 5.057 
miR-148a-3p 5.704 let-7a-5p 4.559 miR-191-5p 4.947 miR-191-5p 4.122 
miR-142-5p 5.213 miR-26a-5p 4.159 miR-181a-5p 3.619 miR-16-5p 3.588 
miR-16-5p 3.929 miR-142-5p 3.854 miR-16-5p 3.321 miR-30d-5p 3.031 
let-7f-5p 3.555 let-7f-5p 3.787 miR-BART10-3p 3.254 miR-92a-3p 3.013 
let-7a-5p 3.472 miR-146a-5p 3.380 miR-22-3p 3.158 let-7a-5p 2.848 
miR-30d-5p 3.379 miR-16-5p 3.123 miR-30d-5p 3.060 miR-22-3p 2.781 
miR-26a-5p 2.887 miR-30d-5p 2.736 miR-BART8-5p 2.975 let-7f-5p 2.746 
miR-21-5p 2.551 miR-182-5p 2.566 let-7a-5p 2.587 miR-148a-3p 2.681 
miR-27b-3p 1.753 miR-30e-5p 1.728 let-7f-5p 2.587 miR-142-3p 2.657 
miR-19b-3p 1.744 miR-20a-5p 1.666 miR-26a-5p 2.549 miR-30e-5p 1.960 
miR-182-5p 1.609 miR-27b-3p 1.625 miR-92a-3p 2.364 miR-28-3p 1.466 
miR-155-5p 1.339 miR-192-5p 1.623 miR-30e-5p 1.862 miR-4792 1.349 
miR-192-5p 1.300 miR-21-5p 1.331 miR-182-5p 1.550 miR-21-3p 1.106 
miR-20a-5p 1.157 let-7g-5p 1.322 miR-BART7-5p 1.367 miR-192-5p 0.881 
miR-30e-5p 1.139 miR-186-5p 1.048 miR-BART19-5p 1.267 let-7g-5p 0.776 
miR-186-5p 0.879 miR-22-3p 0.860 miR-146b-5p 1.188 miR-4485-3p 0.709 
Total sum 
in percent 
81.196  83.618  74.488  85.767 
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In the Ago2-IP-profiles, miR-92a-3p, miR-181a-5p, miR-146a-5p, and miR-148a-3 
had the highest abundance in the U2932 cell lines and miR-21-5p, miR-142-5p, miR-
92a-3p and miR-181a-5p were the most abundant human miRNAs in the SUDHL5 
lines. 
Table 7: Top 20 miRNAs in U2932 and SUDHL5 and their EBV positive 
counterparts in “Ago2-IP” profile at 0.1% cut-off. EBV miRNAs are underlined. 
% of relative expression of Ago2-IP miRNA pool  
U2932 SUDHL5 
miRNA  EBV + miRNA EBV - miRNA EBV + miRNA  EBV - 
miR-92a-3p 26.551 miR-92a-3p 23.235 miR-21-5p 
16.15
1 miR-21-5p 14.373 
miR-181a-5p 10.446 miR-181a-5p 9.224 miR-BHRF1-1 7.030 miR-142-5p 13.376 
miR-146a-5p 10.051 miR-148a-3p 7.232 miR-92a-3p 4.881 miR-181a-5p 8.794 
miR-191-5p 5.372 miR-146a-5p 7.106 miR-148a-3p 4.216 miR-92a-3p 7.077 
miR-16-5p 4.615 miR-191-5p 6.580 miR-BART8-5p 4.154 miR-26a-5p 6.298 
miR-148a-3p 4.096 miR-26a-5p 4.317 miR-181a-5p 4.149 miR-16-5p 5.130 
miR-30d-5p 3.184 miR-16-5p 3.565 miR-22-3p 3.862 miR-22-3p 4.762 
miR-26a-5p 3.124 miR-182-5p 3.089 miR-142-5p 3.435 miR-191-5p 3.399 
let-7f-5p 2.665 miR-30d-5p 3.074 miR-16-5p 3.231 let-7f-5p 3.294 
miR-21-5p 2.581 let-7f-5p 2.949 miR-BART6-3p 3.143 miR-28-3p 3.260 
miR-142-5p 2.074 let-7a-5p 2.257 miR-191-5p 2.883 miR-30d-5p 3.027 
miR-182-5p 1.966 miR-21-5p 1.956 miR-30d-5p 2.617 miR-148a-3p 2.644 
miR-27b-3p 1.916 miR-142-5p 1.939 let-7f-5p 2.566 miR-423-5p 1.639 
miR-155-5p 1.311 miR-27b-3p 1.707 miR-BART10-3p 2.498 miR-30e-5p 1.612 
let-7a-5p 1.153 miR-30e-5p 1.502 miR-26a-5p 2.210 miR-142-3p 1.501 
miR-192-5p 1.080 miR-192-5p 1.470 miR-BART11-3p 1.950 let-7a-5p 1.437 
miR-186-5p 0.865 miR-22-3p 1.289 miR-BART19-5p 1.889 miR-146a-5p 1.258 
miR-30e-5p 0.804 miR-186-5p 1.275 miR-182-5p 1.827 miR-192-5p 1.018 
miR-378a-3p 0.790 miR-378a-3p 0.852 miR-28-3p 1.728 miR-186-5p 0.944 
miR-22-3p 0.756 miR-19b-3p 0.750 miR-BART7-5p 1.677 miR-27b-3p 0.892 
Total sum 
in percent 
85.400  85.368  76.097  85.735 
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3.5 Comparative analysis of up and down regulated miRNAs in 
EBV infected cell line to EBV negative DLBCL cell lines in total 
cellular and Ago2-IP 
EBV encodes 44 mature miRNAs, and the EBV-infection might change the total 
cellular miRNA profile. Therefore it could also influence the loading of the Ago2-
complex with human miRNAs. Accordingly, the fold changes of human miRNAs were 
analyzed and compared, between EBV-infected and their non-infected counterparts. 
For the sake of this comparison, we again considered only miRNAs above the 0.1% 
cut-off level, for functionally relevant miRNAs. The top 10 induced and reduced 
miRNAs, due to EBV infection in total cellular profile are shown in Table 8, and the 
complete lists can be found in the appendix (Tabel A5). 
 
Table 8: Comparison of miRNA profiles in EBV+ vs. EBV- in “Total” profile in 
 U2932 and SUDHL5 at 0.1% cut-off. 
U293. Total SUDHL5 Total 
miRNA  EBV + EBV - 
 Ratio  
EBV +/ - miRNA  EBV + EBV - 
Ratio 
 EBV +/ - 
miR-4485-3p 0.276 0.062 4.432 miR-182-5p 1.55 0.419 3.699 
miR-221-3p 0.21 0.056 3.767 miR-146b-5p 1.188 0.367 3.235 
miR-222-3p 0.122 0.037 3.332 miR-10a-5p 0.155 0.061 2.561 
miR-193b-3p 0.104 0.034 3.087 miR-148a-3p 5.807 2.681 2.166 
miR-18a-5p 0.103 0.035 2.985 miR-148a-5p 0.184 0.103 1.793 
miR-1246 0.151 0.051 2.976 miR-146a-5p 0.799 0.477 1.674 
miR-15a-5p 0.255 0.091 2.787 miR-27a-3p 0.153 0.097 1.579 
miR-155-5p 1.339 0.503 2.663 miR-155-5p 0.219 0.163 1.341 
miR-19b-3p 1.744 0.664 2.626 miR-486-5p 0.403 0.302 1.335 
miR-19a-3p 0.276 0.113 2.454 miR-21-5p 14.164 10.992 1.289 
        
miR-22-3p 0.49 0.86 0.57 miR-28-3p 0.877 1.466 0.598 
miR-210-3p 0.058 0.108 0.537 miR-181b-5p 0.102 0.172 0.592 
miR-30c-5p 0.224 0.422 0.53 miR-181a-3p 0.108 0.197 0.547 
miR-1260b 0.062 0.127 0.488 miR-26a-5p 2.549 5.057 0.504 
miR-1260a 0.061 0.126 0.486 miR-28-5p 0.137 0.277 0.494 
miR-339-3p 0.064 0.142 0.454 miR-4532 0.054 0.138 0.392 
miR-146b-5p 0.073 0.163 0.448 miR-142-5p 6.891 28.391 0.243 
miR-92b-3p 0.049 0.125 0.389 miR-1246 0.069 0.339 0.205 
miR-27a-3p 0.032 0.177 0.179 miR-142-3p 0.468 2.657 0.176 
let-7c-5p 0.024 0.245 0.097 miR-4792 0.095 1.349 0.07 
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In the total cellular profile of U2932-EBV, miR-4485-3p, -221-3p and -222-3p were 
found to be the most strongly induced, while miR-182-5p,-146-5p and -10a-5p had the 
highest induction in SUDHL5-EBV. In contrast, let-7c-5p and miR-27a-3p were most 
strongly reduced in U2932-EBV, and miR-4792 and miR142-3p had the strongest 
reduction in the total cellular miRNA profile in SUDHL5-EBV.  
A comparison of the Ago2-IP in EBV positive versus EBV negative cells are shown in 
Table 9, for the top 10 induced and reduced miRNA, and the complete lists can be  
found in the appendix (Tabel A6). MiRNAs such as miR-15a-5p, -221-3p and- 155-5p 
had the strongest relative presence in the Ago2-complex of 2932-EBV, compared to 
U2932. MiR-363-3p,-182-5p had the strongest induction in SUDHL5-EBV, compared 
to SUDHL5 while miR-let-7c-5p and -27a-3p showed the strongest reduction in 
U2932-EBV as compared to U2932 . MiR-142-3p and -5p were the most strongly 
depleted from the Ago2-complex in SUDHL5-EBV compared to SUDHL5. 
  
 58 
 
Table 9: Comparison of “Ago2-IP”profile in EBV-positive vs. non-infected 
cell lines vs. “Total” profile at 0.1% cut-off. 
U2932 Ago2-IP SUDHL5 Ago2-IP 
miRNA  EBV + EBV - 
 Ratio  
EBV +/- miRNA  EBV + EBV - 
 Ratio  
EBV +/ - 
miR-15a-5p 0.276 0.109 2.539 miR-363-3p 0.105 0.017 6.046 
miR-221-3p 0.114 0.045 2.538 miR-182-5p 1.827 0.667 2.739 
miR-155-5p 1.311 0.730 1.795 miR-146b-5p 0.988 0.472 2.095 
miR-130b-3p 0.145 0.082 1.759 miR-10a-5p 0.189 0.097 1.956 
miR-423-5p 0.738 0.442 1.671 miR-148a-3p 4.216 2.644 1.595 
miR-9-5p 0.286 0.200 1.430 miR-148a-5p 0.126 0.085 1.476 
miR-146a-5p 10.051 7.106 1.414 miR-27a-3p 0.130 0.097 1.336 
miR-181b-5p 0.504 0.368 1.369 miR-21-5p 16.151 14.373 1.124 
miR-21-5p 2.581 1.956 1.320 miR-146a-5p 1.381 1.258 1.098 
miR-16-5p 4.615 3.565 1.294 miR-155-5p 0.338 0.310 1.091 
        
        
miR-25-3p 0.373 0.678 0.550 miR-15a-5p 0.093 0.187 0.501 
miR-183-5p 0.117 0.214 0.547 miR-181b-5p 0.191 0.383 0.498 
let-7b-5p 0.064 0.119 0.542 miR-151a-5p 0.304 0.625 0.486 
miR-339-3p 0.080 0.149 0.536 miR-181a-5p 4.149 8.794 0.472 
miR-30e-5p 0.804 1.502 0.535 miR-186-5p 0.443 0.944 0.469 
let-7a-5p 1.153 2.257 0.511 miR-28-5p 0.189 0.515 0.366 
miR-30c-5p 0.139 0.291 0.480 miR-26a-5p 2.210 6.298 0.351 
miR-146b-5p 0.090 0.191 0.468 miR-486-5p 0.036 0.124 0.292 
miR-27a-3p 0.031 0.143 0.215 miR-142-5p 3.435 13.376 0.257 
let-7c-5p 0.013 0.115 0.116 miR-142-3p 0.219 1.501 0.146 
 
3.6 Differential RISC associated of human and EBV miRNAs in 
comparison to cellular miRNA profile 
As mentioned, the Cullen group challenged the notion that the total cellular miRNA 
profile is a realistic functional indicator of the association of a miRNA with the RISC 
complex. They found a discrepancy in various miRNAs in the Ago2-IP profiling as 
compared to the total cellular profile (FLORES et al., 2014). Accordingly, we also 
analyzed the relative enrichment or depletion of human Ago-bound miRNAs, versus 
the total cellular miRNA profile at 0.1% cut-off for each of the four DLBCL cell lines, 
separately. The top 10 enriched or depleted human miRNAs in Ago2-complex are 
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shown in Table 10, for U2932 and its EBV positive counterpart, and in Table 11 for 
SUDHL5 and its EBV positive counterpart. For instance, miR-423-5p and -5p were 
enriched 2.5-8 fold in Ago2-IP in comparison to the total cellular miRNA profile in the 
four cell lines.  
 
 
 
Table 10:List of miRNAs enriched or depleted from the “Ago2-IP”as compared 
to the “Total” profile in U2932-EBV and U2932 at 0.1% cut-off.  
U2932-EBV U2932 
miRNA 
% of total  
miRNA pool 
% of RISC 
assoc. pool 
RISC   
enriched miRNA 
% of total 
 miRNA pool 
% of RISC  
assoc. pool 
RISC  
enriched 
miR-423-5p 0.217 0.738 3.407 miR-320a 0.064 0.151 2.345 
miR-423-3p 0.233 0.516 2.22 miR-423-5p 0.195 0.442 2.267 
miR-146a-5p 5.849 10.051 1.718 miR-146a-5p 3.38 7.106 2.103 
miR-92a-3p 16.783 26.551 1.582 miR-425-5p 0.333 0.544 1.635 
miR-22-3p 0.49 0.756 1.542 miR-22-3p 0.86 1.289 1.498 
miR-181b-5p 0.334 0.504 1.512 miR-21-5p 1.331 1.956 1.469 
miR-425-5p 0.338 0.484 1.434 miR-155-5p 0.503 0.73 1.452 
miR-181a-5p 7.785 10.446 1.342 let-7i-5p 0.34 0.478 1.407 
miR-28-3p 0.338 0.454 1.342 miR-423-3p 0.313 0.429 1.369 
miR-182-5p 1.609 1.966 1.222 miR-28-3p 0.508 0.695 1.367 
        
        
miR-30b-5p 0.377 0.129 0.343 miR-142-5p 3.854 1.939 0.503 
miR-18a-5p 0.103 0.035 0.342 let-7a-5p 4.559 2.257 0.495 
miR-98-5p 0.399 0.134 0.336 let-7c-5p 0.245 0.115 0.47 
let-7a-5p 3.472 1.153 0.332 let-7g-5p 1.322 0.595 0.45 
miR-20a-5p 1.157 0.355 0.307 miR-98-5p 0.566 0.231 0.408 
miR-19b-3p 1.744 0.505 0.29 miR-20a-5p 1.666 0.54 0.324 
miR-486-5p 0.425 0.033 0.077 miR-486-5p 0.199 0.03 0.15 
miR-4485-3p 0.276 0.004 0.013 miR-4792 0.384 0.003 0.008 
miR-1246 0.151 0.001 0.003 miR-1260b 0.127 0.0005 0.004 
miR-4792 0.287 0.001 0.003 miR-1260a 0.126 0.0004 0.003 
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MiR-4792, -1246 and -4485-3p in U2932-EBV and miR-1260a ,-1260b and -4792 in 
U2932 were identified to be strongly depleted more than 69 fold in the RISC complex, 
as compared to the total cellular miRNA profile. 
In SUDHL5-EBV, miR-486-5p, -260a, -260b,-and -4485-3p were the most strongly 
depleted miRNAs from Ago2-complex, whereas miR-4532, -1260a and -4792 were 
depleted about 78 to 3000 fold, from the Ago2-complex in SUDHL5. 
Table 11: List of miRNAs enriched or depleted in the “Ago2-IP”as compared to the 
“Total” profile in SUDHL5–EBV and SUDHL5 at 0.1 % cut –off. 
SUDHL5-EBV SUDHL5  
miRNA  
% of total 
miRNA 
pool 
% of RISC  
assoc. 
pool 
RISC  
enriched miRNA  
 % of total 
miRNA  
pool 
% of 
RISC 
assoc. 
pool 
RISC 
enriched 
miR-423-5p 0.134 0.936 6.989 miR-423-5p 0.188 1.639 8.721 
miR-423-3p 0.175 0.496 2.834 miR-423-3p 0.254 0.785 3.087 
miR-92a-3p 2.364 4.881 2.064 miR-146a-5p 0.477 1.258 2.636 
miR-28-3p 0.877 1.728 1.972 miR-92a-3p 3.013 7.077 2.349 
let-7i-5p 0.2 0.377 1.886 let-7i-5p 0.283 0.662 2.337 
miR-181b-5p 0.102 0.191 1.873 miR-181b-5p 0.172 0.383 2.225 
miR-146a-5p 0.799 1.381 1.729 miR-28-3p 1.466 3.26 2.224 
miR-155-5p 0.219 0.338 1.547 miR-106b-3p 0.082 0.159 1.932 
miR-28-5p 0.137 0.189 1.381 miR-155-5p 0.163 0.31 1.901 
miR-425-5p 0.108 0.143 1.323 miR-425-5p 0.095 0.179 1.879 
        
        
miR-142-5p 6.891 3.435 0.498 miR-486-5p 0.302 0.124 0.409 
miR-142-3p 0.468 0.219 0.468 miR-30b-5p 0.378 0.153 0.405 
let-7a-5p 2.587 1.06 0.41 miR-20a-5p 0.334 0.118 0.352 
miR-30b-5p 0.332 0.133 0.4 miR-98-5p 0.229 0.081 0.351 
miR-98-5p 0.26 0.077 0.295 miR-4485-3p 0.709 0.009 0.013 
miR-20a-5p 0.302 0.084 0.278 miR-1246 0.339 0.001 0.002 
miR-486-5p 0.403 0.036 0.089 miR-1260b 0.117 0.00012 0.001 
miR-4485-3p 0.517 0.004 0.009 miR-4792 1.349 0.001 0.001 
miR-1260b 0.107 0.0003 0.003 miR-1260a 0.117 0.00009 0.001 
miR-1260a 0.107 0.0002 0.002 miR-4532 0.138 0.00004 0.0003 
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3.7  Presence of EBV miRNAs in the Ago2-containing RISC 
complex. 
We analyzed the presence and abundance of EBV miRNAs in the total cellular fraction 
and the Ago2-miRNA profile in the EBV-infected cell lines. As shown in Table 12, the 
overall amount and the presence of virus-encoded miRNAs varied between the two 
cell lines. As already pointed out, the virus contributed only about 1.3% to the total 
amount of miRNAs in U2932-EBV, while 23.4% of the total miRNA reads were derived 
from the virus in SUDHL5-EBV. In U2932-EBV, EBV-miR-BART10-3p constituted only 
0.43%, and BART8-5p, 0.29% of the total counts. In SUDHL5-EBV, the viral miRNAs 
EBV-miR-BHRF1-1, -BART10-3p and -BART8-5p contributed to 5.97%, 3.25% and 
2.97% of the total miRNA reads, respectively. 
In the Ago2-profiling of the U2932-EBV cell line, EBV-miR-BART8-5p, -BART11-3p 
and -BART6-3p were the most abundant viral miRNAs, with 0.42%, 0.33% and 0.31% 
abundance, respectively. In the SUDHL5-EBV, BHRF1-1, BART8-5p and BART6-3p 
were the most abundant EBV miRNAs in total cellular profile, with 7.02%, 4.15% and 
3.14% abundance, respectively. The most abundant EBV miRNAs in total cellular 
profile were found to be same in the Ago2-complex, while BHRF1-1, BART10-3p and 
BART8-5p were the most abundant miRNA in total cellular profile in SUDHL5 (see 
below). 
 
Table 12: EBV miRNAs in the “Total” and the “Ago2-IP” profile in U2932-EBV 
and SUDHL5-EBV. 
U2932 SUDHL5 
miRNA Total  miRNA Ago miRNA Total miRNA Ago2 
rel. expr. 
% 
rel. expr. 
% 
rel. expr. 
% 
rel. expr. 
% 
BART10-3p 0.4365 BART8-5p 0.42474 BHRF1-1 5.971 BHRF1-1 7.0296 
BART8-5p 0.2964 BART11-3p 0.33851 BART10-3p 3.2542 BART8-5p 4.1537 
BART6-3p 0.1967 BART6-3p 0.31849 BART8-5p 2.9754 BART6-3p 3.1426 
BART11-3p 0.1582 BART10-3p 0.24271 BART7-5p 1.3665 BART10-3p 2.4979 
BART22 0.1281 BART19-5p 0.18918 BART19-5p 1.2667 BART11-3p 1.9503 
BART7-5p 0.1138 BART7-5p 0.13593 BART11-3p 1.1298 BART19-5p 1.889 
    BART6-3p 1.0978 BART7-5p 1.6766 
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The enrichment of EBV miRNAs in the Ago2-complex, in comparison to the total 
cellular profile, was determined. As shown in Table 13, miR-BART11-3p and miR-
BART19-5p were enriched more than 2- fold in U2932-EBV, while miR-BART10-3p 
was depleted from the Ago2-complex by 1.8-fold, as compared to the total cellular 
profile. In SUDHL5-EBV, miR-BART6-3p and miR-BART11-3p were strongly 
enriched, by 2.8 and 1.7 fold, respectively, while EBV-miR-BART5-5p and -BART1-
3p were depleted, below the 0.1% cut-off. 
 
Table 13: List of EBV-miRNA enriched or depleted in the “Ago2-IP”compared to 
“Total” profile in U2932-EBV positive and SUDHL5-EBV at 0.1 % cut-off. 
U2932-EBV SUDHL5-EBV 
EBV miRNA 
% Total 
miRNA 
pool 
% RISC 
assoc. 
pool 
RISC 
enriched 
 fold 
change EBV miRNA 
% Total 
miRNA 
pool 
% RISC 
assoc. 
pool 
RISC 
enriched 
 fold 
change 
miR-BART11-3p 0.158 0.339 2.140 miR-BART6-3p 1.098 3.143 2.863 
miR-BART19-5p 0.092 0.189 2.053 miR-BART11-3p 1.130 1.950 1.726 
miR-BART6-3p 0.197 0.318 1.619 miR-BART17-5p 0.511 0.844 1.653 
miR-BART8-5p 0.296 0.425 1.433 miR-BART19-5p 1.267 1.889 1.491 
miR-BART7-5p 0.114 0.136 1.194 miR-BART16 0.125 0.185 1.476 
 
 
miR-BART8-3p 0.287 0.221 0.769 
miR-BART10-3p 3.254 2.498 0.768 
miR-BART9-5p 0.300 0.201 0.669 
miR-BART7-3p 0.323 0.201 0.623 
miR-BART1-5p 0.131 0.075 0.572 
miR-BART19-3p 0.354 0.175 0.494 
miR-BART17-3p 0.274 0.115 0.418 
miR-BART22 0.128 0.098 0.767 miR-BART1-3p 0.137 0.044 0.320 
miR-BART10-3p 0.436 0.243 0.556 miR-BART5-5p 0.120 0.034 0.281 
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3.8 Validations of sequencing results by RT-qPCR 
In order to validate the NGS sequencing results, 12 miRNAs with different expression 
levels, either up- or down-regulated, were selected for reverse transcription 
quantitative PCR (RT-qPCR), based on their presence above the 0.1% cut-off level. 
The RT-qPCR was carried out in duplicate on independent biological replicates for 
both cell lines and their EBV-infected counterparts, in the total cellular RNA and the 
RNA isolated from the Ago2-IP. 
The RT-qPCR results of 8 out of 12 selected miRNAs gave results corresponding to 
the NGS results of total cellular RNA from U2932-EBV, compared to U2932. As shown 
in Figure 8, we validated the relative upregulation of four miRNAs, including miR-10a-
5p, -146a-5p, -221-3p and -363-3p and the relative downregulation of four miRNA, 
including let7c-5p, miR-283p, miR-423-3p and miR-92a-3p. 
 
Figure 8:RT-qPCR validation for U2932-EBV vs. U2932 in “Total” 
Black bars represent NGS data and white bars represent RT-qPCR results. 
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Furthermore, using RNA extracted from the Ago2-IP of U2932-EBV and U2932, the 
relative upregulation of miR-10a-5p, miR-146a-5p, miR-155-5p, and miR-15a-5p, 
miR-221-3p, miR-363-3p, mi -486-5p, miR-92a-3p and relative downregulation of let-
7c and miR-28-3p were confirmed. These data are presented in Figure 9. 
 
The analogous experiments, employing RNA obtained from whole cells or the Ago2-
IPs were carried out, for comparing SUDHL5-EBV vs. SUDHL5. Here, 10 out of 12 
selected miRNA yielded consistent results for the sequencing of total cellular miRNA 
profile. As shown in Figure 10, we confirmed the relative up-regulation of five miRNAs, 
including miR-10a-5p, -146a-5p, -155-5p, -221-3 and -363-3p and a relative 
downregulation of five miRNAs, including miR-15a-5p, -28-3p, -423-3p, -423-5p and -
92a-3p. 
 
Figure 9:RT-qPCR validation of U2932-EBV vs. U2932 for “Ago2-IP” 
Black bar represent NGS data and open bars represent RT-qPCR results. 
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Figure 10:RT-qPCR validation for SUDHL5-EBV vs. SUDHL5 for “Total” 
Black bars represent NGS data and open bars represent RT-qPCR results. 
 
Using RNA extracted from Ago2-IP for comparing by RT-qPCR SUDHL5-EBV vs. 
SUDHL5, we confirmed the relative up- and downregulation of selected miRNAs as 
shown in Figure 11. In particular, the relative upregulation of miR-10a-5p, -146a-5p, -
155-5p, -221-3p and -363-3p and the relative downregulation of miR-let-7c,-15a-5p, -
28-3p, -423-3p, -423-5p, -486-5p and -92a-3p were validated. 
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Figure 11: RT-qPCR validation for SUDHL5-EBV vs. SUDHL5 for “Ago2-IP”. 
Black bar represent NGS data and open bars represent RT-qPCR results. 
 
3.9 Verification of sequencing by Northern blotting 
 Analysis of total cellular miRNAs  
Northern blotting (NB) is considered the gold standard for validation of miRNA 
expression, as it avoids the false positive results that may arise from the enzymatic 
manipulation and amplifications that are necessary for biochemical reactions during 
the NGS or RT-qPCR procedures. Second, it unambiguously detects differences in 
expression in given cellular settings, like the ones analyzed in this work. For this 
reason, we performed NB as a powerful second validation method for some miRNAs 
that were found to be up- or downregulated by NGS and RT-qPCR.  
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The results of NB from total extracted RNA from U2932, SUDHL5 and their EBV-
positive counterparts, are shown in Figures 12, 13, and 14. In comparison of U2932-
EBV with U2932, we confirmed the upregulation of miR-222-3p, -551b-3p,-142-3p, -
155-5p and -142-5p and the downregulation of hsa-let-7c-5p. In SUDHL5-EBV, we 
also verified the upregulation of miR-363, -21-5p and downregulation of miR-142-5p, 
compared to SUDHL5. 
NGS data from Ago2-IP indicated that miR-4485-3p and 4792-5p were highly depleted 
from the Ago2-IP profile (Table 10 and Table 11), while miR-4485-3p and -4792-5p 
were above 0.1% cut-off level of total known miRNA reads, in the total cellular miRNA 
expression profile. MiR-4485-3p and miR-4792-5p were not present at the 0.1% cut 
off in U2932 and SUDHL5-EBV, respectively. We could not detect a signal either for 
miR-4485-3p or 4792-5p by northern blot (Figure 15). 
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Figure 12: Validation of NGS results by northern blotting. 
Total RNA isolated from U2932, SUDHL5 and their EBV positive counterparts 
(20µg/lane) was assayed using probes for the indicated miRNAs. The EtBr loading 
control is shown beneath each blot.  
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Figure 13: Validation of NGS results by northern blotting. 
Total RNA isolated from U2932 and SUDHL5 and their EBV positive counterparts 
(20µg/lane) was assayed using probes for the indicated miRNAs probes. The EtBr 
loading control is shown beneath each blot. 
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Figure 14: Validation of NGS results by northern blotting. 
Total RNA isolated from U2932 and SUDHL5 and their EBV positive counterparts 
(20µg/lane) and human tissue from a DLBCL patient were assayed by the probes 
for the indicated miRNAs. The EtBr loading control is shown beneath each blot. 
  
 71 
 
 
Figure 15: Validation of NGS results by northern blotting. 
Total RNA isolated from U2932 and SUDHL5 and their EBV positive counterpart 
(20µg/lane) were assayed by NB using probes for miR-4485-3p and miR-4792-5p as 
indicated. No proper signal detected for miR-4485-3p and 4792-5p) while reprobing 
of the same membrane after stripping gave a detectable signal for mir101-3p. The 
EtBr loading control is shown beneath each blot.  
  
 72 
 
 Analysis of Ago2-IP miRNAs by northern blotting. 
From our NGS results and  their validation using RT-qPCR, we found that by 
comparing Ago2-IP in U2932-EBV versus U2932 cell lines, miR-221-3p was strongly 
upregulated (0.114% versus 0.045% ) by 2.5-fold and hsa-let-7c-5p was strongly 
downregulated (0.013% vs. 0.115%) by 8-fold. We then speculated if we could detect 
the difference by NB, using RNA extracted from the Ago2-IP- fraction. We were able 
to isolate RNA from the Ago2-IP and, to a lesser extent, from the control IP. The 
amounts isolated were sufficient to run several Northern blots. We loaded equal 
amounts (200 ng) of RNA extracted from the Ago2-IP and the control-IP of U2932, as 
shown in Figure 16. As expected, miR-221-3p was enriched in both Ago2-IP fraction 
and total cellular lysate in U2932-EBV, in comparison to U2932. By stripping the 
membrane to remove the previous signal (miR-221-3p), and probing with hsa-let7c-
5p, which was downregulated in U2932-EBV cell lines, from Ago2-IP NGS data, we 
observed the depletion of let-7c-5p in U2932-EBV in total cellular lysate and in the 
Ago2-IP. These results were in line with our NGS and RT-qPCR data for miR-221-3p 
and hsa-let7c-5p. 
From our NGS results for SUDHL5-EBV versus SUDHL5, we found that miR363-3p 
(0.105 vs. 0.017) in Ago2-IP has the strongest enrichment of about 6-fold. MiR-423-
5p showed the strongest enrichment in the Ago2-ip, in comparison to the total cellular 
profile, by more than 6- fold in SUDH-EBV (0.134 vs. 0.936 ) and about 8 fold (0.188 
vs. 1.639), in SUDHL5. In addition, miR-423 about 1.75 fold downregulated in Ago2-
IP in SUDHL5-EBV, compared to SUDHL5. By performing Ago2-IP-NB, using again 
200 ng of extracted RNA from Ago2-IP fraction, we found an enrichment of miR-363-
3p in the Ago2-IP of SUDHL5-EBV. After stripping and reprobing the membrane with 
miR423-5p, we observed depletion of mir423-5p in Ago2-IP of SUDHL5, compared to 
SUDHL5-EBV. These results were also in line with our NGS and RT-qPCR data. 
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Figure 16: Validation of Ago2-IP-Seq by northern blotting. 
Total RNA isolated from U2932-EBV and U2932 total cellular and Ago2-IP cell 
lines. (20 µg per lane from total cellular RNA and 200 ng per lane from Ago2-IP) 
were applied to 12.5% urea gel and assayed by NB using the indicated probes. 
First miR-221-3p probe were used and then the membrane was probed with let-7c-
5p (after stripping the membrane to remove the primary signal).The EtBr loading 
control is shown under the blot. Due to the low amount of RNA loaded in Ago2-IP 
fraction (200 ng), no signals were detected in EtBr of Ago2-IPs and Control-IPs. 
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Figure 17: Validation of Ago2-IP-Seq by northern blotting. 
Total RNA isolated from SUDHL5-EBV and SUDHL5 total cellular and Ago2-IP cell 
lines. (20 µg per lane from total cellular RNA and 200 ng per lane from Ago2-IP) 
were applied to 12.5% urea gel and assayed by NB using the indicated probes. 
First miR-363-3p probe were used and then the membrane was probed with miR-
423-5p (after stripping the membrane to remove the primary signal).The EtBr 
loading control is shown under the blot. Due to the low amount of RNA loaded in 
Ago2-IP fraction (200 ng), no signals were detected in EtBr of Ago2-IPs and 
Control-IPs. 
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4 Discussion 
Non-Hodgkin lymphoma (NHL) is the fifth most common type of malignancy globally. 
Of these, diffuse large B-cell lymphoma (DLBCL) is the most common form of NHL 
(BRADSHAW et al., 2016; SKRABEK et al., 2013). DLBCL is a heterogeneous group 
of disease in regard to pathology and clinical and genetic characteristics. The 
heterogeneity arises due to dysregulation of different transcription factors such as B-
cell lymphoma 6 (BCL-6) at different stages of B-cell development (GATTO, BRINK, 
2010; IQBAL et al., 2009; IQBAL et al., 2015). DLBCL is categorized into two common 
types: Activated B-cell like (ABC) and Germinal Center B-cell like (GCB), based on 
gene expression profiling (GEP) (ALIZADEH et al., 2000). Due to difficulties in the 
characterization and differentiation of GCB- from ABC-DLBCL, many investigators 
attempt to identify a miRNA or a set of miRNAs to use as potential diagnostic 
differentiation biomarkers (ALIZADEH et al., 2000; IQBAL et al., 2015; JORGENSEN 
et al., 2015; ROSENWALD et al., 2002). 
Ago2-IP, followed by miRNA sequencing, is becoming an advanced tool to determine 
the miRNA profile of a given tumor and to investigate functionally active miRNA, as it 
has been shown recently by the Cullen group that simply the level of a miRNA in the 
total cellular lysate is not a clear indication of its biological function but rather the 
loading of the Ago-complex (FLORES et al., 2014).  
For this reason, this study was carried out to compare by ultra-deep sequencing the 
miRNAs bound to Ago2 with the overall miRNA present in two sets of DLBCL cell lines 
with and without EBV-conversion. The first cell line was U2932, which has a gene 
expression profile (GEP) similar to ABC-DLBCL (AMINI et al., 2002) and the second 
cell line was SUDHL5, which has a GEP similar to GCB-DLBCL. We investigated 
enriched or depleted miRNAs in the Ago2- associated complex as compared to their 
total cellular miRNA profile. We also validated our results by RT-qPCR and northern 
blot (NB) for a selected set of up or downregulated miRNAs that were deregulated in 
the total cellular RNA and in the Ago2-IP. 
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The total miRNA profiling of the four cell lines yielded between 713-851 different 
miRNAs while the number of miRNAs in the Ago2-IP yielded 1102-1372 different 
miRNAs. Further, the number of sequencing reads increased dramatically, by almost 
ten times, in the Ago2-IP fraction in the four cell lines, as compared to miRNAs 
detected in the total cellular profiles. In addition, the number of detected miRNAs in 
the Ago2-IP fraction was significantly increased, by more than 35% in all four cell lines, 
as compared to the total cellular miRNA profile. The increase in the number of reads 
and detected miRNAs in Ago2-IP fraction is a clear indication of enrichment and 
specificity of our Ago2-IP. In addition, we observed miRNAs expressed at low 
abundance that were not detectable in the total miRNAs profiles. This approach might 
therefore be applied as a very promising tool in the discovery of new miRNAs. Most 
importantly, the Ago-associated miRNAs might be considered as the potentially 
relevant miRNAs to serve as biomarkers for diagnosis and for the determination of 
potential mRNA targets. 
As it had been suggested that functional miRNAs should be present above 0.1% of 
the total reads, a 0.1% cut-off was applied in all cell lines for the selection of 
functionally relevant miRNAs (FLORES et al., 2014; MULLOKANDOV et al., 2012).  
The application of this cut-off left only 59-62 out of more than about 713-851 miRNAs 
that were present overall in the four lines, but the application of this cut-off also left 
only between 50-57 miRNAs in the Ago2-profile. The miRNAs that were left, however, 
were present at different ratios in both U2932 and U2932-EBV as well as SUDHL5 
and SUDHL5-EBV. The miRNAs above the 0.1% cut-off did nevertheless represent 
over 95% of all miRNAs in the four cell lines. 
In the U2932-EBV cells, the EBV-encoded miRNAs represent 1.3% of the total and 
1.6% of all Ago2-bound miRNAs. In this line, EBV was in latency I or II as only EBNA1 
and LMP1 but not significant amounts of EBNA2 were detectable. Here, ebv-miR-
BART10-3p with 0.43% of the total had the highest relative expression of the EBV-
miRNAs, but was not among top 20 miRNA in U2932-EBV. In contrast, ebv-miR-
BART8-5p accounted for 0.4% of Ago2-associated viral miRNAs. In SUDHL5-EBV, 
however, which has the characteristic of EBV-latency type III (high EBNA2, EBNA1, 
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LMP1), EBV miRNAs represented about 23.4% of total cellular profile, and an 
enrichment to about 28.2% of viral miRNAs was observed in the Ago2-IP profile. Here, 
ebv-miR-BHRF1-1, -BART-10-3p and BART8-5p were the most abundant viral 
miRNAs in total miRNA profile with frequencies of 5.9%, 3.2%, 2.9%, respectively. 
BHRF1-1 and BART8-5p with 7.0% and 4.1%, respectively, were also among the most 
abundant miRNAs in Ago2 profile in SUDHL5-EBV. This suggests that under type III 
EBV latency, for example, in EBV-associated PTLD, EBV miRNAs might functionally 
displace a significant amount of human cellular miRNAs from the Ago2-complex. In 
addition, the viral infection had dysregulated the human cellular miRNA expression. 
Alternatively, it might be possible that miRNAs in type III latency are more efficiently 
processed. The changes in the cellular miRNA profile in EBV latency type III, 
compared to type I, were previously reported by Flemington and coworkers 
(CAMERON et al., 2008a). We have also observed elevated expression of miR-21-
5p, miR-27a-3p and miR-146b-5p in SUDHL5-EBV vs. SUDHL5 cells, which is 
consistent with their data.  
The Venn diagrams shown in Figures 18 depict the miRNAs that are not present or 
exclusively in the Ago2-complexes in the four cell lines. We note that miRNAs miR-
1260a/b were not present in the Ago2-complex in U2932, SUDHL5 and SUDHL5-EBV 
and were strongly depleted from Ago2 in U2932-EBV. Likewise, miR-486-5p was 
below the 0.1% cut-off in the Ago2-complex in U2932, U2932-EBV, SUDHL5-EBV 
except in SUDHL5.Surprisingly, the number of cellular miRNAs excluded from the 
Ago2-complex in U2932-EBV and SUDHL5-EBV did not differ significantly as we had 
expected that the large amount of EBV-miRNAs associated with Ago2 in SUDHL5-
EBV (almost 30%) would lead to a stronger loss of cell miRNAs as compared to 
U2932-EBV where the viral miRNAs accounted for only 1.6% of the Ago2-bound 
miRNAs above the 0.1% cut-off. In SUDHL5, miRNAs miR-4485-3p, -4792, and -4532 
were only present in the total profile, and miR-4485-3p was not Ago2-bound in 
SUDHL5-EBV. We assume that these sequences, although listed in miRBASE, are 
not real miRNAs but probably breakdown products of other non-coding RNAs. For 
instance, probing the RNA of the U2932 and SUDHL5 cell line did not yield a 
detectable signal for this sequence at the position where miRNAs migrate in a 
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Northern blot. Again, miR-1260a/b and -98-5p were not present in both cells, leaving 
miR-1246 to be excluded from Ago2 in SUDHL5, while miR-486-5p, 20a-5p, -210-3p, 
-15a-5p and -181a-3p were excluded from Ago2 in SUDHL5-EBV. Likewise, miR-
4792, not present in the SUDHL5- Ago2, was also not Ago2-bound in the 
U2932/U2392-EBV pair. Here, miR-486-5p and miR-301a-3P were Ago2-excluded in 
both lines while U2932-EBV also had no significant amounts of let7b-3p, -miR-17-3p, 
-18a-5p, -21-3p, 193-3p, 222-3p, and miR-1246, the latter also being excluded in the 
SUDHL5-Ago2 complex (Figure 18). It may thus be assumed that the EBV-conversion 
results in a loss of some more miRNAs from the Ago2-complex and that the presence 
of EBV under latency III conditions might result in an overall reduction of cell miRNAs 
associated with the Ago2-complex. The displacement of miRNAs under type III latency 
is somewhat more prominent than type I latency, and the presence of the virus 
nevertheless changes the overall expression of certain cellular miRNAs. This question 
needs further attention in additional experiments beyond the scope of this thesis. 
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MiR-21-5p was the most abundant miRNA in the total and in the Ago2 miRNA profile 
of SUDHL5-EBV cells. It has been shown that EBNA2 induces miR-21 expression, 
due to post-transcriptional mechanisms and in EBV latency type III (CAMERON et al., 
2008a; ROSATO et al., 2012). Upregulation of mir-21 has been reported in different 
type of cancers, such as colorectal (ASANGANI et al., 2008), sinonasal 
 
  
  
Figure 18: Venn diagrams: showing the miRNAs found exclusively either in the 
total RNA or the Ago2-profiling of the U2932, SUDHL5 and their EBV infected 
counterparts. (A) Total miRNA profile vs. Ago2-profile of U2932-EBV, (B) Total miRNA 
profile vs. Ago2-profile of U2932 (C) Total miRNA profile vs. Ago2-profile of SUDHL5-
EBV, (D) Total miRNA profile vs. Ago2-profile of SUDHL5. 
 
B A 
C D 
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(KOVARIKOVA et al., 2017), glioblastoma (CHAN et al., 2005) and breast cancer 
(IORIO et al., 2005).  
Microarray or NGS assay may over- or underestimate the quantification of small 
RNAs, due to different designing platforms (LESHKOWITZ et al., 2013). For example, 
in microarray biases may arise due to primer and/or array design or in the sample 
preparation, differences in labeling, hybridization strength and cross-hybridization 
(LESHKOWITZ et al., 2013). NGS biases could be a consequence of sample 
preparation, such as adapter ligation, cDNA synthesis and PCR (HAFNER et al., 
2011; LESHKOWITZ et al., 2013; LINSEN et al., 2009; TIAN et al., 2010).  
Using microarray to compare the miRNA profiles of U2932-EBV versus U2932, we 
found that only 14 were miRNAs significantly down-regulated in total cellular profile of 
U2932-EBV while 169 human miRNAs were down-regulated in the Ago2-IP. 
In the comparison of U2932-EBV vs. U2932 in total cellular profile only miR-222 was 
upregulated more than 2 fold in both microarray and NGS results. In the Ago2-IP of 
U2932-EBV vs. U2932 in Ago2-IP profile, only miR-27a, miR-339 and miR-30c were 
downregulated more than 2 fold in both microarray and NGS results. By relating these 
findings with EBV infection it could be concluded that a large number of human 
miRNAs were dislocated in the Ago2-IP profile. In sequencing miRNA expression is 
defined as a relative copy number of sequence reads for a miRNA of interest; such a 
quantification can be applied to analyse the enrichment or depletion of a given miRNA, 
whereas such a quantification cannot be applied to microarray data where 
quantification is based on the relative expression value. For this purpose, NGS results 
were used for further analysis as we could not apply our microarray results to compare 
the enrichment or depletion of specific miRNA in the Ago2-complex. In addition, only 
after sequencing it was possible to apply the aforementioned 0.1% cut-off to filter out 
presumably non-functional miRNAs in our analysis (MULLOKANDOV et al., 2012). 
For selected miRNAs, we carried out northern blotting (NB) in addition to the 
confirmation of the NGS data by RT-qPCR. We could confirm the up-or down-
regulation of various miRNAs by this assay which has the advantage of the absence 
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of biochemical manipulations during sample preparation. We could confirm not only 
the changes in total miRNA expression but also a few miRNAs from the Ago2-IP. As 
we had no loading or internal control, we choose to analyze miRNAs that were up- or 
down-regulated. We reasoned that if we saw up-regulation of a miRNA in a given 
sample, then we should conversely observe down-regulation of another miRNA in the 
same sample. This was indeed the case. For this reason, we re-assayed the same 
membrane with consecutive probes and could indeed show up- and down-regulation 
of miRNAs on the same membrane (Figure 16 and Figure 17) additionally confirming 
some of the initial sequencing data. For instance, we could confirm the dramatic 
enrichment of miR-363 into to Ago2-complex of SUDHL5-EBV cells. 
Based on read counts, we detected miR-146a-5p was enriched in Ago2-IP and 
induced in EBV positive cell lines, congruent with previous reports that  miR-146a-5p 
was induced by LMP1 (CAMERON et al., 2008b). MiR-146b-5p is up-regulated in EBV 
positive DLBCL lymphoma (DE ANDRADE et al., 2014). Low expression of MiR-146b-
5p, a tumor suppressor, has been reported to be associated with poor prognosis, in 
DLBCL and gliomas cancer (LIU et al., 2015b; WU et al., 2014). In our data, the miR-
146b was down-regulated in U2932-EBV (type 1 latency) as compare to U2932, while 
the miR-146b-5p was upregulated over two-fold in SUDHL5-EBV as compared to 
SUDHL5, while  this miRNA was depleted over two-fold in total and Ago2-IP complex 
in U2932-EBV. Another tumor suppressor, miR-148a-3p/-5p was found to be down-
regulated in U2932-EBV vs. U2932, while being up-regulated in SUDHL5-EBV vs. 
SUDHL5 (YU et al., 2016) . 
Further, we found a very strong enrichment of the oncogenic miR-363-3p (SUN et al., 
2013) in SUDHL5-EBV. The miR-106-363 cluster has close homology with the miR-
17-92 cluster (LANDAIS et al., 2007). The miR-17-92 cluster (miR-17, miR-18a, miR-
19a, miR-20a, miR-19b-1, and miR-92-1) is located in 13q31.3 (DIOSDADO et al., 
2009). It has been reported that the miR-17-92 cluster undergoes amplification and 
overexpression in lymphoma tumors, such as DLBCL, chronic lymphocytic leukemia 
(CLL), Burkitt’s lymphoma (BL) and mantle cell lymphoma (MCL) (DAL BO et al., 2015; 
DIOSDADO et al., 2009; OTA et al., 2004; TAGAWA, SETO, 2005; VOLINIA et al., 
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2006). From the miR-17-92 cluster, miR-92a-3p showed the strongest expression in 
U2932 cells and was the fourth highly expressed miRNA in the Ago2 profile of 
SUDHL5 and SUDHL5-EBV. 
In SUDHL5, SUDHL5-EBV and also U2932-EBV, miR-423-5p and -3p were the most 
strongly RISC enriched miRNAs, and still the 2nd and 4th enriched in U2932, pointing 
at an important role for miR-423 in DLBCL tumorigenesis. miRNA-423-5p has been 
shown to be down-regulated in the plasma of colorectal cancer (CRC) patients (FANG 
et al., 2015) . However miR-423 is up-regulated in glioblastoma and it has been shown 
that overexpression of miR-423-5p induces proliferation, angiogenesis, and invasion 
in the glioblastoma cell lines U87 and U251 cells (LI et al., 2017). MiR-inhibitor of 
growth family proteins 4 (ING4) is a direct target of 423-5p (LI et al., 2017). It has also 
been shown that in EBV infected cell lines, the EBNA3C protein perturbs the 
interaction between p53 and ING4/5 in EBV infected cell lines, resulting in attenuation 
of p53, apoptosis and induction of cell proliferation (SAHA et al., 2011).  
We observed an almost complete loss of miR-1260a and miR1260b, in the Ago2-IP 
profile, in all cell lines used in this study. MiR-1260a and miR1260b  has an oncogenic 
potential (XU et al., 2015) . MiR-1260a and miR1260b have been shown to be part of 
transfer RNAs (tRNAs) group3 (tRF-3). tRF-3 are generated by Dicer and the RNase 
Z nuclease from 3′ ends of tRNA (LEE et al., 2009; VENKATESH et al., 2016).  It was 
shown that tRF-3s family members are associated with AGO1, 3, and 4, in HEK293 
cells, but not with Ago2. This might explain the failure to detect 1260a/b in the Ago2-
IP (KUMAR et al., 2014) . 
MiR-486-5p is downregulated in lung cancer (WANG et al., 2014). In our experiments, 
miR-486-5p was above 0.1% cut-off level of total known miRNA reads in total cellular 
profile and upregulated in U2932-EBV and SUDHL5-EBV as compare to the 
uninfected cells. Intriguingly miR-486-5p was strongly lost in Ago2-complex with less 
than 0.03% abundance in all cell lines except SUDHL5, and downregulated in SUDHL-
EBV and U2932-EBV compared to uninfected counterparts. We infer from these 
results that the Ago2-IP profile gives a better picture about the tumor suppressor 
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activity of miR-486-5p. As already pointed out above, we have noticed the absence of 
miR-4792, miR-4485-3p and miR-4532 in the Ago2-complexes when compared to the 
total cellular miRNA profiles. No proper signal was detected by using NB. These 
miRNAs might be part of transfer RNAs, associated with other types of Ago protein, 
or could be degraded tRNA products and are therefore most likely not bona fide 
miRNAs. The function of the aforementioned potential miRNAs should be investigated 
in more detail. Mir-221-3p and miR-155-5p were induced in U2932-EBV as compared 
to U2932. These results were consistent with those of Lawrie and co-workers 
(LAWRIE et al., 2007). However, miR-221-3p was not detected in neither of SUDHL5-
EBV or SUDHL5 cell line. 
MiR-142-3p was found to be downregulated in the Ago2 profile of U2932-EBV and 
SUDHL5-EBV cells. In contrast, in the total cellular profile of U2932-EBV cell line, 
miR-142-3p was upregulated. Overall, the depletion of miR-142 in the Ago2 profile 
compared to the total cellular profile and down regulation of miR-142 in EBV-infected 
cells was a clear indication of miR-142 being a tumor suppressor in DLBCL. It has 
been shown that miR-142 is downregulated in many types of cancers and that low 
levels of mir-142 predict a poor outcome. In our group, we have shown that 20% of 
DLBCLs harbor mutations in miR-142 and that the mutations in the seed sequence 
confer loss of activity (KWANHIAN et al., 2012). Here, we propose that in addition to 
point mutations, the depletion of miR142 in the Ago2 complex supports the notion that 
loss of function or loss of Ago-bound miR-142 plays a role in DLBCL. 
Taken together, we conclude that the human miRNA expression profile in the total 
cellular fraction is not always a real indicator of miRNA function and therefore 
functional activity. EBV, by encoding miRNAs, is displacing human miRNAs from the 
Ago complex and changes the balance of human miRNAs in the Ago complex. This 
change is dependent on the type of EBV latency or the origin of lymphoma, in our 
study ABC-DLBCL vs. GCB-DLBCL 
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5 Outlook 
One question that arises from our data and the results from Cullen and co-workers is 
how the cell decides to sequester miRNAs into (a) functionally silent Ago-complex(es) 
or to enrich miRNAs of low abundance into active RISC complexes; in EBV 
transformed cells, the process of functional inactivation might be brought about by 
loading additional, virus-encoded miRNAs into the Ago-complexes. Conversely, the 
infected cell might sequester viral miRNAs that are deleterious for the cells into non-
functional Ago-complexes thus activating otherwise non-functional miRNAs. We have 
found that ebv-miR-BART6 is highly present in the Ago2-complex of SUDHL5-EBV 
cells; this miRNA is known to target Dicer, an important enzyme in miRNA metabolism 
and function.  It might be possible that reduced amounts of Dicer serve to inactivate 
cell miRNAs, for instance those that are necessary to indicate the innate immune 
response to the viral infection.  
As miRNAs are more functional in the Ago complex than in the total cellular lysate, 
performing Ago2-IP followed by sequencing will give a better evaluation and 
understanding of highly functional miRNAs or, conversely, their loss of activity. This 
approach may improve our understanding the contribution of miRNAs in particular 
diseases or in developmental processes. 
Further, the enrichment of miRNAs by the Ago-precipitation will be a promising tool in 
the near future for (1) the discovery of new miRNA due to the high number of reads 
generated by this procedure; (2) for the design and choice of antagomirs (short 
oligonucleotides complementary to miRNAs), based on highly abundant miRNA in the 
Ago2-complex; (3) choosing miRNAs as biomarkers to differentiate ABC-DLBCL from 
GCB-DLBCL, using the Ago-bound miRNA profiles. 
  
 85 
 
6 References 
1. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, 
Yu X, Powell JI, Yang L, Marti GE, Moore T, Hudson J, Jr., Lu L, Lewis DB, Tibshirani R, 
Sherlock G, Chan WC, Greiner TC, Weisenburger DD, Armitage JO, Warnke R, Levy R, Wilson 
W, Grever MR, Byrd JC, Botstein D, Brown PO, Staudt LM (2000) Distinct types of diffuse 
large B-cell lymphoma identified by gene expression profiling. Nature 403:503-511 
2. Allegra D, Bilan V, Garding A, Dohner H, Stilgenbauer S, Kuchenbauer F, Mertens D, Zucknick 
M (2014) Defective DROSHA processing contributes to downregulation of MiR-15/-16 in 
chronic lymphocytic leukemia. Leukemia 28:98-107 
3. Ambros V, Bartel B, Bartel DP, Burge CB, Carrington JC, Chen X, Dreyfuss G, Eddy SR, 
Griffiths-Jones S, Marshall M, Matzke M, Ruvkun G, Tuschl T (2003) A uniform system for 
microRNA annotation. Rna 9:277-279 
4. Ambros V (2004) The functions of animal microRNAs. Nature 431:350-355 
5. Amini RM, Berglund M, Rosenquist R, Von Heideman A, Lagercrantz S, Thunberg U, Bergh J, 
Sundstrom C, Glimelius B, Enblad G (2002) A novel B-cell line (U-2932) established from a 
patient with diffuse large B-cell lymphoma following Hodgkin lymphoma. Leuk Lymphoma 
43:2179-2189 
6. Asangani IA, Rasheed SA, Nikolova DA, Leupold JH, Colburn NH, Post S, Allgayer H (2008) 
MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and 
stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene 27:2128-
2136 
7. Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116:281-
297 
8. Barth S, Pfuhl T, Mamiani A, Ehses C, Roemer K, Kremmer E, Jaker C, Hock J, Meister G, 
Grasser FA (2008) Epstein-Barr virus-encoded microRNA miR-BART2 down-regulates the 
viral DNA polymerase BALF5. Nucleic Acids Res 36:666-675 
9. Basso K, Dalla-Favera R (2015) Germinal centres and B cell lymphomagenesis. Nat Rev 
Immunol 15:172-184 
10. Béguelin W, Popovic R, Teater M, Jiang Y, Bunting KL, Rosen M, Shen H, Yang SN, Wang L, 
Ezponda T, Martinez-Garcia E, Zhang H, Zhang Y, Verma SK, McCabe MT, Ott HM, Van Aller 
GS, Kruger RG, Liu Y, McHugh CF, Scott DW, Chung YR, Kelleher N, Shaknovich R, Creasy CL, 
Gascoyne RD, Wong K-K, Cerchietti LC, Levine RL, Abdel-Wahab O, Licht JD, Elemento O, 
Melnick AM (2013) EZH2 is required for germinal center formation and somatic EZH2 
mutations promote lymphoid transformation. Cancer cell 23:677-692 
11. Bhende PM, Dickerson SJ, Sun X, Feng WH, Kenney SC (2007) X-box-binding protein 1 
activates lytic Epstein-Barr virus gene expression in combination with protein kinase D. J 
Virol 81:7363-7370 
12. Boccellato F, Anastasiadou E, Rosato P, Kempkes B, Frati L, Faggioni A, Trivedi P (2007) 
EBNA2 interferes with the germinal center phenotype by downregulating BCL6 and TCL1 in 
non-Hodgkin's lymphoma cells. J Virol 81:2274-2282 
13. Bohnsack MT, Czaplinski K, Gorlich D (2004) Exportin 5 is a RanGTP-dependent dsRNA-
binding protein that mediates nuclear export of pre-miRNAs. Rna 10:185-191 
14. Bradshaw G, Sutherland HG, Haupt LM, Griffiths LR (2016) Dysregulated MicroRNA 
Expression Profiles and Potential Cellular, Circulating and Polymorphic Biomarkers in Non-
Hodgkin Lymphoma. Genes 7:130 
 86 
 
15. Cai L, Ye Y, Jiang Q, Chen Y, Lyu X, Li J, Wang S, Liu T, Cai H, Yao K, Li JL, Li X (2015) Epstein-
Barr virus-encoded microRNA BART1 induces tumour metastasis by regulating PTEN-
dependent pathways in nasopharyngeal carcinoma. Nat Commun 6:7353 
16. Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, Aldler H, Rattan S, Keating M, Rai 
K, Rassenti L, Kipps T, Negrini M, Bullrich F, Croce CM (2002) Frequent deletions and down-
regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. 
Proc Natl Acad Sci U S A 99:15524-15529 
17. Cameron JE, Fewell C, Yin Q, McBride J, Wang X, Lin Z, Flemington EK (2008a) Epstein-Barr 
virus growth/latency III program alters cellular microRNA expression. Virology 382:257-266 
18. Cameron JE, Yin Q, Fewell C, Lacey M, McBride J, Wang X, Lin Z, Schaefer BC, Flemington EK 
(2008b) Epstein-Barr Virus Latent Membrane Protein 1 Induces Cellular MicroRNA miR-146a, 
a Modulator of Lymphocyte Signaling Pathways. Journal of Virology 82:1946-1958 
19. Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES (2011) The 2008 WHO 
classification of lymphoid neoplasms and beyond: evolving concepts and practical 
applications. Blood 117:5019-5032 
20. Chan JA, Krichevsky AM, Kosik KS (2005) MicroRNA-21 is an antiapoptotic factor in human 
glioblastoma cells. Cancer Res 65:6029-6033 
21. Copie-Bergman C, Plonquet A, Alonso MA, Boulland ML, Marquet J, Divine M, Moller P, 
Leroy K, Gaulard P (2002) MAL expression in lymphoid cells: further evidence for MAL as a 
distinct molecular marker of primary mediastinal large B-cell lymphomas. Mod Pathol 
15:1172-1180 
22. Countryman J, Miller G (1985) Activation of expression of latent Epstein-Barr herpesvirus 
after gene transfer with a small cloned subfragment of heterogeneous viral DNA. 
Proceedings of the National Academy of Sciences of the United States of America 82:4085-
4089 
23. Cullen BR (2004) Transcription and processing of human microRNA precursors. Mol Cell 
16:861-865 
24. Cummin T, Johnson P (2016) Lymphoma: turning biology into cures. Clin Med (Lond) 
16:s125-s129 
25. Dal Bo M, Bomben R, Hernández L, Gattei V (2015) The MYC/miR-17-92 axis in 
lymphoproliferative disorders: A common pathway with therapeutic potential. Oncotarget 
6:19381-19392 
26. de Andrade TA, Evangelista AF, Campos AHF, Poles WA, Borges NM, Camillo CMC, Soares FA, 
Vassallo J, Paes RP, Zerbini MC, Scapulatempo C, Alves AC, Young KH, Colleoni GWB (2014) A 
microRNA signature profile in EBV(+) diffuse large B-cell lymphoma of the elderly. 
Oncotarget 5:11813-11826 
27. De Craene B, Berx G (2013) Regulatory networks defining EMT during cancer initiation and 
progression. Nat Rev Cancer 13:97-110 
28. de Martel C, Ferlay J, Franceschi S, Vignat J, Bray F, Forman D, Plummer M (2012) Global 
burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet 
Oncol 13:607-615 
29. Delecluse HJ, Feederle R, O'Sullivan B, Taniere P (2007) Epstein Barr virus-associated 
tumours: an update for the attention of the working pathologist. J Clin Pathol 60:1358-1364 
30. Dembla M, Wahl S, Katiyar R, Schmitz F (2014) ArfGAP3 is a component of the 
photoreceptor synaptic ribbon complex and forms an NAD(H)-regulated, redox-sensitive 
complex with RIBEYE that is important for endocytosis. J Neurosci 34:5245-5260 
31. Diosdado B, van de Wiel MA, Terhaar Sive Droste JS, Mongera S, Postma C, Meijerink WJ, 
Carvalho B, Meijer GA (2009) MiR-17-92 cluster is associated with 13q gain and c-myc 
 87 
 
expression during colorectal adenoma to adenocarcinoma progression. Br J Cancer 101:707-
714 
32. Dolken L, Malterer G, Erhard F, Kothe S, Friedel CC, Suffert G, Marcinowski L, Motsch N, 
Barth S, Beitzinger M, Lieber D, Bailer SM, Hoffmann R, Ruzsics Z, Kremmer E, Pfeffer S, 
Zimmer R, Koszinowski UH, Grasser F, Meister G, Haas J (2010) Systematic analysis of viral 
and cellular microRNA targets in cells latently infected with human gamma-herpesviruses by 
RISC immunoprecipitation assay. Cell Host Microbe 7:324-334 
33. Dölken L, Malterer G, Erhard F, Kothe S, Friedel CC, Suffert G, Marcinowski L, Motsch N, 
Barth S, Beitzinger M, Lieber D, Bailer SM, Hoffmann R, Ruzsics Z, Kremmer E, Pfeffer S, 
Zimmer R, Koszinowski UH, Grässer F, Meister G, Haas J (2010) Systematic Analysis of Viral 
and Cellular MicroRNA Targets in Cells Latently Infected with Human γ-Herpesviruses by 
RISC Immunoprecipitation Assay. Cell Host & Microbe 7:324-334 
34. Dunleavy K, Grant C, Wilson WH (2013) Using biologic predictive factors to direct therapy of 
diffuse large B-cell lymphoma. Therapeutic Advances in Hematology 4:43-57 
35. Elkayam E, Kuhn C-D, Tocilj A, Haase AD, Greene EM, Hannon GJ, Joshua-Tor L (2012) The 
Structure of Human Argonaute-2 in Complex with miR-20a. Cell 150:100-110 
36. Epstein MA, Achong BG, Barr YM (1964) VIRUS PARTICLES IN CULTURED LYMPHOBLASTS 
FROM BURKITT'S LYMPHOMA. Lancet 1:702-703 
37. Fang Z, Tang J, Bai Y, Lin H, You H, Jin H, Lin L, You P, Li J, Dai Z, Liang X, Su Y, Hu Q, Wang F, 
Zhang Z-Y (2015) Plasma levels of microRNA-24, microRNA-320a, and microRNA-423-5p are 
potential biomarkers for colorectal carcinoma. Journal of Experimental & Clinical Cancer 
Research : CR 34:86 
38. Fehlmann T, Meese E, Keller A (2017) Exploring ncRNAs in Alzheimer's disease by 
miRMaster. Oncotarget 8:3771-3772 
39. Flores O, Kennedy EM, Skalsky RL, Cullen BR (2014) Differential RISC association of 
endogenous human microRNAs predicts their inhibitory potential. Nucleic Acids Res 
42:4629-4639 
40. Gatto D, Brink R (2010) The germinal center reaction. J Allergy Clin Immunol 126:898-907; 
quiz 908-899 
41. Gross H, Barth S, Palermo RD, Mamiani A, Hennard C, Zimber-Strobl U, West MJ, Kremmer E, 
Grasser FA (2010) Asymmetric Arginine dimethylation of Epstein-Barr virus nuclear antigen 2 
promotes DNA targeting. Virology 397:299-310 
42. Grundhoff A, Sullivan CS, Ganem D (2006) A combined computational and microarray-based 
approach identifies novel microRNAs encoded by human gamma-herpesviruses. Rna 12:733-
750 
43. Ha M, Kim VN (2014) Regulation of microRNA biogenesis. Nat Rev Mol Cell Biol 15:509-524 
44. Hafner M, Renwick N, Brown M, Mihailovic A, Holoch D, Lin C, Pena JT, Nusbaum JD, 
Morozov P, Ludwig J, Ojo T, Luo S, Schroth G, Tuschl T (2011) RNA-ligase-dependent biases 
in miRNA representation in deep-sequenced small RNA cDNA libraries. Rna 17:1697-1712 
45. Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, Muller-Hermelink HK, 
Campo E, Braziel RM, Jaffe ES, Pan Z, Farinha P, Smith LM, Falini B, Banham AH, Rosenwald 
A, Staudt LM, Connors JM, Armitage JO, Chan WC (2004) Confirmation of the molecular 
classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue 
microarray. Blood 103:275-282 
46. Healy JA, Dave SS (2015) The Role of EBV in the Pathogenesis of Diffuse Large B Cell 
Lymphoma. Curr Top Microbiol Immunol 390:315-337 
 88 
 
47. Hsu C-Y, Yi Y-H, Chang K-P, Chang Y-S, Chen S-J, Chen H-C (2014) The Epstein-Barr Virus-
Encoded MicroRNA MiR-BART9 Promotes Tumor Metastasis by Targeting E-Cadherin in 
Nasopharyngeal Carcinoma. PLOS Pathogens 10:e1003974 
48. Iizasa H, Wulff B-E, Alla NR, Maragkakis M, Megraw M, Hatzigeorgiou A, Iwakiri D, Takada K, 
Wiedmer A, Showe L, Lieberman P, Nishikura K (2010) Editing of Epstein-Barr Virus-encoded 
BART6 MicroRNAs Controls Their Dicer Targeting and Consequently Affects Viral Latency. 
Journal of Biological Chemistry 285:33358-33370 
49. Imig J, Motsch N, Zhu JY, Barth S, Okoniewski M, Reineke T, Tinguely M, Faggioni A, Trivedi 
P, Meister G, Renner C, Grasser FA (2011) microRNA profiling in Epstein-Barr virus-
associated B-cell lymphoma. Nucleic Acids Res 39:1880-1893 
50. Intlekofer AM, Younes A (2014) Precision therapy for lymphoma--current state and future 
directions. Nat Rev Clin Oncol 11:585-596 
51. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, 
Campiglio M, Menard S, Palazzo JP, Rosenberg A, Musiani P, Volinia S, Nenci I, Calin GA, 
Querzoli P, Negrini M, Croce CM (2005) MicroRNA gene expression deregulation in human 
breast cancer. Cancer Res 65:7065-7070 
52. Iqbal J, Liu Z, Deffenbacher K, Chan WC (2009) Gene expression profiling in lymphoma 
diagnosis and management. Best Pract Res Clin Haematol 22:191-210 
53. Iqbal J, Shen Y, Huang X, Liu Y, Wake L, Liu C, Deffenbacher K, Lachel CM, Wang C, Rohr J, 
Guo S, Smith LM, Wright G, Bhagavathi S, Dybkaer K, Fu K, Greiner TC, Vose JM, Jaffe E, 
Rimsza L, Rosenwald A, Ott G, Delabie J, Campo E, Braziel RM, Cook JR, Tubbs RR, Armitage 
JO, Weisenburger DD, Staudt LM, Gascoyne RD, McKeithan TW, Chan WC (2015) Global 
microRNA expression profiling uncovers molecular markers for classification and prognosis 
in aggressive B-cell lymphoma. Blood 125:1137-1145 
54. Jorgensen LK, Poulsen MO, Laursen MB, Marques SC, Johnsen HE, Bogsted M, Dybkaer K 
(2015) MicroRNAs as novel biomarkers in diffuse large B-cell lymphoma--a systematic 
review. Dan Med J 62 
55. Kanda T, Miyata M, Kano M, Kondo S, Yoshizaki T, Iizasa H (2015) Clustered microRNAs of 
the Epstein-Barr virus cooperatively downregulate an epithelial cell-specific metastasis 
suppressor. J Virol 89:2684-2697 
56. Khan G, Hashim MJ (2014) Global burden of deaths from Epstein-Barr virus attributable 
malignancies 1990-2010. Infect Agent Cancer 9:38 
57. Kieff  E, Rickinson  A (2007) Epstein-Barr Virus and Its Replication, Vol 2 (Philadelphia, PA., 
Lippincott Williams & Wilkins, ). 
58. Kim VN (2005) MicroRNA biogenesis: coordinated cropping and dicing. Nat Rev Mol Cell Biol 
6:376-385 
59. Kim VN, Han J, Siomi MC (2009) Biogenesis of small RNAs in animals. Nat Rev Mol Cell Biol 
10:126-139 
60. Koganti S, de la Paz A, Freeman AF, Bhaduri-McIntosh S (2014) B lymphocytes from patients 
with a hypomorphic mutation in STAT3 resist Epstein-Barr virus-driven cell proliferation. J 
Virol 88:516-524 
61. Kovarikova H, Bubancova I, Laco J, Sieglova K, Vosmikova H, Vosmik M, Dundr P, Nemejcova 
K, Michalek J, Palicka V, Chmelarova M (2017) Deregulation of selected microRNAs in 
sinonasal carcinoma: Value of miR-21 as prognostic biomarker in sinonasal squamous cell 
carcinoma. Head Neck 
62. Kozomara A, Griffiths-Jones S (2014) miRBase: annotating high confidence microRNAs using 
deep sequencing data. Nucleic Acids Research 42:D68-D73 
 89 
 
63. Krichevsky AM, Gabriely G (2009) miR-21: a small multi-faceted RNA. J Cell Mol Med 13:39-
53 
64. Kumar P, Anaya J, Mudunuri SB, Dutta A (2014) Meta-analysis of tRNA derived RNA 
fragments reveals that they are evolutionarily conserved and associate with AGO proteins to 
recognize specific RNA targets. BMC Biology 12:78 
65. Kurosu T, Fukuda T, Miki T, Miura O (2003) BCL6 overexpression prevents increase in 
reactive oxygen species and inhibits apoptosis induced by chemotherapeutic reagents in B-
cell lymphoma cells. Oncogene 22:4459-4468 
66. Kwanhian W, Lenze D, Alles J, Motsch N, Barth S, Doll C, Imig J, Hummel M, Tinguely M, 
Trivedi P, Lulitanond V, Meister G, Renner C, Grasser FA (2012) MicroRNA-142 is mutated in 
about 20% of diffuse large B-cell lymphoma. Cancer Med 1:141-155 
67. Laichalk LL, Thorley-Lawson DA (2005) Terminal Differentiation into Plasma Cells Initiates 
the Replicative Cycle of Epstein-Barr Virus In Vivo. Journal of Virology 79:1296-1307 
68. Landais S, Landry S, Legault P, Rassart E (2007) Oncogenic potential of the miR-106-363 
cluster and its implication in human T-cell leukemia. Cancer Res 67:5699-5707 
69. Langmead B, Trapnell C, Pop M, Salzberg SL (2009) Ultrafast and memory-efficient 
alignment of short DNA sequences to the human genome. Genome Biology 10:R25-R25 
70. Lawrie CH, Soneji S, Marafioti T, Cooper CD, Palazzo S, Paterson JC, Cattan H, Enver T, Mager 
R, Boultwood J, Wainscoat JS, Hatton CS (2007) MicroRNA expression distinguishes between 
germinal center B cell-like and activated B cell-like subtypes of diffuse large B cell 
lymphoma. Int J Cancer 121:1156-1161 
71. Lee KT, Tan JK, Lam AK, Gan SY (2016) MicroRNAs serving as potential biomarkers and 
therapeutic targets in nasopharyngeal carcinoma: A critical review. Crit Rev Oncol Hematol 
103:1-9 
72. Lee RC, Feinbaum RL, Ambros V (1993) The C. elegans heterochronic gene lin-4 encodes 
small RNAs with antisense complementarity to lin-14. Cell 75:843-854 
73. Lee YS, Shibata Y, Malhotra A, Dutta A (2009) A novel class of small RNAs: tRNA-derived RNA 
fragments (tRFs). Genes Dev 23:2639-2649 
74. Lenz G, Wright GW, Emre NCT, Kohlhammer H, Dave SS, Davis RE, Carty S, Lam LT, Shaffer 
AL, Xiao W, Powell J, Rosenwald A, Ott G, Muller-Hermelink HK, Gascoyne RD, Connors JM, 
Campo E, Jaffe ES, Delabie J, Smeland EB, Rimsza LM, Fisher RI, Weisenburger DD, Chan WC, 
Staudt LM (2008) Molecular subtypes of diffuse large B-cell lymphoma arise by distinct 
genetic pathways. Proceedings of the National Academy of Sciences of the United States of 
America 105:13520-13525 
75. Leshkowitz D, Horn-Saban S, Parmet Y, Feldmesser E (2013) Differences in microRNA 
detection levels are technology and sequence dependent. Rna 19:527-538 
76. Leung AK, Young AG, Bhutkar A, Zheng GX, Bosson AD, Nielsen CB, Sharp PA (2011) 
Genome-wide identification of Ago2 binding sites from mouse embryonic stem cells with 
and without mature microRNAs. Nat Struct Mol Biol 18:237-244 
77. Li S, Zeng A, Hu Q, Yan W, Liu Y, You Y (2017) miR-423-5p contributes to a malignant 
phenotype and temozolomide chemoresistance in glioblastomas. Neuro Oncol 19:55-65 
78. Lieberman PM (2015) Chromatin Structure of Epstein-Barr Virus Latent Episomes. Curr Top 
Microbiol Immunol 390:71-102 
79. Lin S, Gregory RI (2015) MicroRNA biogenesis pathways in cancer. Nat Rev Cancer 15:321-
333 
80. Linsen SE, de Wit E, Janssens G, Heater S, Chapman L, Parkin RK, Fritz B, Wyman SK, de 
Bruijn E, Voest EE, Kuersten S, Tewari M, Cuppen E (2009) Limitations and possibilities of 
small RNA digital gene expression profiling. Nat Methods 6:474-476 
 90 
 
81. Liu G, Sun Y, Ji P, Li X, Cogdell D, Yang D, Parker Kerrigan BC, Shmulevich I, Chen K, Sood AK, 
Xue F, Zhang W (2014) MiR-506 suppresses proliferation and induces senescence by directly 
targeting the CDK4/6-FOXM1 axis in ovarian cancer. J Pathol 233:308-318 
82. Liu G, Yang D, Rupaimoole R, Pecot CV, Sun Y, Mangala LS, Li X, Ji P, Cogdell D, Hu L, Wang Y, 
Rodriguez-Aguayo C, Lopez-Berestein G, Shmulevich I, De Cecco L, Chen K, Mezzanzanica D, 
Xue F, Sood AK, Zhang W (2015a) Augmentation of response to chemotherapy by microRNA-
506 through regulation of RAD51 in serous ovarian cancers. J Natl Cancer Inst 107 
83. Liu J, Carmell MA, Rivas FV, Marsden CG, Thomson JM, Song JJ, Hammond SM, Joshua-Tor L, 
Hannon GJ (2004) Argonaute2 is the catalytic engine of mammalian RNAi. Science 305:1437-
1441 
84. Liu J, Xu J, Li H, Sun C, Yu L, Li Y, Shi C, Zhou X, Bian X, Ping Y, Wen Y, Zhao S, Xu H, Ren L, An 
T, Wang Q, Yu S (2015b) miR-146b-5p functions as a tumor suppressor by targeting TRAF6 
and predicts the prognosis of human gliomas. Oncotarget 6:29129-29142 
85. Liu XS, Fan BY, Pan WL, Li C, Levin AM, Wang X, Zhang RL, Zervos TM, Hu J, Zhang XM, Chopp 
M, Zhang ZG (2016) Identification of miRNomes associated with adult neurogenesis after 
stroke using Argonaute 2-based RNA sequencing. RNA Biol:1-12 
86. Lo AK, To KF, Lo KW, Lung RW, Hui JW, Liao G, Hayward SD (2007) Modulation of LMP1 
protein expression by EBV-encoded microRNAs. Proc Natl Acad Sci U S A 104:16164-16169 
87. Ludwig N, Kim YJ, Mueller SC, Backes C, Werner TV, Galata V, Sartorius E, Bohle RM, Keller A, 
Meese E (2015) Posttranscriptional deregulation of signaling pathways in meningioma 
subtypes by differential expression of miRNAs. Neuro Oncol 17:1250-1260 
88. Lund E, Guttinger S, Calado A, Dahlberg JE, Kutay U (2004) Nuclear export of microRNA 
precursors. Science 303:95-98 
89. Lung RW, Tong JH, Sung YM, Leung PS, Ng DC, Chau SL, Chan AW, Ng EK, Lo KW, To KF 
(2009) Modulation of LMP2A expression by a newly identified Epstein-Barr virus-encoded 
microRNA miR-BART22. Neoplasia 11:1174-1184 
90. Martello G, Rosato A, Ferrari F, Manfrin A, Cordenonsi M, Dupont S, Enzo E, Guzzardo V, 
Rondina M, Spruce T, Parenti AR, Daidone MG, Bicciato S, Piccolo S (2010) A MicroRNA 
targeting dicer for metastasis control. Cell 141:1195-1207 
91. Matsui M, Li L, Janowski BA, Corey DR (2015) Reduced Expression of Argonaute 1, Argonaute 
2, and TRBP Changes Levels and Intracellular Distribution of RNAi Factors. Scientific Reports 
5:12855 
92. Meister G (2013) Argonaute proteins: functional insights and emerging roles. Nat Rev Genet 
14:447-459 
93. Melo SA, Moutinho C, Ropero S, Calin GA, Rossi S, Spizzo R, Fernandez AF, Davalos V, 
Villanueva A, Montoya G, Yamamoto H, Schwartz S, Jr., Esteller M (2010) A genetic defect in 
exportin-5 traps precursor microRNAs in the nucleus of cancer cells. Cancer Cell 18:303-315 
94. Mendell JT (2008) miRiad roles for the miR-17-92 cluster in development and disease. Cell 
133:217-222 
95. Miyashita EM, Yang B, Lam KM, Crawford DH, Thorley-Lawson DA (1995) A novel form of 
Epstein-Barr virus latency in normal B cells in vivo. Cell 80:593-601 
96. Miyazaki K (2016) Treatment of Diffuse Large B-Cell Lymphoma. J Clin Exp Hematop 56:79-
88 
97. Mugnaini EN, Ghosh N (2016) Lymphoma. Prim Care 43:661-675 
98. Mullokandov G, Baccarini A, Ruzo A, Jayaprakash AD, Tung N, Israelow B, Evans MJ, 
Sachidanandam R, Brown BD (2012) High-throughput assessment of microRNA activity and 
function using microRNA sensor and decoy libraries. Nat Methods 9:840-846 
 91 
 
99. Ota A, Tagawa H, Karnan S, Tsuzuki S, Karpas A, Kira S, Yoshida Y, Seto M (2004) 
Identification and characterization of a novel gene, C13orf25, as a target for 13q31-q32 
amplification in malignant lymphoma. Cancer Res 64:3087-3095 
100. Parekh S, Prive G, Melnick A (2008) Therapeutic targeting of the BCL6 oncogene for diffuse 
large B-cell lymphomas. Leuk Lymphoma 49:874-882 
101. Parker JS, Roe SM, Barford D (2005) Structural insights into mRNA recognition from a PIWI 
domain-siRNA guide complex. Nature 434:663-666 
102. Pasquinelli AE, Reinhart BJ, Slack F, Martindale MQ, Kuroda MI, Maller B, Hayward DC, Ball 
EE, Degnan B, Muller P, Spring J, Srinivasan A, Fishman M, Finnerty J, Corbo J, Levine M, 
Leahy P, Davidson E, Ruvkun G (2000) Conservation of the sequence and temporal 
expression of let-7 heterochronic regulatory RNA. Nature 408:86-89 
103. Pekarsky Y, Croce CM (2015) Role of miR-15/16 in CLL. Cell Death and Differentiation 22:6-
11 
104. Pfeffer S, Zavolan M, Grasser FA, Chien M, Russo JJ, Ju J, John B, Enright AJ, Marks D, Sander 
C, Tuschl T (2004) Identification of virus-encoded microRNAs. Science 304:734-736 
105. Reinhart BJ, Slack FJ, Basson M, Pasquinelli AE, Bettinger JC, Rougvie AE, Horvitz HR, Ruvkun 
G (2000) The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis 
elegans. Nature 403:901-906 
106. Rosato P, Anastasiadou E, Garg N, Lenze D, Boccellato F, Vincenti S, Severa M, Coccia EM, 
Bigi R, Cirone M, Ferretti E, Campese AF, Hummel M, Frati L, Presutti C, Faggioni A, Trivedi P 
(2012) Differential regulation of miR-21 and miR-146a by Epstein-Barr virus-encoded EBNA2. 
Leukemia 26:2343-2352 
107. Roschewski M, Staudt LM, Wilson WH (2014) Diffuse large B-cell 
lymphoma[mdash]treatment approaches in the molecular era. Nat Rev Clin Oncol 11:12-23 
108. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, Gascoyne RD, Muller-
Hermelink HK, Smeland EB, Giltnane JM, Hurt EM, Zhao H, Averett L, Yang L, Wilson WH, 
Jaffe ES, Simon R, Klausner RD, Powell J, Duffey PL, Longo DL, Greiner TC, Weisenburger DD, 
Sanger WG, Dave BJ, Lynch JC, Vose J, Armitage JO, Montserrat E, Lopez-Guillermo A, 
Grogan TM, Miller TP, LeBlanc M, Ott G, Kvaloy S, Delabie J, Holte H, Krajci P, Stokke T, 
Staudt LM (2002) The use of molecular profiling to predict survival after chemotherapy for 
diffuse large-B-cell lymphoma. N Engl J Med 346:1937-1947 
109. Rupaimoole R, Ivan C, Yang D, Gharpure KM, Wu SY, Pecot CV, Previs RA, Nagaraja AS, 
Armaiz-Pena GN, McGuire M, Pradeep S, Mangala LS, Rodriguez-Aguayo C, Huang L, Bar-Eli 
M, Zhang W, Lopez-Berestein G, Calin GA, Sood AK (2016) Hypoxia-upregulated microRNA-
630 targets Dicer, leading to increased tumor progression. Oncogene 35:4312-4320 
110. Rupaimoole R, Slack FJ (2017) MicroRNA therapeutics: towards a new era for the 
management of cancer and other diseases. Nat Rev Drug Discov 16:203-222 
111. Saha A, Bamidele A, Murakami M, Robertson ES (2011) EBNA3C attenuates the function of 
p53 through interaction with inhibitor of growth family proteins 4 and 5. J Virol 85:2079-
2088 
112. Sample J, Young L, Martin B, Chatman T, Kieff E, Rickinson A, Kieff E (1990) Epstein-Barr virus 
types 1 and 2 differ in their EBNA-3A, EBNA-3B, and EBNA-3C genes. J Virol 64:4084-4092 
113. Sasaki T, Shiohama A, Minoshima S, Shimizu N (2003) Identification of eight members of the 
Argonaute family in the human genome. Genomics 82:323-330 
114. Schirle NT, MacRae IJ (2012) The crystal structure of human Argonaute2. Science 336:1037-
1040 
115. Scott DW, Wright GW, Williams PM, Lih C-J, Walsh W, Jaffe ES, Rosenwald A, Campo E, Chan 
WC, Connors JM, Smeland EB, Mottok A, Braziel RM, Ott G, Delabie J, Tubbs RR, Cook JR, 
 92 
 
Weisenburger DD, Greiner TC, Glinsmann-Gibson BJ, Fu K, Staudt LM, Gascoyne RD, Rimsza 
LM (2014) Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene 
expression in formalin-fixed paraffin-embedded tissue. Blood 123:1214-1217 
116. Shankland KR, Armitage JO, Hancock BW (2012) Non-Hodgkin lymphoma. Lancet 380:848-
857 
117. Shen J, Xia W, Khotskaya YB, Huo L, Nakanishi K, Lim SO, Du Y, Wang Y, Chang WC, Chen CH, 
Hsu JL, Wu Y, Lam YC, James BP, Liu X, Liu CG, Patel DJ, Hung MC (2013) EGFR modulates 
microRNA maturation in response to hypoxia through phosphorylation of AGO2. Nature 
497:383-387 
118. Skrabek P, Turner D, Seftel M (2013) Epidemiology of non-Hodgkin lymphoma. Transfus 
Apher Sci 49:133-138 
119. Sun Q, Zhang J, Cao W, Wang X, Xu Q, Yan M, Wu X, Chen W (2013) Dysregulated miR-363 
affects head and neck cancer invasion and metastasis by targeting podoplanin. Int J Biochem 
Cell Biol 45:513-520 
120. Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, Advani R, Ghielmini M, Salles 
GA, Zelenetz AD, Jaffe ES (2016) The 2016 revision of the World Health Organization 
classification of lymphoid neoplasms. Blood 127:2375-2390 
121. Tagawa H, Seto M (2005) A microRNA cluster as a target of genomic amplification in 
malignant lymphoma. Leukemia 19:2013-2016 
122. Tashiro H, Brenner MK (2017) Immunotherapy against cancer-related viruses. Cell Res 
27:59-73 
123. Thorley-Lawson DA (2001) Epstein-Barr virus: exploiting the immune system. Nat Rev 
Immunol 1:75-82 
124. Tian G, Yin X, Luo H, Xu X, Bolund L, Zhang X, Gan SQ, Li N (2010) Sequencing bias: 
comparison of different protocols of microRNA library construction. BMC Biotechnol 10:64 
125. Tokumaru S, Suzuki M, Yamada H, Nagino M, Takahashi T (2008) let-7 regulates Dicer 
expression and constitutes a negative feedback loop. Carcinogenesis 29:2073-2077 
126. Tomita N, Takasaki H, Fujisawa S, Miyashita K, Ogusa E, Kishimoto K, Matsuura S, Sakai R, 
Koharazawa H, Yamamoto W, Fujimaki K, Fujita H, Ishii Y, Taguchi J, Kuwabara H, Motomura 
S, Ishigatsubo Y (2013) Standard R-CHOP therapy in follicular lymphoma and diffuse large B-
cell lymphoma. J Clin Exp Hematop 53:121-125 
127. Venkatesh T, Suresh PS, Tsutsumi R (2016) tRFs: miRNAs in disguise. Gene 579:133-138 
128. Victora GD, Nussenzweig MC (2012) Germinal centers. Annu Rev Immunol 30:429-457 
129. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, 
Ferracin M, Prueitt RL, Yanaihara N, Lanza G, Scarpa A, Vecchione A, Negrini M, Harris CC, 
Croce CM (2006) A microRNA expression signature of human solid tumors defines cancer 
gene targets. Proc Natl Acad Sci U S A 103:2257-2261 
130. Wang J, Tian X, Han R, Zhang X, Wang X, Shen H, Xue L, Liu Y, Yan X, Shen J, Mannoor K, 
Deepak J, Donahue JM, Stass SA, Xing L, Jiang F (2014) Downregulation of miR-486-5p 
contributes to tumor progression and metastasis by targeting protumorigenic ARHGAP5 in 
lung cancer. Oncogene 33:1181-1189 
131. Wilson WH, Young RM, Schmitz R, Yang Y, Pittaluga S, Wright G, Lih CJ, Williams PM, Shaffer 
AL, Gerecitano J, de Vos S, Goy A, Kenkre VP, Barr PM, Blum KA, Shustov A, Advani R, Fowler 
NH, Vose JM, Elstrom RL, Habermann TM, Barrientos JC, McGreivy J, Fardis M, Chang BY, 
Clow F, Munneke B, Moussa D, Beaupre DM, Staudt LM (2015) Targeting B cell receptor 
signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med 21:922-926 
 93 
 
132. Wu PY, Zhang XD, Zhu J, Guo XY, Wang JF (2014) Low expression of microRNA-146b-5p and 
microRNA-320d predicts poor outcome of large B-cell lymphoma treated with 
cyclophosphamide, doxorubicin, vincristine, and prednisone. Hum Pathol 45:1664-1673 
133. Xu L, Li L, Li J, Li H, Shen Q, Ping J, Ma Z, Zhong J, Dai L (2015) Overexpression of miR-1260b 
in Non-small Cell Lung Cancer is Associated with Lymph Node Metastasis. Aging Dis 6:478-
485 
134. Ye Z, Jin H, Qian Q (2015) Argonaute 2: A Novel Rising Star in Cancer Research. J Cancer 
6:877-882 
135. Young LS, Yap LF, Murray PG (2016) Epstein-Barr virus: more than 50 years old and still 
providing surprises. Nat Rev Cancer 16:789-802 
136. Yu B, Lv X, Su L, Li J, Yu Y, Gu Q, Yan M, Zhu Z, Liu B (2016) MiR-148a Functions as a Tumor 
Suppressor by Targeting CCK-BR via Inactivating STAT3 and Akt in Human Gastric Cancer. 
PLoS One 11:e0158961 
137. Yu X, Li Z (2015) New insights into MicroRNAs involves in drug resistance in diffuse large B 
cell lymphoma. American Journal of Translational Research 7:2536-2542 
138. Zhai L, Wang L, Teng F, Zhou L, Zhang W, Xiao J, Liu Y, Deng W (2016) Argonaute and 
Argonaute-Bound Small RNAs in Stem Cells. Int J Mol Sci 17:208 
139. Zhang J, Grubor V, Love CL, Banerjee A, Richards KL, Mieczkowski PA, Dunphy C, Choi W, Au 
WY, Srivastava G, Lugar PL, Rizzieri DA, Lagoo AS, Bernal-Mizrachi L, Mann KP, Flowers C, 
Naresh K, Evens A, Gordon LI, Czader M, Gill JI, Hsi ED, Liu Q, Fan A, Walsh K, Jima D, Smith 
LL, Johnson AJ, Byrd JC, Luftig MA, Ni T, Zhu J, Chadburn A, Levy S, Dunson D, Dave SS (2013) 
Genetic heterogeneity of diffuse large B-cell lymphoma. Proc Natl Acad Sci U S A 110:1398-
1403 
 
  
 94 
 
7 Appendices 
Table A1.Highly expressed miRNAs in U2932 and SUDHL5 and their EBV positive 
counterparts in “Total” profile at 0.1% cut-off. 
 
% of  total cellular miRNA pool 
U2932 SUDHL5 
miRNA  
EBV 
Positive miRNA 
EBV 
Negative miRNA 
EBV 
Positive miRNA   
EBV 
Negative 
miR-92a-3p 16.783 miR-92a-3p 17.205 miR-21-5p 14.164 miR-142-5p 28.391 
miR-191-5p 9.169 miR-191-5p 11.556 miR-142-5p 6.891 miR-21-5p 10.992 
miR-181a-5p 7.785 miR-148a-3p 8.417 miR-BHRF1-1 5.971 miR-181a-5p 5.613 
miR-146a-5p 5.849 miR-181a-5p 7.073 miR-148a-3p 5.807 miR-26a-5p 5.057 
miR-148a-3p 5.704 let-7a-5p 4.559 miR-191-5p 4.947 miR-191-5p 4.122 
miR-142-5p 5.213 miR-26a-5p 4.159 miR-181a-5p 3.619 miR-16-5p 3.588 
miR-16-5p 3.929 miR-142-5p 3.854 miR-16-5p 3.321 miR-30d-5p 3.031 
let-7f-5p 3.555 let-7f-5p 3.787 miR-BART10-3p 3.254 miR-92a-3p 3.013 
let-7a-5p 3.472 miR-146a-5p 3.380 miR-22-3p 3.158 let-7a-5p 2.848 
miR-30d-5p 3.379 miR-16-5p 3.123 miR-30d-5p 3.060 miR-22-3p 2.781 
miR-26a-5p 2.887 miR-30d-5p 2.736 miR-BART8-5p 2.975 let-7f-5p 2.746 
miR-21-5p 2.551 miR-182-5p 2.566 let-7a-5p 2.587 miR-148a-3p 2.681 
miR-27b-3p 1.753 miR-30e-5p 1.728 let-7f-5p 2.587 miR-142-3p 2.657 
miR-19b-3p 1.744 miR-20a-5p 1.666 miR-26a-5p 2.549 miR-30e-5p 1.960 
miR-182-5p 1.609 miR-27b-3p 1.625 miR-92a-3p 2.364 miR-28-3p 1.466 
miR-155-5p 1.339 miR-192-5p 1.623 miR-30e-5p 1.862 miR-4792 1.349 
miR-192-5p 1.300 miR-21-5p 1.331 miR-182-5p 1.550 miR-21-3p 1.106 
miR-20a-5p 1.157 let-7g-5p 1.322 miR-BART7-5p 1.367 miR-192-5p 0.881 
miR-30e-5p 1.139 miR-186-5p 1.048 miR-BART19-5p 1.267 let-7g-5p 0.776 
miR-186-5p 0.879 miR-22-3p 0.860 miR-146b-5p 1.188 miR-4485-3p 0.709 
let-7g-5p 0.858 miR-17-5p 0.778 miR-BART11-3p 1.130 miR-25-3p 0.680 
miR-103a-3p 0.808 miR-378a-3p 0.685 miR-BART6-3p 1.098 miR-27b-3p 0.659 
miR-378a-3p 0.803 miR-103a-3p 0.675 miR-BART22 0.935 miR-378a-3p 0.624 
miR-17-5p 0.728 miR-19b-3p 0.664 miR-28-3p 0.877 miR-186-5p 0.598 
let-7i-5p 0.530 miR-26b-5p 0.577 miR-192-5p 0.849 miR-146a-5p 0.477 
miR-22-3p 0.490 miR-98-5p 0.566 miR-21-3p 0.841 miR-26b-5p 0.456 
miR-142-3p 0.437 miR-25-3p 0.556 miR-146a-5p 0.799 miR-182-5p 0.419 
miR-BART10-3p 0.436 miR-28-3p 0.508 let-7g-5p 0.664 miR-151a-5p 0.379 
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miR-101-3p 0.429 miR-155-5p 0.503 miR-378a-3p 0.650 miR-30b-5p 0.378 
miR-486-5p 0.425 miR-101-3p 0.474 miR-BHRF1-3 0.644 miR-103a-3p 0.370 
miR-25-3p 0.409 miR-30c-5p 0.422 miR-27b-3p 0.564 miR-146b-5p 0.367 
miR-98-5p 0.399 miR-142-3p 0.399 miR-26b-5p 0.520 miR-1246 0.339 
miR-93-5p 0.386 miR-4792 0.384 miR-4485-3p 0.517 miR-20a-5p 0.334 
miR-9-5p 0.385 miR-93-5p 0.369 miR-BART17-5p 0.511 miR-101-3p 0.307 
miR-30b-5p 0.377 let-7i-5p 0.340 miR-BART13-5p 0.494 miR-486-5p 0.302 
miR-28-3p 0.338 miR-425-5p 0.333 miR-25-3p 0.485 miR-19b-3p 0.293 
miR-425-5p 0.338 miR-30b-5p 0.319 miR-142-3p 0.468 miR-30c-5p 0.291 
miR-181b-5p 0.334 miR-423-3p 0.313 miR-103a-3p 0.424 miR-93-5p 0.289 
miR-26b-5p 0.332 miR-29a-3p 0.289 miR-486-5p 0.403 let-7i-5p 0.283 
miR-29a-3p 0.324 miR-181b-5p 0.280 miR-BART18-3p 0.401 miR-28-5p 0.277 
miR-BART8-5p 0.296 let-7c-5p 0.245 miR-186-5p 0.394 miR-423-3p 0.254 
miR-4792 0.287 miR-9-5p 0.240 miR-BART19-3p 0.354 miR-98-5p 0.229 
miR-19a-3p 0.276 miR-148a-5p 0.223 miR-30c-5p 0.343 miR-17-5p 0.213 
miR-4485-3p 0.276 miR-486-5p 0.199 miR-30b-5p 0.332 miR-181a-3p 0.197 
miR-15a-5p 0.255 miR-183-5p 0.198 miR-BART7-3p 0.323 miR-423-5p 0.188 
miR-423-3p 0.233 miR-423-5p 0.195 miR-101-3p 0.304 miR-151a-3p 0.184 
miR-30c-5p 0.224 let-7d-5p 0.187 miR-20a-5p 0.302 miR-29a-3p 0.184 
miR-423-5p 0.217 let-7b-5p 0.181 miR-BART9-5p 0.300 miR-181b-5p 0.172 
miR-221-3p 0.210 miR-27a-3p 0.177 miR-BART2-5p 0.290 miR-210-3p 0.168 
miR-148a-5p 0.206 miR-769-5p 0.170 miR-BART6-5p 0.288 miR-155-5p 0.163 
miR-21-3p 0.202 miR-146b-5p 0.163 miR-BART8-3p 0.287 miR-15a-5p 0.154 
miR-BART6-3p 0.197 miR-339-3p 0.142 miR-BHRF1-2-3p 0.287 let-7d-5p 0.153 
let-7d-5p 0.176 miR-1260b 0.127 miR-BART17-3p 0.274 miR-140-3p 0.143 
miR-107 0.167 miR-1260a 0.126 miR-98-5p 0.260 miR-4532 0.138 
miR-BART11-3p 0.158 miR-92b-3p 0.125 miR-93-5p 0.257 miR-769-5p 0.138 
miR-769-5p 0.156 miR-140-3p 0.122 miR-BART14-3p 0.252 miR-941 0.120 
miR-1246 0.151 miR-19a-3p 0.113 miR-151a-5p 0.249 miR-1260a 0.117 
let-7b-5p 0.142 miR-210-3p 0.108 miR-155-5p 0.219 miR-1260b 0.117 
miR-130b-3p 0.132 miR-15b-5p 0.108 let-7i-5p 0.200 miR-148a-5p 0.103 
miR-BART22 0.128 miR-107 0.106 miR-17-5p 0.195   
miR-140-3p 0.124 miR-301a-3p 0.102 miR-19b-3p 0.193   
miR-222-3p 0.122   miR-148a-5p 0.184   
miR-183-5p 0.121   miR-151a-3p 0.183   
miR-BART7-5p 0.114   miR-423-3p 0.175   
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miR-17-3p 0.111   miR-10a-5p 0.155   
miR-301a-3p 0.110   miR-27a-3p 0.153   
miR-193b-3p 0.104   miR-BART3-5p 0.153   
miR-18a-5p 0.103   miR-28-5p 0.137   
    miR-BART1-3p 0.137   
    miR-423-5p 0.134   
    miR-BART1-5p 0.131   
    miR-210-3p 0.129   
    miR-BART16 0.125   
    miR-BART5-5p 0.120   
    let-7d-5p 0.118   
    miR-29a-3p 0.116   
    miR-15a-5p 0.110   
    miR-425-5p 0.108   
    miR-181a-3p 0.108   
    miR-941 0.107   
    miR-1260a 0.107   
    miR-1260b 0.107   
    miR-181b-5p 0.102   
    miR-140-3p 0.100   
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Table A2.Highly expressed miRNAs in U2932 and SUDHL5 and their EBV positive 
counterparts in “Ago2-IP” profile at 0.1% cut-off. 
% of Ago2-IP miRNA pool 
U2932 SUDHL5 
miRNA  
EBV 
Positive miRNA 
EBV 
Negative miRNA 
EBV  
Positive miRNA   
EBV  
Negative 
miR-92a-3p 26.551 miR-92a-3p 23.235 miR-21-5p 16.151 miR-21-5p 14.373 
miR-181a-5p 10.446 miR-181a-5p 9.224 miR-BHRF1-1 7.030 miR-142-5p 13.376 
miR-146a-5p 10.051 miR-148a-3p 7.232 miR-92a-3p 4.881 miR-181a-5p 8.794 
miR-191-5p 5.372 miR-146a-5p 7.106 miR-148a-3p 4.216 miR-92a-3p 7.077 
miR-16-5p 4.615 miR-191-5p 6.580 miR-BART8-5p 4.154 miR-26a-5p 6.298 
miR-148a-3p 4.096 miR-26a-5p 4.317 miR-181a-5p 4.149 miR-16-5p 5.130 
miR-30d-5p 3.184 miR-16-5p 3.565 miR-22-3p 3.862 miR-22-3p 4.762 
miR-26a-5p 3.124 miR-182-5p 3.089 miR-142-5p 3.435 miR-191-5p 3.399 
let-7f-5p 2.665 miR-30d-5p 3.074 miR-16-5p 3.231 let-7f-5p 3.294 
miR-21-5p 2.581 let-7f-5p 2.949 miR-BART6-3p 3.143 miR-28-3p 3.260 
miR-142-5p 2.074 let-7a-5p 2.257 miR-191-5p 2.883 miR-30d-5p 3.027 
miR-182-5p 1.966 miR-21-5p 1.956 miR-30d-5p 2.617 miR-148a-3p 2.644 
miR-27b-3p 1.916 miR-142-5p 1.939 let-7f-5p 2.566 miR-423-5p 1.639 
miR-155-5p 1.311 miR-27b-3p 1.707 miR-BART10-3p 2.498 miR-30e-5p 1.612 
let-7a-5p 1.153 miR-30e-5p 1.502 miR-26a-5p 2.210 miR-142-3p 1.501 
miR-192-5p 1.080 miR-192-5p 1.470 miR-BART11-3p 1.950 let-7a-5p 1.437 
miR-186-5p 0.865 miR-22-3p 1.289 miR-BART19-5p 1.889 miR-146a-5p 1.258 
miR-30e-5p 0.804 miR-186-5p 1.275 miR-182-5p 1.827 miR-192-5p 1.018 
miR-378a-3p 0.790 miR-378a-3p 0.852 miR-28-3p 1.728 miR-186-5p 0.944 
miR-22-3p 0.756 miR-19b-3p 0.750 miR-BART7-5p 1.677 miR-27b-3p 0.892 
miR-423-5p 0.738 miR-155-5p 0.730 miR-146a-5p 1.381 miR-25-3p 0.879 
let-7i-5p 0.588 miR-28-3p 0.695 miR-30e-5p 1.280 miR-423-3p 0.785 
miR-103a-3p 0.566 miR-25-3p 0.678 let-7a-5p 1.060 miR-378a-3p 0.767 
miR-423-3p 0.516 miR-103a-3p 0.598 miR-146b-5p 0.988 miR-182-5p 0.667 
miR-19b-3p 0.505 let-7g-5p 0.595 miR-BART22 0.951 let-7i-5p 0.662 
miR-181b-5p 0.504 miR-425-5p 0.544 miR-423-5p 0.936 miR-151a-5p 0.625 
miR-425-5p 0.484 miR-20a-5p 0.540 miR-BART17-5p 0.844 miR-21-3p 0.594 
let-7g-5p 0.475 miR-17-5p 0.513 miR-192-5p 0.743 miR-28-5p 0.515 
miR-17-5p 0.469 let-7i-5p 0.478 miR-378a-3p 0.733 let-7g-5p 0.493 
miR-28-3p 0.454 miR-93-5p 0.459 miR-BART13-5p 0.725 miR-146b-5p 0.472 
miR-93-5p 0.446 miR-423-5p 0.442 miR-BHRF1-3 0.659 miR-181b-5p 0.383 
miR-BART8-5p 0.425 miR-423-3p 0.429 miR-27b-3p 0.605 miR-93-5p 0.368 
miR-25-3p 0.373 miR-101-3p 0.398 miR-25-3p 0.565 miR-103a-3p 0.360 
miR-20a-5p 0.355 miR-181b-5p 0.368 miR-21-3p 0.561 miR-155-5p 0.310 
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miR-BART11-3p 0.339 miR-29a-3p 0.343 miR-423-3p 0.496 miR-26b-5p 0.305 
miR-BART6-3p 0.318 miR-26b-5p 0.318 miR-186-5p 0.443 miR-101-3p 0.245 
miR-9-5p 0.286 miR-30c-5p 0.291 let-7i-5p 0.377 miR-30c-5p 0.245 
miR-15a-5p 0.276 miR-98-5p 0.231 miR-103a-3p 0.364 miR-19b-3p 0.242 
miR-29a-3p 0.263 miR-142-3p 0.228 let-7g-5p 0.349 miR-151a-3p 0.224 
miR-BART10-3p 0.243 miR-183-5p 0.214 miR-BART18-3p 0.338 miR-29a-3p 0.204 
miR-101-3p 0.240 miR-9-5p 0.200 miR-155-5p 0.338 miR-15a-5p 0.187 
miR-BART19-5p 0.189 miR-146b-5p 0.191 miR-BHRF1-2-3p 0.326 miR-140-3p 0.182 
miR-26b-5p 0.183 miR-148a-5p 0.185 miR-151a-5p 0.304 miR-425-5p 0.179 
miR-142-3p 0.172 miR-30b-5p 0.183 miR-BART6-5p 0.287 let-7d-5p 0.175 
miR-130b-3p 0.145 let-7d-5p 0.159 miR-26b-5p 0.261 miR-17-5p 0.170 
let-7d-5p 0.144 miR-92b-3p 0.152 miR-93-5p 0.255 miR-106b-3p 0.159 
miR-148a-5p 0.144 miR-769-5p 0.152 miR-BART14-3p 0.253 miR-30b-5p 0.153 
miR-30c-5p 0.139 miR-320a 0.151 miR-101-3p 0.244 miR-181a-3p 0.145 
miR-BART7-5p 0.136 miR-339-3p 0.149 miR-BART2-5p 0.235 miR-210-3p 0.138 
miR-107 0.135 miR-140-3p 0.148 miR-30c-5p 0.235 miR-941 0.138 
miR-98-5p 0.134 miR-27a-3p 0.143 miR-BART8-3p 0.221 miR-15b-5p 0.132 
miR-30b-5p 0.129 miR-19a-3p 0.134 miR-142-3p 0.219 miR-769-5p 0.126 
miR-183-5p 0.117 miR-15b-5p 0.132 miR-BART7-3p 0.201 miR-486-5p 0.124 
miR-221-3p 0.114 let-7b-5p 0.119 miR-BART9-5p 0.201 miR-20a-5p 0.118 
miR-19a-3p 0.114 let-7c-5p 0.115 miR-181b-5p 0.191   
miR-769-5p 0.107 miR-15a-5p 0.109 miR-10a-5p 0.189   
miR-140-3p 0.103 miR-107 0.107 miR-28-5p 0.189   
    miR-151a-3p 0.186   
    miR-BART16 0.185   
    miR-BART3-5p 0.176   
    miR-BART19-3p 0.175   
    miR-19b-3p 0.144   
    miR-425-5p 0.143   
    miR-30b-5p 0.133   
    miR-27a-3p 0.130   
    miR-148a-5p 0.126   
    miR-140-3p 0.116   
    miR-BART17-3p 0.115   
    miR-941 0.113   
    miR-17-5p 0.109   
    miR-29a-3p 0.107   
    miR-363-3p 0.105   
    let-7d-5p 0.104   
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Table A3. List of miRNAs enriched or depleted from the “Ago2-IP”as compared to 
the “Total” profile in U2932-EBV and U2932 at 0.1% cut-off. 
 
U2932-EBV  U2932 
miRNA 
% of total 
miRNA 
pool 
% of RISC 
assoc. 
pool 
RISC   
enriched miRNA 
% of total 
miRNA 
pool 
% of RISC 
assoc. 
pool 
RISC 
enriched 
miR-423-5p 0.217 0.738 3.407 miR-320a 0.064 0.151 2.345 
miR-423-3p 0.233 0.516 2.22 miR-423-5p 0.195 0.442 2.267 
miR-146a-5p 5.849 10.051 1.718 miR-146a-5p 3.38 7.106 2.103 
miR-92a-3p 16.783 26.551 1.582 miR-425-5p 0.333 0.544 1.635 
miR-22-3p 0.49 0.756 1.542 miR-22-3p 0.86 1.289 1.498 
miR-181b-5p 0.334 0.504 1.512 miR-21-5p 1.331 1.956 1.469 
miR-425-5p 0.338 0.484 1.434 miR-155-5p 0.503 0.73 1.452 
miR-181a-5p 7.785 10.446 1.342 let-7i-5p 0.34 0.478 1.407 
miR-28-3p 0.338 0.454 1.342 miR-423-3p 0.313 0.429 1.369 
miR-182-5p 1.609 1.966 1.222 miR-28-3p 0.508 0.695 1.367 
miR-16-5p 3.929 4.615 1.175 miR-92a-3p 17.205 23.235 1.35 
miR-93-5p 0.386 0.446 1.156 miR-181b-5p 0.28 0.368 1.317 
let-7i-5p 0.53 0.588 1.109 miR-181a-5p 7.073 9.224 1.304 
miR-130b-3p 0.132 0.145 1.093 miR-93-5p 0.369 0.459 1.245 
miR-27b-3p 1.753 1.916 1.093 miR-378a-3p 0.685 0.852 1.244 
miR-15a-5p 0.255 0.276 1.083 miR-15b-5p 0.108 0.132 1.221 
miR-26a-5p 2.887 3.124 1.082 miR-25-3p 0.556 0.678 1.218 
miR-21-5p 2.551 2.581 1.012 miR-186-5p 1.048 1.275 1.217 
miR-186-5p 0.879 0.865 0.984 miR-92b-3p 0.125 0.152 1.214 
miR-378a-3p 0.803 0.79 0.984 miR-140-3p 0.122 0.148 1.209 
miR-155-5p 1.339 1.311 0.979 miR-182-5p 2.566 3.089 1.204 
miR-183-5p 0.121 0.117 0.968 miR-19a-3p 0.113 0.134 1.192 
miR-30d-5p 3.379 3.184 0.942 miR-15a-5p 0.091 0.109 1.189 
miR-25-3p 0.409 0.373 0.912 miR-29a-3p 0.289 0.343 1.186 
miR-192-5p 1.3 1.08 0.831 miR-146b-5p 0.163 0.191 1.172 
miR-140-3p 0.124 0.103 0.826 miR-16-5p 3.123 3.565 1.142 
let-7d-5p 0.176 0.144 0.818 miR-19b-3p 0.664 0.75 1.13 
miR-29a-3p 0.324 0.263 0.811 miR-30d-5p 2.736 3.074 1.124 
miR-107 0.167 0.135 0.811 miR-183-5p 0.198 0.214 1.079 
miR-17-3p 0.111 0.088 0.791 miR-27b-3p 1.625 1.707 1.051 
let-7f-5p 3.555 2.665 0.75 miR-339-3p 0.142 0.149 1.05 
miR-9-5p 0.385 0.286 0.743 miR-26a-5p 4.159 4.317 1.038 
miR-148a-3p 5.704 4.096 0.718 miR-107 0.106 0.107 1.012 
miR-30e-5p 1.139 0.804 0.706 miR-192-5p 1.623 1.47 0.906 
miR-103a-3p 0.808 0.566 0.7 miR-769-5p 0.17 0.152 0.894 
miR-148a-5p 0.206 0.144 0.699 miR-103a-3p 0.675 0.598 0.885 
miR-769-5p 0.156 0.107 0.689 miR-30e-5p 1.728 1.502 0.869 
miR-222-3p 0.122 0.08 0.651 miR-148a-3p 8.417 7.232 0.859 
miR-17-5p 0.728 0.469 0.645 let-7d-5p 0.187 0.159 0.85 
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miR-30c-5p 0.224 0.139 0.624 miR-101-3p 0.474 0.398 0.839 
miR-301a-3p 0.11 0.068 0.619 miR-9-5p 0.24 0.2 0.833 
miR-191-5p 9.169 5.372 0.586 miR-148a-5p 0.223 0.185 0.831 
miR-101-3p 0.429 0.24 0.559 miR-27a-3p 0.177 0.143 0.809 
let-7g-5p 0.858 0.475 0.553 let-7f-5p 3.787 2.949 0.779 
miR-26b-5p 0.332 0.183 0.552 miR-301a-3p 0.102 0.079 0.774 
miR-221-3p 0.21 0.114 0.544 miR-210-3p 0.108 0.082 0.758 
miR-193b-3p 0.104 0.048 0.462 miR-30c-5p 0.422 0.291 0.688 
let-7b-5p 0.142 0.064 0.453 miR-17-5p 0.778 0.513 0.659 
miR-21-3p 0.202 0.084 0.413 let-7b-5p 0.181 0.119 0.657 
miR-19a-3p 0.276 0.114 0.413 miR-30b-5p 0.319 0.183 0.574 
miR-142-5p 5.213 2.074 0.398 miR-142-3p 0.399 0.228 0.572 
miR-142-3p 0.437 0.172 0.394 miR-191-5p 11.556 6.58 0.569 
miR-30b-5p 0.377 0.129 0.343 miR-26b-5p 0.577 0.318 0.552 
miR-18a-5p 0.103 0.035 0.342 miR-142-5p 3.854 1.939 0.503 
miR-98-5p 0.399 0.134 0.336 let-7a-5p 4.559 2.257 0.495 
let-7a-5p 3.472 1.153 0.332 let-7c-5p 0.245 0.115 0.47 
miR-20a-5p 1.157 0.355 0.307 let-7g-5p 1.322 0.595 0.45 
miR-19b-3p 1.744 0.505 0.29 miR-98-5p 0.566 0.231 0.408 
miR-486-5p 0.425 0.033 0.077 miR-20a-5p 1.666 0.54 0.324 
miR-4485-3p 0.276 0.004 0.013 miR-486-5p 0.199 0.03 0.15 
miR-1246 0.151 0.001 0.003 miR-4792 0.384 0.003 0.008 
miR-4792 0.287 0.001 0.003 miR-1260b 0.127 0.0005 0.004 
    miR-1260a 0.126 0.0004 0.003 
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Table A4. List of miRNAs enriched or depleted from the “Ago2-IP”as compared to 
the “Total” profile in SUDHL5-EBV and SUDHL5 at 0.1% cut-off 
 
SUDHL5-EBV SUDHL5 
miRNA  
% of total 
miRNA   
pool 
% of RISC 
assoc. 
pool 
RISC   
enriched miRNA  
  % of 
total 
miRNA 
pool 
% of RISC 
assoc. 
pool 
RISC 
enriched 
miR-423-5p 0.134 0.936 6.989 miR-423-5p 0.188 1.639 8.721 
miR-423-3p 0.175 0.496 2.834 miR-423-3p 0.254 0.785 3.087 
miR-92a-3p 2.364 4.881 2.064 miR-146a-5p 0.477 1.258 2.636 
miR-28-3p 0.877 1.728 1.972 miR-92a-3p 3.013 7.077 2.349 
let-7i-5p 0.2 0.377 1.886 let-7i-5p 0.283 0.662 2.337 
miR-181b-5p 0.102 0.191 1.873 miR-181b-5p 0.172 0.383 2.225 
miR-146a-5p 0.799 1.381 1.729 miR-28-3p 1.466 3.26 2.224 
miR-155-5p 0.219 0.338 1.547 miR-106b-3p 0.082 0.159 1.932 
miR-28-5p 0.137 0.189 1.381 miR-155-5p 0.163 0.31 1.901 
miR-425-5p 0.108 0.143 1.323 miR-425-5p 0.095 0.179 1.879 
miR-22-3p 3.158 3.862 1.223 miR-28-5p 0.277 0.515 1.861 
miR-151a-5p 0.249 0.304 1.221 miR-22-3p 2.781 4.762 1.712 
miR-10a-5p 0.155 0.189 1.219 miR-151a-5p 0.379 0.625 1.651 
miR-363-3p 0.089 0.105 1.179 miR-182-5p 0.419 0.667 1.592 
miR-182-5p 1.55 1.827 1.179 miR-186-5p 0.598 0.944 1.579 
miR-25-3p 0.485 0.565 1.165 miR-181a-5p 5.613 8.794 1.567 
miR-140-3p 0.1 0.116 1.152 miR-16-5p 3.588 5.13 1.43 
miR-181a-5p 3.619 4.149 1.146 miR-27b-3p 0.659 0.892 1.354 
miR-21-5p 14.164 16.151 1.14 miR-15b-5p 0.099 0.132 1.328 
miR-378a-3p 0.65 0.733 1.128 miR-21-5p 10.992 14.373 1.308 
miR-186-5p 0.394 0.443 1.124 miR-25-3p 0.68 0.879 1.293 
miR-27b-3p 0.564 0.605 1.073 miR-146b-5p 0.367 0.472 1.284 
miR-941 0.107 0.113 1.05 miR-93-5p 0.289 0.368 1.272 
miR-151a-3p 0.183 0.186 1.012 miR-140-3p 0.143 0.182 1.271 
miR-93-5p 0.257 0.255 0.992 miR-26a-5p 5.057 6.298 1.245 
let-7f-5p 2.587 2.566 0.992 miR-378a-3p 0.624 0.767 1.228 
miR-16-5p 3.321 3.231 0.973 miR-151a-3p 0.184 0.224 1.218 
miR-29a-3p 0.116 0.107 0.92 miR-15a-5p 0.154 0.187 1.214 
let-7d-5p 0.118 0.104 0.881 let-7f-5p 2.746 3.294 1.2 
miR-192-5p 0.849 0.743 0.875 miR-192-5p 0.881 1.018 1.155 
miR-26a-5p 2.549 2.21 0.867 miR-941 0.12 0.138 1.148 
miR-103a-3p 0.424 0.364 0.858 let-7d-5p 0.153 0.175 1.143 
miR-30d-5p 3.06 2.617 0.855 miR-29a-3p 0.184 0.204 1.107 
miR-15a-5p 0.11 0.093 0.852 miR-30d-5p 3.031 3.027 0.999 
miR-27a-3p 0.153 0.13 0.848 miR-148a-3p 2.681 2.644 0.986 
miR-146b-5p 1.188 0.988 0.832 miR-103a-3p 0.37 0.36 0.973 
miR-101-3p 0.304 0.244 0.803 miR-769-5p 0.138 0.126 0.917 
miR-19b-3p 0.193 0.144 0.746 miR-30c-5p 0.291 0.245 0.841 
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miR-148a-3p 5.807 4.216 0.726 miR-148a-5p 0.103 0.085 0.831 
miR-181a-3p 0.108 0.077 0.711 miR-19b-3p 0.293 0.242 0.826 
miR-210-3p 0.129 0.089 0.691 miR-191-5p 4.122 3.399 0.825 
miR-30e-5p 1.862 1.28 0.687 miR-30e-5p 1.96 1.612 0.822 
miR-148a-5p 0.184 0.126 0.684 miR-210-3p 0.168 0.138 0.822 
miR-30c-5p 0.343 0.235 0.684 miR-101-3p 0.307 0.245 0.798 
miR-21-3p 0.841 0.561 0.667 miR-17-5p 0.213 0.17 0.798 
miR-191-5p 4.947 2.883 0.583 miR-181a-3p 0.197 0.145 0.736 
miR-17-5p 0.195 0.109 0.558 miR-26b-5p 0.456 0.305 0.669 
let-7g-5p 0.664 0.349 0.526 let-7g-5p 0.776 0.493 0.635 
miR-26b-5p 0.52 0.261 0.502 miR-142-3p 2.657 1.501 0.565 
miR-142-5p 6.891 3.435 0.498 miR-21-3p 1.106 0.594 0.537 
miR-142-3p 0.468 0.219 0.468 let-7a-5p 2.848 1.437 0.505 
let-7a-5p 2.587 1.06 0.41 miR-142-5p 28.391 13.376 0.471 
miR-30b-5p 0.332 0.133 0.4 miR-486-5p 0.302 0.124 0.409 
miR-98-5p 0.26 0.077 0.295 miR-30b-5p 0.378 0.153 0.405 
miR-20a-5p 0.302 0.084 0.278 miR-20a-5p 0.334 0.118 0.352 
miR-486-5p 0.403 0.036 0.089 miR-98-5p 0.229 0.081 0.351 
miR-4485-3p 0.517 0.004 0.009 miR-4485-3p 0.709 0.009 0.013 
miR-1260b 0.107 0.0003 0.003 miR-1246 0.339 0.001 0.002 
miR-1260a 0.107 0.0002 0.002 miR-1260b 0.117 0.00012 0.001 
    miR-4792 1.349 0.001 0.001 
    miR-1260a 0.117 0.00009 0.001 
    miR-4532 0.138 0.00004 0.0003 
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Table A5. Comparison of miRNA profiles in EBV + vs. EBV - in “Total” profile in 
 U2932 and SUDHL5 cell lines at 0.1% cut-off. 
 
U2932 total SUDHL5 total 
miRNA  
EBV 
Positive 
EBV 
Negative 
  Ratio  
EBV +/ 
EBV- miRNA  
EBV 
Positive 
EBV 
Negative 
Ratio 
EBV +/EBV - 
miR-4485-3p 0.276 0.062 4.432 miR-182-5p 1.55 0.419 3.699 
miR-221-3p 0.21 0.056 3.767 miR-146b-5p 1.188 0.367 3.235 
miR-222-3p 0.122 0.037 3.332 miR-10a-5p 0.155 0.061 2.561 
miR-193b-3p 0.104 0.034 3.087 miR-148a-3p 5.807 2.681 2.166 
miR-18a-5p 0.103 0.035 2.985 miR-148a-5p 0.184 0.103 1.793 
miR-1246 0.151 0.051 2.976 miR-146a-5p 0.799 0.477 1.674 
miR-15a-5p 0.255 0.091 2.787 miR-27a-3p 0.153 0.097 1.579 
miR-155-5p 1.339 0.503 2.663 miR-155-5p 0.219 0.163 1.341 
miR-19b-3p 1.744 0.664 2.626 miR-486-5p 0.403 0.302 1.335 
miR-19a-3p 0.276 0.113 2.454 miR-21-5p 14.164 10.992 1.289 
miR-486-5p 0.425 0.199 2.138 miR-191-5p 4.947 4.122 1.2 
miR-21-3p 0.202 0.098 2.07 miR-30c-5p 0.343 0.291 1.178 
miR-21-5p 2.551 1.331 1.916 miR-103a-3p 0.424 0.37 1.145 
miR-130b-3p 0.132 0.076 1.737 miR-26b-5p 0.52 0.456 1.14 
miR-146a-5p 5.849 3.38 1.731 miR-22-3p 3.158 2.781 1.136 
miR-9-5p 0.385 0.24 1.603 miR-98-5p 0.26 0.229 1.134 
miR-107 0.167 0.106 1.58 miR-425-5p 0.108 0.095 1.132 
let-7i-5p 0.53 0.34 1.561 miR-378a-3p 0.65 0.624 1.04 
miR-142-5p 5.213 3.854 1.352 miR-30d-5p 3.06 3.031 1.01 
miR-17-3p 0.111 0.083 1.348 miR-151a-3p 0.183 0.184 0.997 
miR-16-5p 3.929 3.123 1.258 miR-101-3p 0.304 0.307 0.99 
miR-30d-5p 3.379 2.736 1.235 miR-192-5p 0.849 0.881 0.963 
miR-103a-3p 0.808 0.675 1.197 miR-30e-5p 1.862 1.96 0.95 
miR-181b-5p 0.334 0.28 1.193 let-7f-5p 2.587 2.746 0.942 
miR-30b-5p 0.377 0.319 1.183 miR-16-5p 3.321 3.588 0.926 
miR-378a-3p 0.803 0.685 1.172 miR-17-5p 0.195 0.213 0.916 
miR-29a-3p 0.324 0.289 1.121 miR-1260a 0.107 0.117 0.915 
miR-423-5p 0.217 0.195 1.112 miR-1260b 0.107 0.117 0.914 
miR-181a-5p 7.785 7.073 1.101 let-7a-5p 2.587 2.848 0.908 
miR-142-3p 0.437 0.399 1.096 miR-20a-5p 0.302 0.334 0.905 
miR-27b-3p 1.753 1.625 1.079 miR-941 0.107 0.12 0.893 
miR-301a-3p 0.11 0.102 1.078 miR-93-5p 0.257 0.289 0.891 
miR-93-5p 0.386 0.369 1.046 miR-30b-5p 0.332 0.378 0.877 
miR-425-5p 0.338 0.333 1.014 miR-27b-3p 0.564 0.659 0.857 
miR-140-3p 0.124 0.122 1.014 let-7g-5p 0.664 0.776 0.856 
miR-92a-3p 16.783 17.205 0.975 miR-92a-3p 2.364 3.013 0.785 
let-7d-5p 0.176 0.187 0.943 let-7d-5p 0.118 0.153 0.77 
let-7f-5p 3.555 3.787 0.939 miR-210-3p 0.129 0.168 0.77 
miR-17-5p 0.728 0.778 0.935 miR-21-3p 0.841 1.106 0.76 
miR-148a-5p 0.206 0.223 0.923 miR-4485-3p 0.517 0.709 0.729 
miR-769-5p 0.156 0.17 0.918 miR-15a-5p 0.11 0.154 0.713 
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miR-101-3p 0.429 0.474 0.904 miR-25-3p 0.485 0.68 0.713 
miR-15b-5p 0.091 0.108 0.842 miR-423-5p 0.134 0.188 0.713 
miR-186-5p 0.879 1.048 0.838 miR-769-5p 0.098 0.138 0.708 
miR-192-5p 1.3 1.623 0.801 let-7i-5p 0.2 0.283 0.707 
miR-191-5p 9.169 11.556 0.793 miR-140-3p 0.1 0.143 0.7 
let-7b-5p 0.142 0.181 0.786 miR-423-3p 0.175 0.254 0.688 
let-7a-5p 3.472 4.559 0.762 miR-186-5p 0.394 0.598 0.659 
miR-4792 0.287 0.384 0.748 miR-19b-3p 0.193 0.293 0.658 
miR-423-3p 0.233 0.313 0.743 miR-151a-5p 0.249 0.379 0.658 
miR-25-3p 0.409 0.556 0.735 miR-181a-5p 3.619 5.613 0.645 
miR-98-5p 0.399 0.566 0.704 miR-29a-3p 0.116 0.184 0.633 
miR-20a-5p 1.157 1.666 0.694 miR-28-3p 0.877 1.466 0.598 
miR-26a-5p 2.887 4.159 0.694 miR-181b-5p 0.102 0.172 0.592 
miR-148a-3p 5.704 8.417 0.678 miR-181a-3p 0.108 0.197 0.547 
miR-28-3p 0.338 0.508 0.665 miR-26a-5p 2.549 5.057 0.504 
miR-30e-5p 1.139 1.728 0.659 miR-28-5p 0.137 0.277 0.494 
let-7g-5p 0.858 1.322 0.649 miR-4532 0.054 0.138 0.392 
miR-182-5p 1.609 2.566 0.627 miR-142-5p 6.891 28.391 0.243 
miR-183-5p 0.121 0.198 0.61 miR-1246 0.069 0.339 0.205 
miR-26b-5p 0.332 0.577 0.576 miR-142-3p 0.468 2.657 0.176 
miR-22-3p 0.49 0.86 0.57 miR-4792 0.095 1.349 0.07 
miR-210-3p 0.058 0.108 0.537     
miR-30c-5p 0.224 0.422 0.53     
miR-1260b 0.062 0.127 0.488     
miR-1260a 0.061 0.126 0.486     
miR-339-3p 0.064 0.142 0.454     
miR-146b-5p 0.073 0.163 0.448     
miR-92b-3p 0.049 0.125 0.389     
miR-27a-3p 0.032 0.177 0.179     
let-7c-5p 0.024 0.245 0.097     
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Table A6. Comparison of miRNA profiles in EBV+ vs. EBV- in “Ago2-IP” profile in 
 U2932 and SUDHL5 cell lines at 0.1% cut-off. 
 
U2932 Ago2-IP SUDHL5 Ago2-IP 
miRNA  
EBV  
Positive 
EBV 
Negative 
  Ratio  
EBV +/ 
EBV- miRNA  
EBV  
Positive 
EBV 
Negative 
  Ratio  
EBV +/ 
EBV- 
miR-15a-5p 0.276 0.109 2.539 miR-363-3p 0.105 0.017 6.046 
miR-221-3p 0.114 0.045 2.538 miR-182-5p 1.827 0.667 2.739 
miR-155-5p 1.311 0.730 1.795 miR-146b-5p 0.988 0.472 2.095 
miR-130b-3p 0.145 0.082 1.759 miR-10a-5p 0.189 0.097 1.956 
miR-423-5p 0.738 0.442 1.671 miR-148a-3p 4.216 2.644 1.595 
miR-9-5p 0.286 0.200 1.430 miR-148a-5p 0.126 0.085 1.476 
miR-146a-5p 10.051 7.106 1.414 miR-27a-3p 0.130 0.097 1.336 
miR-181b-5p 0.504 0.368 1.369 miR-21-5p 16.151 14.373 1.124 
miR-21-5p 2.581 1.956 1.320 miR-146a-5p 1.381 1.258 1.098 
miR-16-5p 4.615 3.565 1.294 miR-155-5p 0.338 0.310 1.091 
miR-107 0.135 0.107 1.266 miR-103a-3p 0.364 0.360 1.009 
let-7i-5p 0.588 0.478 1.231 miR-101-3p 0.244 0.245 0.997 
miR-423-3p 0.516 0.429 1.205 miR-30c-5p 0.235 0.245 0.958 
miR-92a-3p 26.551 23.235 1.143 miR-378a-3p 0.733 0.767 0.956 
miR-181a-5p 10.446 9.224 1.132 miR-21-3p 0.561 0.594 0.944 
miR-27b-3p 1.916 1.707 1.122 miR-30b-5p 0.133 0.153 0.868 
miR-142-5p 2.074 1.939 1.070 miR-30d-5p 2.617 3.027 0.865 
miR-30d-5p 3.184 3.074 1.036 miR-26b-5p 0.261 0.305 0.856 
miR-93-5p 0.446 0.459 0.972 miR-191-5p 2.883 3.399 0.848 
miR-103a-3p 0.566 0.598 0.947 miR-151a-3p 0.186 0.224 0.828 
miR-378a-3p 0.790 0.852 0.927 miR-941 0.113 0.138 0.817 
miR-17-5p 0.469 0.513 0.916 miR-22-3p 3.862 4.762 0.811 
let-7d-5p 0.144 0.159 0.908 miR-425-5p 0.143 0.179 0.797 
let-7f-5p 2.665 2.949 0.904 miR-30e-5p 1.280 1.612 0.794 
miR-425-5p 0.484 0.544 0.890 let-7f-5p 2.566 3.294 0.779 
miR-19a-3p 0.114 0.134 0.850 let-7a-5p 1.060 1.437 0.738 
miR-191-5p 5.372 6.580 0.816 miR-192-5p 0.743 1.018 0.730 
let-7g-5p 0.475 0.595 0.798 miR-20a-5p 0.084 0.118 0.713 
miR-148a-5p 0.144 0.185 0.777 let-7g-5p 0.349 0.493 0.709 
miR-29a-3p 0.263 0.343 0.767 miR-93-5p 0.255 0.368 0.695 
miR-142-3p 0.172 0.228 0.753 miR-92a-3p 4.881 7.077 0.690 
miR-192-5p 1.080 1.470 0.735 miR-27b-3p 0.605 0.892 0.679 
miR-26a-5p 3.124 4.317 0.724 miR-210-3p 0.089 0.138 0.648 
miR-769-5p 0.107 0.152 0.708 miR-25-3p 0.565 0.879 0.643 
miR-30b-5p 0.129 0.183 0.707 miR-17-5p 0.109 0.170 0.640 
miR-140-3p 0.103 0.148 0.693 miR-140-3p 0.116 0.182 0.635 
miR-186-5p 0.865 1.275 0.678 miR-423-3p 0.496 0.785 0.632 
miR-19b-3p 0.505 0.750 0.673 miR-16-5p 3.231 5.130 0.630 
miR-15b-5p 0.088 0.132 0.672 miR-15b-5p 0.081 0.132 0.612 
miR-20a-5p 0.355 0.540 0.657 miR-19b-3p 0.144 0.242 0.595 
miR-28-3p 0.454 0.695 0.653 let-7d-5p 0.104 0.175 0.594 
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miR-182-5p 1.966 3.089 0.636 miR-769-5p 0.073 0.126 0.579 
miR-92b-3p 0.096 0.152 0.631 miR-423-5p 0.936 1.639 0.571 
miR-101-3p 0.240 0.398 0.602 let-7i-5p 0.377 0.662 0.570 
miR-22-3p 0.756 1.289 0.586 miR-106b-3p 0.085 0.159 0.532 
miR-98-5p 0.134 0.231 0.580 miR-28-3p 1.728 3.260 0.530 
miR-26b-5p 0.183 0.318 0.576 miR-181a-3p 0.077 0.145 0.529 
miR-320a 0.086 0.151 0.572 miR-29a-3p 0.107 0.204 0.526 
miR-148a-3p 4.096 7.232 0.566 miR-15a-5p 0.093 0.187 0.501 
miR-25-3p 0.373 0.678 0.550 miR-181b-5p 0.191 0.383 0.498 
miR-183-5p 0.117 0.214 0.547 miR-151a-5p 0.304 0.625 0.486 
let-7b-5p 0.064 0.119 0.542 miR-181a-5p 4.149 8.794 0.472 
miR-339-3p 0.080 0.149 0.536 miR-186-5p 0.443 0.944 0.469 
miR-30e-5p 0.804 1.502 0.535 miR-28-5p 0.189 0.515 0.366 
let-7a-5p 1.153 2.257 0.511 miR-26a-5p 2.210 6.298 0.351 
miR-30c-5p 0.139 0.291 0.480 miR-486-5p 0.036 0.124 0.292 
miR-146b-5p 0.090 0.191 0.468 miR-142-5p 3.435 13.376 0.257 
miR-27a-3p 0.031 0.143 0.215 miR-142-3p 0.219 1.501 0.146 
let-7c-5p 0.013 0.115 0.116     
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Table A7.   
Abundance of EBV miRNAs in total- and Ago2-miRNA profiles in U2932-EBV and 
SUDHL5-EBV infected cell line. 
 
U2932-EBV SUDHL5-EBV 
miRNA Total  miRNA Ago miRNA Total miRNA Ago2 
rel. expr. 
% 
rel. expr. % rel. expr. 
% 
rel. expr. % 
BART10-3p 0.4365 BART8-5p 0.42474 BHRF1-1 5.971 BHRF1-1 7.0296 
BART8-5p 0.2964 BART11-3p 0.33851 BART10-3p 3.2542 BART8-5p 4.1537 
BART6-3p 0.1967 BART6-3p 0.31849 BART8-5p 2.9754 BART6-3p 3.1426 
BART11-3p 0.1582 BART10-3p 0.24271 BART7-5p 1.3665 BART10-3p 2.4979 
BART22 0.1281 BART19-5p 0.18918 BART19-5p 1.2667 BART11-3p 1.9503 
BART7-5p 0.1138 BART7-5p 0.13593 BART11-3p 1.1298 BART19-5p 1.889 
BART19-5p 0.0922 BART22 0.09825 BART6-3p 1.0978 BART7-5p 1.6766 
BHRF1-1 0.0871 BHRF1-1 0.08756 BART22 0.9351 BART22 0.9512 
BART7-3p 0.0829 BART17-5p 0.07884 BHRF1-3 0.6435 BART17-5p 0.8444 
BART18-3p 0.0701 BART18-3p 0.05162 BART17-5p 0.5107 BART13-5p 0.7252 
BART17-5p 0.0589 BART13-5p 0.04266 BART13-5p 0.4936 BHRF1-3 0.6585 
BART16 0.0538 BART16 0.03831 BART18-3p 0.4007 BART18-3p 0.3384 
BART8-3p 0.0409 BART2-5p 0.03258 BART19-3p 0.3536 BHRF1-2-3p 0.3256 
BART9-5p 0.0408 BART7-3p 0.03072 BART7-3p 0.3231 BART6-5p 0.2869 
BART2-5p 0.0403 BART6-5p 0.03005 BART9-5p 0.3 BART14-3p 0.2532 
BART13-5p 0.0394 BART14-3p 0.02783 BART2-5p 0.2895 BART2-5p 0.2351 
BART14-3p 0.0342 BART8-3p 0.02579 BART6-5p 0.2882 BART8-3p 0.2212 
BART6-5p 0.034 BART9-5p 0.02475 BART8-3p 0.2875 BART7-3p 0.2011 
BART5-5p 0.0307 BART3-5p 0.02096 BHRF1-2-3p 0.2872 BART9-5p 0.2006 
BART3-5p 0.0276 BART9-3p 0.0136 BART17-3p 0.2741 BART16 0.1845 
BART1-3p 0.0255 BART11-5p 0.01217 BART14-3p 0.2516 BART3-5p 0.1761 
BART17-3p 0.0224 BART17-3p 0.01134 BART3-5p 0.153 BART19-3p 0.1746 
BART1-5p 0.0208 BART19-3p 0.00716 BART1-3p 0.1365 BART17-3p 0.1147 
BART19-3p 0.0187 BART3-3p 0.00692 BART1-5p 0.131 BART9-3p 0.0764 
BART3-3p 0.0147 BART1-5p 0.00685 BART16 0.1251 BART1-5p 0.0749 
BART11-5p 0.0123 BHRF1-2-3p 0.00683 BART5-5p 0.1204 BART4-5p 0.0705 
BART4-5p 0.0115 BHRF1-3 0.0068 BART11-5p 0.082 BART11-5p 0.0664 
BART9-3p 0.0115 BART1-3p 0.00633 BART4-5p 0.0626 BART1-3p 0.0437 
BHRF1-3 0.0096 BART4-5p 0.00563 BART9-3p 0.0622 BART18-5p 0.0392 
BART18-5p 0.009 BART18-5p 0.00473 BART18-5p 0.0605 BART5-5p 0.0339 
BART13-3p 0.0068 BART5-5p 0.00323 BART3-3p 0.0581 BART3-3p 0.0192 
BHRF1-2-3p 0.0066 BART4-3p 0.002 BART13-3p 0.0287 BART13-3p 0.0136 
BART21-3p 0.0064 BART15 0.00131 BART21-3p 0.0276 BART12 0.0134 
BART4-3p 0.0029 BART12 0.00099 BART15 0.0145 BART21-5p 0.0116 
BART15 0.0026 BART13-3p 0.00091 BART21-5p 0.0145 BART20-3p 0.011 
BART12 0.0017 BART21-5p 0.00087 BART14-5p 0.0145 BART15 0.0107 
BART21-5p 0.0014 BART21-3p 0.00075 BART12 0.0142 BART14-5p 0.0099 
BART20-3p 0.0011 BART14-5p 0.00068 BART20-3p 0.0123 BART21-3p 0.0059 
BART10-5p 0.0007 BART20-3p 0.00059 BHRF1-2-5p 0.009 BART4-3p 0.0054 
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BART14-5p 0.0005 BART10-5p 0.00017 BART4-3p 0.0075 BHRF1-2-5p 0.0045 
BART5-3p 0.0002 BART2-3p 0.00015 BART10-5p 0.0038 BART10-5p 0.0021 
BHRF1-2-5p 0.0002 BART20-5p 0.00006 BART20-5p 0.0028 BART2-3p 0.0014 
BART2-3p 0.0001 BHRF1-2-5p 0.00005 BART5-3p 0.0014 BART20-5p 0.0008 
BART20-5p 0.0001 BART5-3p 0.00004 BART2-3p 0.0013 BART5-3p 0.0004 
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Table A8.  
List of EBV-miRNAs enriched or depleted from the “Ago2-IP”as compared to the 
“Total” profile in U2932-EBV and SUDHL5-EBV   
 
U2932-EBV SUDHL5-EBV 
EBV miRNA 
% Total 
miRNA 
pool 
% RISC 
assoc. 
pool 
RISC 
enriched 
 fold 
change EBV miRNA 
% Total 
miRNA 
pool 
% RISC 
assoc. 
pool 
RISC 
enriched 
 fold 
change 
miR-BART11-3p 0.158 0.339 2.140 miR-BART6-3p 1.098 3.143 2.863 
miR-BART19-5p 0.092 0.189 2.053 miR-BART11-3p 1.130 1.950 1.726 
miR-BART6-3p 0.197 0.318 1.619 miR-BART17-5p 0.511 0.844 1.653 
miR-BART8-5p 0.296 0.425 1.433 miR-BART19-5p 1.267 1.889 1.491 
miR-BART7-5p 0.114 0.136 1.194 miR-BART16 0.125 0.185 1.476 
miR-BART22 0.128 0.098 0.767 miR-BART13-5p 0.494 0.725 1.469 
miR-BART10-3p 0.436 0.243 0.556 miR-BART8-5p 2.975 4.154 1.396 
    miR-BART7-5p 1.367 1.677 1.227 
    miR-BHRF1-1 5.971 7.030 1.177 
    miR-BART3-5p 0.153 0.176 1.151 
    miR-BHRF1-2-3p 0.287 0.326 1.133 
    miR-BHRF1-3 0.644 0.659 1.023 
    miR-BART22 0.935 0.951 1.017 
    miR-BART14-3p 0.252 0.253 1.006 
    miR-BART6-5p 0.288 0.287 0.995 
    miR-BART18-3p 0.401 0.338 0.845 
    miR-BART2-5p 0.290 0.235 0.812 
    miR-BART8-3p 0.287 0.221 0.769 
    miR-BART10-3p 3.254 2.498 0.768 
    miR-BART9-5p 0.300 0.201 0.669 
    miR-BART7-3p 0.323 0.201 0.623 
    miR-BART1-5p 0.131 0.075 0.572 
    miR-BART19-3p 0.354 0.175 0.494 
    miR-BART17-3p 0.274 0.115 0.418 
    miR-BART1-3p 0.137 0.044 0.320 
    miR-BART5-5p 0.120 0.034 0.281 
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Table A9.Up and down regulated miRNAs in “Ago2-IP”U2932-EBV vs. U2932 
measured by microarray 
 
miR-551b 8.85 miR-339-3p -2.23 miR-7 -2.71 miR-574-3p -3.89 
miR-137 6.89 miR-139-5p -2.23 miR-3654 -2.71 miR-30e* -3.92 
miR-363 6.53 miR-1286 -2.24 miR-365 -2.73 miR-1207-3p -3.92 
miR-494 6.37 miR-499-5p -2.25 miR-192* -2.73 miR-505* -3.96 
miR-449a 5.08 miR-627 -2.25 miR-3656 -2.73 miR-128 -3.98 
miR-130a 4.77 miR-188-3p -2.26 miR-32 -2.74 miR-532-3p -3.99 
miR-630 3.48 miR-500a -2.27 miR-548b-3p -2.76 miR-590-5p -4.00 
miR-3651 2.87 miR-181a-2* -2.28 miR-577 -2.77 miR-342-3p -4.01 
miR-10a 2.75 miR-625* -2.28 miR-629 -2.78 miR-25* -4.01 
miR-718 2.67 miR-188-5p -2.30 miR-140-3p -2.78 miR-4306 -4.13 
miR-1268 2.20 miR-1301 -2.30 miR-378* -2.79 miR-501-3p -4.19 
miR-450a 2.16 miR-331-5p -2.31 miR-374a -2.80 miR-3194 -4.42 
miR-4299 2.14 miR-103-2* -2.34 miR-660 -2.80 miR-500a* -4.45 
miR-3659 2.10 let-7d* -2.35 miR-193a-5p -2.83 miR-421 -4.45 
miR-15a 2.08 miR-132 -2.35 miR-1307 -2.84 miR-185 -4.56 
miR-4317 -2.00 miR-425* -2.36 miR-454* -2.88 miR-374c -4.62 
miR-30c-1* -2.00 miR-155* -2.37 miR-502-5p -2.89 miR-7-1* -4.79 
miR-1973 -2.01 miR-331-3p -2.37 miR-92a-1* -2.93 miR-140-5p -4.80 
miR-1280 -2.01 miR-642b -2.38 miR-129-5p -2.93 miR-769-3p -4.81 
miR-192 -2.02 miR-19a* -2.39 miR-106b* -2.96 miR-589* -4.82 
miR-19b-1* -2.02 miR-95 -2.40 miR-152 -2.97 miR-191 -4.88 
miR-200b -2.02 miR-29c* -2.40 miR-23a -2.99 miR-944 -5.07 
miR-3198 -2.03 miR-361-3p -2.41 miR-362-5p -3.09 miR-362-3p -5.07 
miR-16-2* -2.03 miR-30d* -2.42 miR-570 -3.11 miR-129* -5.19 
miR-22* -2.04 miR-18a* -2.44 miR-769-5p -3.16 miR-550a* -5.22 
miR-628-3p -2.04 miR-125a-3p -2.44 miR-148b -3.16 miR-21* -5.39 
miR-148b* -2.05 miR-1908 -2.44 miR-27a -3.17 miR-1270 -5.40 
miR-3195 -2.05 miR-22 -2.47 miR-422a -3.19 miR-582-5p -5.40 
miR-181d -2.06 miR-423-3p -2.47 miR-24 -3.22 miR-1303 -5.43 
miR-25 -2.09 miR-183 -2.50 miR-548b-5p -3.24 miR-4291 -5.43 
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miR-4284 -2.09 miR-24-1* -2.50 miR-186 -3.26 miR-502-3p -5.46 
miR-491-5p -2.12 miR-624 -2.53 miR-342-5p -3.31 miR-4286 -5.64 
miR-874 -2.13 miR-215 -2.53 miR-15b* -3.32 miR-148a* -5.69 
miR-330-3p -2.17 miR-548e -2.55 miR-181a* -3.33 miR-199b-5p -5.85 
miR-597 -2.18 miR-193b* -2.56 miR-744 -3.40 miR-1180 -6.19 
miR-30b* -2.19 miR-182 -2.57 miR-374b -3.50 miR-193a-3p -6.25 
miR-3934 -2.19 miR-598 -2.58 miR-3074 -3.50 miR-126 -6.44 
miR-1224-5p -2.19 miR-182* -2.63 miR-505 -3.53 miR-624* -6.45 
miR-30a -2.19 miR-193b -2.63 miR-766 -3.53 miR-345 -6.48 
miR-1285 -2.19 miR-378 -2.63 miR-197 -3.54 miR-1260 -7.17 
miR-548c-5p -2.20 miR-628-5p -2.64 miR-296-5p -3.58 miR-1260b -7.32 
miR-4323 -2.21 miR-29b-1* -2.65 miR-652 -3.58 miR-1274b -8.48 
miR-183* -2.21 miR-3150b -2.66 miR-93* -3.65 miR-720 -10.62 
miR-429 -2.22 miR-532-5p -2.68 miR-1255a -3.70 miR-340* -12.56 
miR-339-5p -2.22 miR-625 -2.69 miR-28-5p -3.71 miR-1274a -12.75 
miR-550a -2.23 miR-4327 -2.70 miR-199a-3p -3.75 miR-340 -75.41 
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8 Abbreviations 
  Ago  Argonaute Protein 
Ago2-RIP-seq Ago2-based RNA immunoprecipitation (RIP) 
APS Ammonium persulfate 
Bcl-2 B-cell CLL/lymphoma 2 
BHRF1 Bam HI fragment H rightward open reading frame 1 
DNA Deoxyribonucleic acid 
dNTP Desoxyribonucleosidtriphosphate 
EDTA Ethylenediaminetetraacetic acid 
FCS Fetal Calf Serum 
CACNG8 Calcium Voltage-Gated Channel Auxiliary Subunit Gamma 8 
H2O2 Hydrogen Peroxide 
HCL Hydrogen Chloride 
KCl Potassium Chloride 
kDa Kilo Dalton 
M Molar 
mA Milliampere 
mg Milligram 
MgCl2 Magnesium Chloride 
min Minute 
ml Milliliter 
mRNA Messenger RNA 
Na2HPO4 Sodium Hydrogen Phosphate 
NaOH Sodium Hydroxide 
NTP Nucleoside Triphosphate 
PBS Phosphate Buffered Saline 
RISC RNA Induced Silencing Complex 
RNA Ribonucleic Acid 
RPM Rotations Per Minute 
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RPMI-1640 Roswell Park Memorial Instiute-1640 
SDS Sodium Dodecyl Sulphate 
SDS-PAGE 
Sodium Dodecyl Sulphate- Polyacrylamide Gel 
Electrophoresis 
sec Second 
SSC Saline Sodium Citrate 
TAE Tris base, acetic acid, EDTA 
TBE Tris base, boric acid, EDTA 
TE Tris base, EDTA 
TEMED N,N,N’,N’-tetramethylethane-1,2-diamine 
TNRC6A Trinucleotide repeat containing 6 A 
V Volt 
W Watt 
μL Microliter 
μg  Microgram 
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